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Abstract
The most favoured amino acid in protein-nucleic acid interfaces is arginine due to the 
existence of the guanidinium group in its structure that can form good hydrogen-bonding 
geometries. In addition, the length of the side chain gives it a great deal of torsional freedom 
and therefore permits the guanidinium group to orient itself to interact with a wide range of 
targets through bidentate H-bonding. A torsional constraint for the guanidine group could be 
achieved by its conversion into a bicyclic framework, resulting in unidirectional hydrogen 
bonding with its targets and reducing the loss of the conformational entropy as a result of its 
binding. The aim of this research is to synthesise nucleic acid targeting oligopeptides which 
will include non-natural analogues of arginine as part of their sequence with the purpose of 
activating or inhibiting biological functions. The synthesis of different sized rings of bicyclic 
guanidine derivatives could be a means to control the hydrophobic interaction with DNA, with 
hydrophobicity increasing as the size of the ring of the bicyclic guanidine increases. In 
addition, the high basicity of guanidine leads to production of the corresponding guanidinium 
cation upon protonation. Therefore, the formation of guanidinium cation leads to hydrogen 
bonding and electrostatic interactions with anions like phosphate groups. So, the purpose of 
preparing differently sized rings of bicyclic guanidine in the current work is to compare their 
interactions with DNA. There are four themes in our research concerned with the design and 
synthesis of bicyclic guanidine derivatives and non-natural amino acids. The first theme 
concerns the synthesis of a protected bicyclic guanidine methylene amine that was achieved 
by utilising Boc-L-methioninol as a precursor and converting it to the corresponding azide.
However, incorporation of this bicyclic guanidine into an amino acid moiety proved difficult 
and thus the modified amino acid was not formed. The second theme of the project considers 
a novel strategy to generate a bicyclic guanidine methylene alcohol with a variably sized ring 
in a high yield starting from an azido alkane amine and Boc-L-methionine as precursors. This 
modification to the route will open a promising way to produce the functionalised bicyclic 
guanidine. Bicyclic guanidine methylene chloride was synthesised that gave us a way to insert 
bicyclic guanidine into a tyrosine amino acid moiety so that a protected L-tyrosine possessing 
bicyclic guanidine with a differently sized ring could be synthesised. The third theme involved 
the new strategy towards the synthesis of bicyclic guanidine methylene amine followed by 
conjugation with Fmoc-Glu-OAll to produce a modified amino acid. The fourth, and final, 
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theme of our research includes the preparation of dimers of bicyclic guanidine. Furthermore, 
a crystal structure for the protected bicyclic guanidine intermediate in this theme has also 
been obtained.
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Ac Acetyl
Ar Aryl
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DMC 2-Chloro-1, 3-dimethylimidazolinium chloride
DMF Dimethylformamide
DMSO Dimethyl sulfoxide
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EDC 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
Et2O Diethylether
Fmoc Fluorenylmethyloxycarbonyl  
g Gram
H-tbd 1, 6, 8-triazabicyclo [5.3.0] dec-7-ene
H-tbn 1, 4, 6-triazabicyclo [4.3.0] non-6-ene
H-tbu 1, 6, 8-triazabicyclo [5.4.0] undec-7-ene
HCl Hydrochloric acid
HOBt 1-Hydroxybenzotriazole
HPLC High-performance liquid chromatography
hppH 1, 5, 7-triazabicyclo [4.4.0] dec-5-ene
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IR Infrared
m/z Mass to charge ratio (in mass spectrometry)
Me Methyl
MeOTf Methyl trifluoromethanesulfonate
Mtt 4-Methyltrityl
n-BuLi n- Butyllithium
NEt3 Triethylamine
NMR Nuclear magnetic resonance
Pbf 2, 2, 4, 6, 7-Pentamethyl-2, 3-dihydrobenzofuran
PbfNH2 2, 2, 4, 6, 7-Pentamethyl-2, 3-dihydrobenzofuran-5-sulfonamide
PPh3 Triphenylphosphine
ppm Parts per million
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PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate
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r.t. Room temperature
Red-Al Sodium bis (2-methoxyethoxy) aluminumhydride
RNA Ribonucleic acid
rRNA Ribosomal ribonucleic acid
TBAF Tetra-n-butylammonium fluoride
TBS/TBDMS Tert-butyldimethylsilyl
TEA Triethylamine
TFA Trifluoroacetic acid
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Tr Triphenylmethyl chloride
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1.1 Motivation
DNA can interact with ligands, e.g. from peptide libraries containing a non-natural amino acid,
for the purpose of activating or inhibiting biological functions. Certain amino acids with basic 
residues, such as arginine, display selective binding for specific nucleobases. The significant 
functional group in the arginine amino acid is a guanidine group, which can play an important 
role in the recognition between peptides and their nucleic acid targets. The synthesis of 
functionalised and non-functionalised bicyclic guanidine has attracted increasing interest 
during the past few decades due to its properties and various uses in different fields of 
chemistry. Bioconjugation is an approach to introduce small molecules into an amino acid 
moiety that can achieve relatively quick syntheses of a wide range of compounds that contain 
the same sub-structure but with different steric and electronic properties. The insertion of
modified amino acids into peptides through parallel chemistry is an important procedure in 
medicinal chemistry and biochemistry. In the following sections, the background of many 
subjects is discussed, related to the main goal of our research. The discussion starts with the
general concepts of nucleic acids, then moves to their interactions with proteins and the 
involvement of particular amino acids, focussing especially on the interactions of the arginine 
residues in these complexes. The next section includes the properties of guanidine groups, 
bicyclic guanidine and then describes the strategies used to synthesise guanidine and bicyclic 
guanidine. Bioconjugation as a general concept is described, followed by the different 
linkages that have been used to conjugate small molecules to biomolecules. Finally, I describe
the aim of my research.
1.2 Nucleic acids
Nucleic acids1 (DNA and RNA) are molecules that are responsible for many crucial functions 
in organisms. Although nucleic acids were described in 1869 by Friedrich Miescher,2 it was 
only in the 1940s that their significance as the holders of hereditary information became 
obvious.3 They are found in a free state or linked to proteins to create nucleoproteins. Nucleic 
acids contain carbon, hydrogen, oxygen, phosphorus and nitrogen. Generally, there are two
types of nucleic acid: deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The main 
functions of DNA are to store, and transfer, genetic information. DNA also acts as a template 
to produce new DNA and RNAs; while protein synthesis occurs via RNAs. Numerous reactions 
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are involved in the synthesis of such macromolecules, and this process is a challenge to the 
cell. The cell uses a modular method for the assembly of macromolecules by combining 
monomers called nucleotides. A phosphodiester linkage is used to join these monomers to 
synthesise a polynucleotide. There are three units forming a nucleotide: a nitrogenous base, 
a five-carbon sugar, and a phosphate group4 as outlined in Figure 1.1.
Figure 1.1: The structures of nucleobases, RNA nucleotides and DNA nucleotides.
1. Nitrogenous base: The nitrogenous bases1 in DNA are adenine, guanine, cytosine and 
thymine while RNA consists of the same nitrogenous bases except it has uracil instead of 
thymine.
2. The five-carbon sugar is ribose in RNA and deoxyribose in DNA. Importantly, the position 
of the hydroxyl group at the 2′-carbon of ribose contributes effectively to the secondary 
structure of RNA. RNA can be distinguished from DNA chemically by utilising alkaline 
solutions, due to the possibility for the deprotonation of the hydroxyl group of the sugar 
moiety causing hydrolysis of RNA strands.5
3. The third part of a nucleotide is the phosphate group that results from the esterification 
of phosphoric acid via connection to the hydroxyl group of a sugar at C5 to generate a 
phosphate ester. 
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The nitrogenous bases are connected to the sugar through a glycosidic bond to form a 
nucleotide; C1 at the sugar connects to N1 in a pyrimidine or to N9 of a purine. Common 
structures for nucleotides in DNA are shown in Figure 1.2.1
Figure 1.2: Common structures for deoxynucleotides.
It was revealed that one chemical defect in DNA involved the easy loss of an amino group 
from cytosine, thus changing the genetic information. Normally, cytosine interacts with 
guanine through hydrogen bonding in DNA double strands, but if the amino group is lost and 
it subsequently forms uracil, the resulting nucleobases would have the propensity to pair with 
adenine which could lead to undesired mutation.6 Lindahl concluded that the cell must have 
the ability to protect itself from this chemical defect. In 1974, he reported his detection of the 
bacterial enzyme that is responsible for the fixing of this damage to cytosine of DNA. This 
bacterial enzyme7 is named uracil-DNA glycosylase. 
In DNA and RNA, the phosphodiester linkage is formed by the connection of the 5′-phosphate 
group of one nucleotide with the 3′-hydroxyl of the sugar of the following nucleotide. Thus, 
the terminus of the resulting oligonucleotide derived from the 3′-hydroxyl of the sugar is 
named the 3′-end while that derived from the 5′-hydroxyl group is called the 5′-end. 
Consequently, their sequences are conventionally depicted from the 5′-end (left hand) to the 
3′-end (right hand). Principally, RNA occurs as a single-strand molecule that folds itself in such 
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a way as to make internal hydrogen bonding interactions that lead to characteristic secondary 
and tertiary structures, these then allow for a wide range of functional activities.8, 9
Structurally, RNA exists in all major life forms as three forms: ribosomal RNA (rRNA), transfer 
RNA (tRNA) and messenger RNA (mRNA). Ribosomal RNA represents approximately 80% of 
the total RNA in the cell and is complexed with protein to produce the ribosomes. The 
ribosome can be classified as two parts, the larger proportion is RNA that accounts for about 
65% and the smaller proportion is protein that accounts for about 35% of the total 
ribosome.10
The second form of RNA is tRNA that represents about 15% of the whole RNA in a cell and it
is found in many sequences, each one specifies a particular amino acid. The smallest part of 
RNA (less than 5%) belongs to mRNA which, in eukaryotes, is produced within the nucleus and 
transfers to the cytoplasm prior to protein synthesis. Functionally, the next step after 
producing mRNA is its translation into a protein. In this case, a “language” barrier exists. A 4-
letter code (A, U, C, and G) is utilised to write the mRNA while a 20-letter code is used to make 
proteins. Codons are represented by three nucleotides at a time. Each codon possesses the 
information limited to one amino acid. Mathematically, more than 20 codons exist (64 
possible codons) and there are only 20 amino acids that are directly genetically encoded with 
a codon. The overlap among of the codons is the reason that there are 64 codons, comprising 
only 61 codons for amino acids, with 3 stop codons.
DNA exists in the nucleus of the cell of eukaryotes and can also be found in organelles such 
as the mitochondria, but is free roaming around the cytoplasm of prokaryotes. In 1953, 
Watson and Crick introduced magnificent work on DNA structure by proposing an anti-parallel 
double helix structure of DNA. They reported that B-DNA is composed of two strands that are 
coiled around each other to generate a right-handed helix.11 The specificity of the double helix 
would be achieved via hydrogen bonding interaction between the nitrogenous bases 
between the two strands. There are two grooves on the surface of the strands with different 
width and depth and they are known as major (wide and deep) and minor grooves (narrow 
and shallow)12 as shown in Figure 1.3.
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Figure 1.3: Major and minor groove of the B- helix and schematic of the hydrogen bonding 
between nitrogenous base pairs, PDB 5F9I.13
This discovery, the complementarity of the double helix, caused a fundamental shift in the 
biological sciences through understanding how genetic information can be precisely 
replicated. After Watson and Crick’s deduction, it was discovered that DNA possesses many 
different structural forms. In addition, there are other forms of DNA double strands that could 
exist such as A and Z-DNA. The second type of DNA is A-form that also contains a right-hand 
double-helix like the B-form. The major groove in A-DNA tends to be narrow and deep while 
it is wide and shallow in the minor groove. A third type, Z-DNA has a remarkably different 
secondary structure from the other types of DNA. Structurally, the helix is left handed. The 
sugar–phosphate backbone takes on an asymmetrical zigzag. As mentioned before, RNA has 
a hydroxyl group at the carbon 2 position of the ribose sugar backbone and this prevents the 
formation of a B-form helix and triggers adoption of the A-form. The double helix of RNA is 
quite similar to the A-DNA form. The major groove of A-RNA is deeper and narrower than the 
minor groove thus leading to the minor groove being more accessible to contact with protein.
Introduction                                                                                      Chapter one
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1.2.1 DNA-Protein interactions
Nucleic acids and proteins are two of the most significant biomolecules in living systems.14 
Small molecules and proteins can interact with DNA15 through three distinguishable binding
modes: external interaction with the sugar-phosphate backbone, internal interactions in the 
major or minor groove, and intercalation. Electrostatic interactions primarily occur on the 
sugar-phosphate backbone. The protein-nucleic acid complex is formed by interaction 
between the side-chains of amino acids of the protein with the nitrogenous bases and sugar-
phosphate backbone. Hydrogen bonding is considered one of the most important forces in 
protein-DNA interaction, forming both sequence specific and non-sequence specific bonds 
between protein and DNA. The salient characteristics of DNA that can be recognised by 
protein are the major groove and minor groove, giving sequence specific interactions. Many 
forces contribute to binding in the protein-DNA structure. These forces include van der Waals, 
electrostatic forces, hydrogen bonding and water mediated hydrogen bonding. Many families 
of DNA-binding proteins have been identified16 and each family’s members possesses the 
same DNA-binding motif. These families involve helix-turn-helix (HTH) proteins, the 
homeodomains (HDs), zinc finger (coordinating) proteins, the steroid receptors, leucine 
zipper proteins and the helix-loop-helix proteins. The helix-turn-helix motif is considered the 
most known and most intensively studied motif that exists in DNA-binding proteins, both in
prokaryotes and eukaryotes. RNA polymerase and DNA polymerase are enzymatic examples
of natural proteins that bind to nucleic acid targets.17 Another example of natural proteins 
that bind with DNA is zinc fingers (Figure 1.4). The chain of zinc fingers folds along the DNA or 
RNA segments, binding in the grooves and extending the amino acids’ side chains to read the 
bases. Each zinc finger possesses an arginine amino acid extending from the alpha helix, 
which forms a hydrogen bond with Nitrogen 7 and also Oxygen 6 of the guanine that lies at 
the 3′ end of the binding site. The crystal structure of a zinc finger protein–DNA interaction, 
Zif268, was published in 1991.18 Recent studies of structures in the Protein Data Bank (PDB) 
showed that the majority of all protein interactions with DNA minor grooves at AT-tracks, are 
formed by arginine or lysine.19 The reagent p-hydroxyphenyl glyoxal (HPG) is widely used for 
determining if arginine side chains are included in mediating the binding between a protein 
and other ligands, by the modification of the guanidyl group when HPG reacts with exposed 
arginine residues.20
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Figure 1.4: Biological assembly of DNA with zinc fingers, PDB ID 4F6M.21
Many scientists have utilised these features in an attempt to design chemical compounds 
which can interact with several sites of the nucleic acid target to inhibit the expression of 
specific genes. Distamycin and netropsin are representative examples of natural small 
molecule heterocyclic polyamides that display sequence-selective binding to DNA. Distamycin 
has three N-methyl pyrrole heterocyclic amides, while netropsin has two N-methyl pyrrole 
heterocyclic amides. They are selective for binding to AT rich sites in the minor groove of DNA 
because the 2-amino groups of guanine blocks distamycin from binding to GC base pairs in 
the minor groove by steric hindrance.22 Figure 1.5 shows the interaction between distamycin 
and DNA. In addition, the recognition23 of AT-rich regions by minor groove binders is achieved 
by a combination of hydrophobic interactions, hydrogen bonding and electrostatic 
interactions. Thus, these cationic polyamides24 not only contribute to electrostatic 
interactions and hydrogen bonds with the polyanionic DNA, but also take part in van der 
Waals binding in the minor groove.
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Figure 1.5: Distamycin-DNA binding, PDB ID 2DND.25
Seeman et al.23 postulated that discrimination between different bases in a Watson-Crick 
double helix could be achieved by certain amino acids; thus, a molecular recognition code 
could be found. Seeman et al.26 and then Hélène et al.27 have suggested that the guanidine 
group in the arginine amino acid shows only hydrogen bond donors and could preferably form 
double H-bonds with the exposed edges of the guanine (Figure 1.6).
Figure 1.6: Seeman suggested double H-bonding between the guanidine group and the 
Hoogsteen face of guanine.
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Pabo is another researcher who has supported this supposition; he predicted that direct 
contact was achieved between the alpha helix of the protein and the major groove of the 
DNA.28 It was claimed by Matthews29 that the code for recognition is not simple due to the 
complexity of different DNA-protein complexes. Based on the survey of the crystal structure 
of many DNA-transcription factor complexes, Suzuki demonstrated30 those residues of some 
amino acids recognise a couple of chemical groups on the same DNA base and the interactions 
will be stronger in bidentate H-bonds than single H-bonding. Furthermore, it has been 
reported that Arg is more likely to be binding with guanine rather than any other of the 
nitrogenous bases, frequently through bidentate H-bonding. Gutfreund et al. agreed with 
Suzuki’s hypothesis and also reported that there is a specific binding between arginine and 
guanine.31 Luscombe et al. reported that the side chain of the arginine amino acid can be 
arranged in several geometries in order to donate dual H-bonds.32 To enhance the impact of 
the investigation performed by Seeman et al., Luscombe et al. have also reported that two 
possible interaction conformations could be observed: the end-on approach represents the 
most common conformation, which is contact with one or two of the distal nitrogen atoms 
Nη1 and Nη2 (Figure 1.7 A); and the side-on approach interacts with the side chain where the 
Nε and Nη2 are used for H-bond donation (Figure 1.7 B). Furthermore, it was observed that a 
single N atom in the guanidine group could donate two H-bonds and behave like a lysine 
residue to form bidentate interactions (Figure 1.7 C and D).
Figure 1.7: Bidentate interactions between arginine residue and the Hoogsteen edge of 
guanine noticed by Luscombe et al.32
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Based on computational analysis of 26 non-homologous protein-DNA complexes, which were 
taken from the Protein Data Bank and Nucleic Acid Database (NDB), Jones et al. have 
emphasised that the interactions between protein and DNA take place predominantly in the 
major grooves of the complexes.33 It is clear that the minor groove is too compressed to host 
common binding motifs. Other studies have suggested that the arginine amino acid has 
another feature which contributes to contact with DNA through electrostatic interactions i.e.
between the positively charged side chain and the negatively charged phosphate backbone 
of the DNA.31, 33, 34 These interactions contribute effectively to the stabilisation of the protein-
DNA complex.32, 35 In DNA-protein interactions, conformational change could be induced in 
the DNA’s secondary structure and the level of deformation can be expected to range from a 
slight kink,36 to the large bends noticed in the structure of the nucleosome.37 It has been 
noticed that the arginine side chain interacts regularly within this cramped minor groove.38 
This minor groove binding has been mainly located in distorted protein-DNA complexes.39 
1.2.2 Protein-RNA interactions
RNA-protein interactions play a significant role in many biological processes, such as 
translation and splicing. Structurally, protein-RNA complexes are much more diverse than 
protein-DNA complexes. The specific mechanisms of protein-DNA interactions are more well-
understood than those of protein-RNA interactions.16, 19, 40 Helical RNA is composed of
Watson-Crick base pairings of the four nucleobases. Instead of the classic B-form helices 
usually found with DNA, RNA forms A-form helices due to the steric hindrance from the 2′ OH 
of ribose. Furthermore, the major groove in the classic A-form helices is deeper and less 
accessible than the major groove in B-form helices and thus inhibits base binding between 
the arginine and guanine Hoogsteen edge. Non-Watson-Crick pairs in an RNA duplex, such as 
the GU wobble, GG and AA, also have a higher potential of becoming unpaired. As a result of
these non-WC base pairs loops, bulges and hairpins can form giving a flexible tertiary 
structure.41 An understanding of the molecular recognition of protein-RNA binding has 
proved difficult, due to little statistical information being available owing to a lack of x-ray 
crystal structure data. Jones et al. have achieved a structural survey of 32 protein-RNA 
structures from the PDB.42 They emphasised that arginine has a high tendency to be found in 
the binding site of protein-RNA complexes and that the interactions take place through 
hydrogen bonding with the phosphates. However, it has been reported that arginine residues 
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can interact strongly with phosphate oxygen atoms through electrostatic interaction, without 
the suitable geometry to form hydrogen bonds being found.43 Some researchers have 
suggested that arginine residues bind to the phosphate groups at the beginning and do not 
have hydrogen bonding specificity towards the bases.42, 44, 45 On the other hand, another 
proposal shows that bidentate interactions could take place between arginine residues and 
the Hoogsteen edge of guanine at O6 and N7 positions which corresponds with the 
interactions in protein-DNA complexes, although this is much less common for RNA.43, 46, 47, 48 
As a result of NMR experiments including the TAR RNA complex, it has been observed that 
the base-specific binding of arginine residues with the Hoogsteen edge of guanine leads to 
the formation of a nucleobase triple.41 Burke proposed that this binding is also necessary for 
aminoacyl-tRNA synthetases to catalyse the combination of an amino acid to its cognate tRNA 
in Escherichia coli.49 However, it has been noted that unpaired cytosine also interacts with the 
arginine residue, through dual H-bonds, at the Watson-Crick base edge (Figure 1.8 A),43, 46, 48, 
50, 51 Nη1 and Nη2 of an arginine residue can donate H-bonds to N3 and O2 in cytosine. Other 
interactions of arginine residues with nitrogenous bases in RNA have been reported. Kim has 
explained that a bidentate interaction takes place between arginine and uracil.51 This 
happened between O2 of uracil and Nε and Nη of the arginine residue (Figure 1.8 B).
Figure 1.8: Bidentate interactions between cytosine and an arginine residue (A) and 
bidentate interactions between uracil and an arginine residue in protein-RNA complexes (B).
Several studies have been carried out to explain the nature of the binding in protein-RNA 
interactions, and conflicting results have justified the difficulty in recognising a specific code 
for the recognition of a protein for its RNA target. Other functional classes of RNA can interact 
with protein, as Jones has reported.42 There are different classes of RNA that can interact with 
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proteins namely messenger RNA (mRNA), transfer RNA (tRNA) and viral RNA (vRNA). These 
classes of RNA have a higher number of contacts compared with ribosomal RNA (rRNA) due 
to more frequent helical structures in rRNA.45 However, it has been concluded that arginine 
has a much higher propensity than other amino acids to interact with different RNA functional 
classes.44 Overall, this part of the introduction has discussed many issues concerned with the 
molecular recognition between a protein and its RNA target. It can be summarised that the 
arginine amino acid is most likely to be present at the binding interface and although there 
have been different particular interactions reported, most research concludes that base-
specific interactions occur between arginine residues and the exposed edges of various base 
pairs.
1.2.3 Guanidines
Guanidine has attracted significant attention due to its useful applications and unique 
properties that cannot be easily replicated by other functional groups. It can, for example,
contribute to the stabilisation of protein conformations through hydrogen bonding, due to 
the hydrophilic nature of the guanidine group.52 There are three resonance structures of 
guanidinium and all are equivalent (Figure 1.9), thus, resulting in a large delocalisation energy 
and stabilisation of the positive charge. This leads to an increase in the basicity of guanidine. 
The pKa of guanidine is 13.6 so it is considered the strongest common organic nitrogenous 
base.53 In physiological conditions, guanidine is protonated and the cationic result 
(guanidinium) tends to be highly stable in an aqueous solution; therefore, it can form 
electrostatic interactions with opposite charges, such as that previously mentioned between 
arginine residue and the phosphate group in RNA and DNA. 
Figure 1.9: The resonance structures of the guanidinium cation.
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Experimentally, it was recorded53 that the protonation of guanidine occurs at the imino 
nitrogen because the other amino groups are less basic than the imine group atom by 30 
kcal/mol. On the other hand, electron-donating substituents such as an alkyl group on the 
nitrogen atom in guanidines causes slight increases in its basicity while attaching electron-
withdrawing groups such as OCH3, COCH3, CN and NO2 results in the reverse effect. However,
increasing the number of amino groups in the molecule causes a strong effect on the gas 
phase basicity. In general, molecules containing bi-guanidine groups are stronger bases than 
others having one guanidine. Table 1 shows the pKa values for guanidine derivatives.
Table 1: Experimental data of the pKa values for guanidine derivatives. n.d. – not 
determined.50 
 
The following sections are about synthetic strategies towards substituted guanidines.
1.2.3.1 The synthesis of guanidine from thiourea
Several reagents have been used to convert a thiourea moiety into guanidinium 
functionalities. These reagents include N,N-dicyclohexylcarbodiimide (DCC), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), mercury (II) chloride 
(HgCl2), mercury (II) oxide (HgO) and 2-chloro-1-methylpyridinium iodide (Mukaiyama’s 
reagent).
Base pKa (MeCN) pKa (EtOH)
n.d. 17.1
25.96 n.d.
24.55 n.d.
19.43 n.d.
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1.2.3.1.1 DCC coupling
A novel guanidinium functionality has been synthesised54 through DCC coupling by Iwanowicz 
and co-workers and these guanidines have since been used as inhibitors of inosine 
monophosphate dehydrogenase. The synthetic route to 2 and 4 are depicted in Scheme 1.1.
Scheme 1.1: Utilising DCC coupling to produce a novel guanidinium functionality.
1.2.3.1.2 EDC coupling
Another approach to synthesise a guanidine derivative has been achieved by Jefferson and 
co-workers through the EDC coupling reagent as outlined in Scheme 1.2.55 
Scheme 1.2: The synthetic route to bicyclic guanidine by using the EDC reagent. 
Furthermore, cyanoguanidine 11 was synthesised by Wolin and co-workers through EDC 
coupling as in Scheme 1.3.56 
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Scheme 1.3: The preparation of cyanoguanidines by Wolin and co-workers.53
1.2.3.1.3 Mukaiyama’s Reagent 
This approach has utilised Mukaiyama’s Reagent (2-chloro-1-methylpyridinium iodide) to 
generate N,N′-substituted guanidine derivatives via an aromatic sulfonyl-activated thiourea 
intermediate as in Scheme 1.4.57 The first step in this synthetic route consisted of the 
conversion of a primary amine to the corresponding pentafluorophenyl thiocarbamate. This 
was converted to an aryl sulfonyl-activated thiourea by using PbfNHK. The final step involved 
the production of the guanidine derivative by the treatment of 13 with a secondary amine in 
the presence of Mukaiyama’s reagent in excellent yield.
Scheme 1.4: Utilising Mukaiyama reagent to generate N,N´-substituted guanidine
derivatives. a) Pentafluorophenyl chloroformate, DIPEA, CH2Cl2; b) Pbf-NH2, 
potassium t-butoxide, DMSO; c) Mukaiyama’s reagent, DIPEA, THF/DMF.
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Nagashima et al.58 have developed an efficient synthesis to produce malonamide derivatives as αvβ3 
antagonists that contain a guanidine moiety in their structure as outlined in Scheme 1.5. The protocol 
involved the guanylation of compound 18 with N,N´-bis (tert-butoxycarbonyl) thiourea, by utilising 
Mukaiyama´s reagent and trimethylamine, to produce the tert-butoxycarbonyl (Boc) protected 
guanidine derivative 20. The Boc protecting group was then removed by using 4 M HCl in dioxane to 
obtain the desired guanidine compound 21.
Scheme 1.5: The production of malonamide derivatives having the guanidine group 
in their structure.58 
The initial work towards the synthesis of functional guanidine has since been advanced by 
Rao while attempting to produce anti-viral drug leads.59 This synthetic route included 
preparation of a urea and then conversion to the corresponding thiourea 23 by using 
Lawesson’s reagent in dioxane. Production of a cyclic guanidine 24 was achieved via 
subjecting the thiourea to NH3AgSO3CF3 (Scheme 1.6).
Scheme 1.6: Rao’s methodology to synthesise cyclic guanidine.59 
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Another approach to synthesise a cyclic guanidine, this time possessing a quinazolinone 
heterocyclic skeleton has been reported by Jizhen et al.60 This cyclic guanidine 28 was 
generated by the reaction between Pbf-activated thiourea 26 and a primary amine via iodine-
mediated guanidinylation as outlined in Scheme 1.7. 
Scheme 1.7: The synthetic route to cyclic guanidine 28.
Girard et al. have published the preparation of a new bicyclic lactam having a guanidine group 
in the side chain (Scheme 1.8).61 The production of compound 30 was achieved through the 
coupling of 29 with N,N´-bis-t-butoxycarbonylthiourea 29A in the presence of HgCl2. The final 
step involved the hydrolysis of the ester, by adding sodium hydroxide, followed by the 
removal of the protecting groups, by adding TFA, to generate 5-(guanidinocarboxamido 
propyl)-1-azabicyclo [5.2.0] nonan-2-one-8-propionic acid 31.
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Scheme 1.8: Synthesis of a bicyclic lactam having a guanidine group in the side chain.
1.2.4 The chemistry of bicyclic guanidine
It could be expected that the conversion of the guanidine group into a rigid bicyclic guanidine 
framework gives the guanidine a specific hydrogen bonding direction, in a single face, giving 
new properties to its interaction with DNA or RNA strands.62 The formation of a rigid bicyclic 
guanidine framework gives new features to the guanidine; their impact is limited to three 
areas related to the steric and electronic features. The efficiency with which charge is
distributed over the molecule is one of these significant characteristics. The charge could be 
negative for guanidinate anions or positive for guanidinium cations (Figure 1.10). The 
delocalisation of charge can be explained as a simple orbital overlap between the nitrogen 
lone-pairs and the p-orbital of the sp2 carbon within the CN3 unit. Constraining the 
substituents of the non-amidine nitrogen N (3) atom, into the ring system (tertiary nitrogen),
leads to a preferable alignment for the lone-pair of this atom to be involved in the 
delocalisation scheme. However, the localised N (2)-C=N (1) is an essential fragment of neutral 
guanidines, and is where the majority of chemical processes shown by these molecules take 
place. The tertiary nitrogen N (3) therefore participates in specifying the electronic and 
physical properties of guanidines. 
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Figure 1.10: Resonance forms of the bicyclic guanidinate anion and bicyclic guanidinium 
cation.
The size of the rings of bicyclic guanidine imposes an additional geometric constraint on the 
molecule. This constraint determines the orientation of the frontier orbitals of the amidine 
nitrogen atoms. A wide projection band on purely geometric arguments is introduced by 
reducing the ring size from 6 to 5 membered rings. The differences among the molecular 
structures of guanidine, bicyclic guanidine (6-membered ring) and bicyclic guanidine (5-
membered ring) are shown in Figure 1.11.
Figure 1.11: Comparison between the projection of frontier orbitals for the {6, 6} - and {5, 5}
- bicyclic derivatives.
1.2.5 The synthesis of bicyclic guanidine
The synthesis of bicyclic guanidines has attracted remarkable attention over the past 60 years 
because of its uses in many fields of chemistry. Two strategies have been used to prepare the 
bicyclic guanidinium moiety. The earlier work implemented the cyclization of a mono-cyclic 
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guanidine,63- 67 while the second strategy centred on attaching the central carbon atom of the 
guanidine to a triamine.68-70
1.2.5.1 Differently sized rings for bicyclic guanidines
There are many different sized rings of unfunctionalised bicyclic guanidine and their 
abbreviations are as shown below in Scheme 1.9A.62 Earlier work to synthesise non-
functionalised bicyclic guanidines has used multi-step procedures,65 or expensive starting 
materials.70 In the patent literature, a simple method was published in 1990 to synthesise {6, 
6} - and {5, 5} - guanidines, hppH and Htbo, that involved a one- pot method (Scheme 1.9 B).71
As it is the simplest method to produce bicyclic guanidine, this procedure has been used 
commercially, driven by the potential use of the products in organocatalysis.72 Producing a 
non-symmetric {6, 5} - bicyclic model has also been achieved by using the same procedure as 
mentioned above.68 
Scheme 1.9: A. Different sized rings of bicyclic guanidine, B. Preparation of H-tbo and H-tbn.
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Another approach to construct differently sized rings of bicyclic guanidine has been reported 
as outlined in Scheme 1.10.66 The synthesis of these compounds has been started by the 
reaction between carbon disulfide, and 1, 4-diaminobutane 40, in ethanol to synthesise an
thiourea 41 followed by methylation at the sulfur atom to generate the intermediate 42. The 
reaction between compound 42 and ethanolic amine gave 43 that was converted to the 
corresponding halide 46 by treatment with PBr3. Next, the generation of Htbu 49 was 
achieved by the treatment of 46 with NaOH, finally producing 50 and 51 by using propanol 
amine and butanol amine respectively.
Scheme 1.10: Production of differently sized rings of bicyclic guanidine.
X-ray diffraction data showed a comparison of structural features of the differently size rings 
of bicyclic guanidine including {5, 5}, {6, 5}, {6, 6}, {7, 5} and {7, 6} and are listed in Figure 
1.12.68 In the “N (2)-C=N (1)” amidine component, it could be clearly observed that the 
distribution of carbon-nitrogen bond distances is equal for each molecule and were clearly 
defined for the C–N (1) and C–N (2) bonds. However, for N (3), there are a wide range of values 
for the degree of pyramidalisation (DP%) that are finally affecting the value of ∆C–N. It is 
unlikely to form a planar configuration (higher DP% values) in the presence of nitrogen N (3) 
(tertiary amine) especially with the bicyclic guanidine having five-membered rings, such as H-
tbo, H-tbn and H-tbd (n=5). This is in agreement with the retention of electron density at this 
position, thus, decreasing any delocalisation of these neutral compounds over the CN3 core 
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with greater values of ∆CN. However, these compounds have only recently been synthesised 
and they need further investigation,66 especially the implication of the changes in charge 
delocalisation. This will lead to a different effect in these compounds on their neutral, cationic 
and anionic forms, which is expected to lead to changes in chemical behaviour.
Figure 1.12: Definition of parameters used in the comparison of structural data.65
Another procedure to synthesise bicyclic guanidine is by using high-boiling point polyether 
solvents.73 These harsh conditions involving high reaction temperatures (200-250 °C), and 
long reaction times (2-3 days), are applied to avoid the use of the hazardous reagent carbon 
H-tbo H-tbn hppH H-tbd H-tbu
C-N1 1.346(2) 1.290(3) 1.328(2) 1.233(2) 1.293(2)
C-N2 1.297(2) 1.347(3) 1.367(2) 1.354(2) 1.356(2)
C-N3 1.391(2) 1.383(3) 1.331(2) 1.355(2) 1.394(2)
DP% 26.58 18.19 0.11 20.74 4.20
∆CN 0.048 0.057 0.039 0.062 0.090
∆'CN 0.070 0.065 0.038 0.069 0.034
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disulfide (CS2). The highest yields of 94% have been obtained when acyclic urea 52 was used 
as a starting material (Scheme 1.11). 
Scheme 1.11: The synthesis of bicyclic guanidine from monocyclic urea.
1.2.6 Substituted bicyclic guanidines
The synthetic route to produce a variety of aryl substituted bicyclic guanidines, has been 
described by Van Gelder et al.74 The formation of these compounds was achieved through 
two steps. The first step is to produce the aryl substituted monocyclic alcohols (Scheme 1.12
A). The second is the formation of the bicyclic guanidine by condensation or de-halogenation. 
In the same way, the alkylation of the N-benzyl monocyclic guanidine leads to the production 
of benzyl substituted bicyclic guanidines (Scheme 1.12 B). 
Scheme 1.12: The route to produce aryl substituted bicyclic guanidines by Van Gelder’s
synthesis.74 
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Another method to synthesise 2, 2- and 3, 3-diphenyl substituted {5, 5} bicyclic guanidines
(79 and 81 respectively) was described by Kosasayama et al. (Scheme 1.13).67 Formation of 
monocyclic guanidino alcohol was achieved in the first step, and then conversion of the 
alcohol group to the chloride 77 and 78, followed by intramolecular nucleophilic substitution 
then Red-Al reduction which produces the 2, 2-diphenyl derivatives 79 and 80. Increasing the 
temperature of this reaction to 200 °C leads to the production of 3, 3-diphenyl derivatives 81
and 82 which were thus synthesised by using this method.
Scheme 1.13: Preparation of 2, 2 and 3, 3-diphenyl bicyclic guanidines. i. (C2H5)3OBF4, 
CH2Cl2, Δ (88%); ii. H2NCH2(CH2)nOH, EtOH, Δ (n=1 85%, n=2 88%); iii. SOCl2, Δ (n=1 97%, n=2 
94%); iv. NaH, DMF (n=1 87%, n=2 88%); v. NaAlH2 (OCH2CH2OCH3)2, THF, Δ (n=1 57%, n=2 
62%); vi. NaH, DMF, Δ (n=1 88%, n=2 90%); vii. NaAlH2 (OCH2CH2OCH3)2, THF (n=1 29%, n=2 
81%). 
Schmidtchen described the first synthetic route to produce alkyl and allyl substituted bicyclic 
guanidine in 1980.70 The first step in this synthetic route comprises the conversion of 83 to its 
corresponding di-iodide and then the resulting product was alkylated with 83A (Scheme 1.14). 
The tetra-substituted di-ester product was converted to the corresponding di-acid 84 by an 
acid hydrolysis process. The next step included the preparation of the carboxylic azide
followed by a Curtius rearrangement and hydrolysis, which yielded the first part in 
Schmidtchen’s route to tetra-substituted diamines 86 and 87 respectively.
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Scheme 1.14: Schmidtchen’s route to produce the tetra-substituted diamine.70 i. MsCl, TEA, 
CH2Cl2 (90%); ii. NaI, (CH3)2CO (70%); iii. LDA, 83A, THF, 0 °C; iv. KOH, H2O, Δ (84 = 75%, 85 = 
73% 2 steps); v. Oxalyl chloride, DMF, PhH; vi. NaN3, H2O, (CH3)2CO, Δ, CCl4; vii. 6 M HCl, 
H2O, THF (86 = 71%, 87 = 72% 3 steps).
The final step in Schmidtchen’s protocol included the de-protection of the tosyl group to 
furnish a triamine. A thiouronium compound was then produced by the reaction between 90
and thiophosgene, followed by methylation to generate 94. The final step to produce α, α, α’, 
α’- [6, 6]-bicyclic guanidines 96 was achieved by treatment of 94 with sodium methoxide in 
methanol (Scheme 1.15).
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Scheme 1.15: The final steps in Schmidtchen’s route to produce tetramethyl and 
tetrapropenyl α, α, α’, α’- [6, 6]-bicyclic guanidines. i. Li, NH3 (l), THF (90 = 75%, 91 = 81%); ii. 
CSCl2, TEA, CH2Cl2 (92 = 80%, 93 = 81%); iii. MeI, CH3NO2; iv. NaOCH3, CH3OH or KOt-Bu, t-
BuOH (96 = 79%, 97 = 70% 2 steps). 
A synthetic route to methyl and ethyl β, β, β’, β’- [6, 6]-bicyclic guanidine derivatives has been 
published by Cotton and co-workers.75 The synthetic route involved using a Mannich-style 
reaction to get an intermediate compound (tetra-methyl and ethyl triamine) followed by 
Raney® nickel hydrogenolysis, the final step being a cyclisation to obtain substituted bicyclic 
guanidine 101 (Scheme 1.16).
Scheme 1.16: The synthetic route to methyl and ethyl β, β, β’, β’- [6, 6]-bicyclic guanidines 
as reported by Cotton.75 
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Building on prior developments in the synthesis of substituted bicyclic guanidine, the bicyclic 
guanidino tetra ester has been synthesised by Jadhav et al,76 using a Pinner reaction to 
produce the iminium intermediate 105 (Scheme 1.17). The next step included hydrogenolysis, 
after which the cyclisation was achieved by heating in TEA to generate bicyclic guanidine 106. 
Scheme 1.17: The synthetic route to bicyclic guanidine tetraethyl ester.76 
A C2 symmetric chiral bicyclic guanidine has been synthesised as early as 1989 by Corey and 
Ohtani (Scheme 1.18).77 Many steps have been used in their synthetic route; the first step 
included using α-phenylglycine methyl ester as a starting material to synthesise a 
monoprotected diamine 110, and an N-protected amino acid 108. These are then coupled to 
produce substituted a triamine 111 followed by hydrogenolysis and reduction. The formation 
of thiourea 112 was achieved by reaction with thiophosgene and then cyclisation was induced 
by the methylation of the sulfur atom to yield the C2 symmetric chiral bicyclic guanidine 113.
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Scheme 1.18: Synthesis of chiral C2 symmetric chiral bicyclic guanidine by Corey et al.77 i. H2, 
PtO2-H2O, AcOH, 23 °C; ii. Cbz-Cl, Py, CH2Cl2, 0 °C, 1 h; iii. NaOH, H2O/MeOH, 23 °C; iv. NH3, 
MeOH, 0 °C, 3 h, 23 °C, 16 h, 84%; v. H2, PtO2-H2O, AcOH, 23 °C, 40 h (87%); vi. TrCl, TEA, 
CH2Cl2, 23 °C, 97%; vii. LiAlH4, Et2O, reflux, 95%; viii. DCC, HOBt, 108, THF, 77%; ix. H2, 10% 
Pd/C, 1:1 THF/MeOH, 23 °C, 100%; x. Red-Al, PhH, reflux, 76%; xi. CSCl2, Na2CO3, 1:1 
CH2Cl2/H2O, 95%; xii. MeI, MeOH, 60 °C, 100%; xii. DMF, 100 °C, 60%; xii. MeI, MeOH, 60 °C; 
xiii. DMF, 100 °C, (55% over 2 steps).
Schmidtchen and co-workers have synthesised asymmetric chiral bicyclic guanidines as 
anchor modules for oxoanionic functions i.e. the interaction of bicyclic guanidine with 
oxoanionic functions such as carboxylate.78, 79 L-methionine and L-asparagine were starting 
materials in their synthetic route. L-methioninol was produced, silyl protected and then 
reacted with thiophosgene to obtain the corresponding isothiocyanate 117. Next this was 
coupled to a tosyl protected diamino alcohol 114A (prepared from L-asparagine) to obtain 
thiourea. Methylation of 118 at the sulfur atoms gave chiral bicyclic guanidine 119 (Scheme 
1.19).
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Scheme 1.19: Synthetic route to synthesise asymmetric chiral bicyclic guanidine. i.Ts-Cl, 
(CH3)2CO (80%); ii. LiBH4, TMS-Cl, THF (86%); iii. BH3.DMS, THF (85%); iv. TBDPS-Cl, 
imidazole, CH3CN (yield not given); v. CSCl2, Na2CO3, CH2Cl2/H2O (1:1) (87%); vi. 114A, CH3CN 
(85%); vii. TBDPS-Cl, imidazole, CH2Cl2 (91%); viii. a) TEA, MeOTf, b) TEA (87%).
Jadhav et al.80 have reported another strategy to synthesise substituted bicyclic guanidino 
compounds as outlined in Scheme 1.20. This strategy included guanidinylation of L-α-
methionine, and then induced cyclisation via methylation at the sulfur atom and the addition 
of an excess of base to obtain 123.
Scheme 1.20: Guanidinylation of L- methionine to synthesise di-substituted bicyclic 
guanidine.
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The reagent 2-chloro-1,3-dimethylimidazolinium chloride (DMC) has been used by Isobe et 
al.81 to synthesise diphenylbenzyl and triphenyl substituted bicyclic guanidines (Scheme 1.21). 
A number of silylated amino alcohols were converted in two steps to isothiocyanates 130-132
which were reacted with a protected diamine to synthesise thioureas 133-135. Monocyclic 
guanidine 136-138 were produced from the thiourea by adding DMC, followed by removal of 
the silyl protecting group. A second treatment with DMC then afforded the bicyclic guanidines 
139-141.
Scheme 1.21: Isobe’s approach to produce triaryl substituted bicyclic guanidine.81 i. TBDMS-
Cl, TEA, DMAP, CH2Cl2 (100%); ii. CS2, TEA, CH2Cl2; iii. DMC, TEA, CH2Cl2 (96% 2 steps); iv. 
CH2Cl2, reflux (98%); v. DMC, TEA, MeCN, reflux (88%); vi. TBAF, THF (96%); vii. DMC, TEA, 
MeCN, reflux (57%); viii. NaOMe, MeOH (89%).
Turočkin et al.82 have reported the synthetic route to produce tricyclic guanidinium salts
(Scheme 1.22), inspired by the strategy that Kim reported to generate a guanidine salt, using
the reaction of bis-Boc-thiourea with pyrrolidine (143) in the presence of mercury chloride.83 
The resulting product 145 was reacted with compound 142, in the presence of NaH in 
anhydrous DMF, to produce 146. Removal of the protecting groups followed by chlorination 
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gave compound 148. The final product 149 was synthesised through intramolecular 
substitution by the treatment of 148 with strong base NaH.
Scheme 1.22: The synthesis of a chiral benzoguanidinium cation.
A synthetic route to bicyclic guanidine fused to aromatic rings and displaying variable 
substituents has been published by Molina as outlined in Scheme 1.23.84, 85, 86 The core 
principle of this synthetic route involved the treatment of bis(iminophosphoranes) with aryl 
isocyanates or isothiocyanates to generate a wide variety of tetracyclic compounds which 
possess bicyclic guanidino functionality.
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Scheme 1.23: Molina’s synthesis of bicyclic guanidine derivatives.
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Grillot and Hart have reported a procedure to synthesise a bicyclic guanidine functionalised 
at the C3 position as in Scheme 1.24.87 The central consideration in their synthetic route is 
the production of substituted triamine 158.
Scheme 1.24: The synthesis of substituted triamine 158.87
Removal of the Cbz and benzyl protecting groups was achieved and then the thiourea 
compound 159 was produced. The final step involved methylation at the sulfur atom and then 
intramolecular nucleophilic substitution to form the bicyclic guanidine 160 followed by
removal of the protecting groups to generate 161 as shown in Scheme 1.25. 
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Scheme 1.25: The synthesis of a bicyclic guanidine functionalised at the C3 position.
Batzelladines A – I are natural products that possess a polycyclic guanidine alkaloid in their 
structure. These natural products have been isolated by a SmithKline-Beecham group from 
Bahamian (batzelladines A – E) and Jamaican sponges (batzelladines F – I). 88, 89 The synthetic 
route to produce batzelladine D has been reported by Ishiwata and co-workers90 as outlined 
in Scheme 1.26. Compound 164 has been produced by the treatment of the 2, 5- disubstituted 
pyrrolidine with bis-Z-2-methyl-2-isothiourea in the presence of mercury(II) chloride and 
triethylamine. The production of 165 has been successfully performed in 86% yield over 7 
steps.
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Scheme 1.26: The synthetic route to batzelladine D by Ishiwata et al.90
An interesting strategy involving the use of solid phase chemistry was applied to produce a 
series of functionalised bicyclic guanidines by Nefzi et al. as shown in Scheme 1.27.91 By 
utilising borane as a reducing agent, tripeptides containing different functional groups were 
converted to their corresponding triamines. Cyclisation was then achieved by utilising 
thiocarbonyl diimidazole reagent and then removal from the resin led to the production of a 
library of trialkyl-substituted bicyclic guanidines. Later on, this strategy was used to synthesise 
libraries of bicyclic guanidines tri-substituted with a variety of amino acid side chains.92
Scheme 1.27: The synthesis of functionalised bicyclic guanidine by utilising solid phase 
chemistry.
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1.2.7 Synthetic modification of peptides and proteins
This synthetic modification can be achieved by first modification of an amino acid side chain, 
followed by incorporation of the amino acid into the peptide/peptidomimetic or protein by 
chemical or biochemical (translation) synthesis. Alternatively, the bioconjugation strategy can 
be followed in which peptide/protein is synthesised first, and then an amino acid selectively 
modified. This is easier to apply to proteins, as these are challenging to make by chemical 
synthesis. Bioconjugation plays an important role in bio-organic synthesis,93 and this synthetic 
approach is utilised to covalently join a biomolecule to another component to produce a 
stable conjugate that combines the properties of both components. This technique gives 
researchers potential access to a wide range of natural or synthetically valuable products that 
prove difficult to synthesise by stepwise chemical synthesis.94 The ability to produce 
complicated molecules by conjugation reactions that could be used in many fields such as 
therapeutics,95 or diagnostics,96 is of particular importance. A bioconjugation reaction should 
have a number of desirable properties,97 namely: chemoselectivity and bio-harmony (non-
toxic), does not perturb the system of interest in an undesirable way and bio-orthogonality. 
If the conjugation reaction is to take place in a cell, then the reagent must enter the cell and 
reach the target for modification while not reacting with other molecules in the cell. A goal of 
our project is to make bicyclic guanidine (BCG) mimics of arginine. To achieve this, the BCG 
needs to be attached to a peptide. One way of doing this is to use asymmetric synthesis, chiral 
auxiliaries and/or resolution to produce an enantiopure BCG amino acid from scratch. A 
potentially simpler method is to make use of the reactivity of a natural amino acid side chain 
through which to attach the BCG. An advantage is that the existing amino acid provides the 
chirality. A variety of bioconjugation reactions for functionalising amino acids have been 
reported in the literature, the chemistry is therefore well established. In the following 
sections, the conjugation chemistry for covalently attaching molecules to amino acids will be 
briefly reviewed.
1.2.7.1 Thioether linkage
A good example of a potent nucleophile is the thiolate group in aqueous solution.98 Thus,
derivatives of proteins can be produced via the thiolate group of a cysteine side chain, and 
this approach is now considered a common protocol of bioconjugation.99 Interestingly, due 
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to their limited presence in natural proteins, site-specific conjugation can be generated at a
unique cysteine moiety.100 Scheme 1.28 shows bioconjugation through formation of either 
thioethers or disulfides by reaction of a halo acetamide, maleimide, or disulfide with cysteine.
Scheme 1.28: Bioconjugation through thioethers or disulfides. The treatment of thiolates 
with (A) a haloacetamide, (B) a maleimide, and (C) a disulfide, X= halogen.
Iodoacetamides were used to detect the presence of free cysteines in proteins because the 
thiolate on the cysteine moiety reacts more rapidly than other amino acid functional 
groups (Scheme 1.28 A).101 Recent studies reported that chloroacetamides displayed greater 
specificity than iodoacetamides toward cysteine moieties.93 In addition, maleimides could be 
used as electrophiles for thiol-mediated bioconjugation.102, 103 Succinimidyl thioethers have 
been formed via Michael addition by the reaction between the thiolate and maleimide 
(Scheme 1.28 B).98 Reactions A and B produced linkages that are stable in vivo. However, 
conjugation through a disulfide gives a linkage that is easily cleaved in vivo through reduction 
by glutathione. Thus, disulfides are best utilised specifically for in vitro applications, for 
example the crosslinking,104, 105 and immobilisation,106 of peptides and proteins. Martos et 
al.107 have reported another approach for the generation of thioether-linked chiral bicyclic 
guanidinium oligomers that are utilised for cell internalisation purposes. A Merrifield-like 
peptide synthesis technique was used to investigate this goal as given in (Scheme 1.29) below.
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Scheme 1.29: The synthesis of thioether-linked chiral bicyclic guanidinium oligomers.
1.2.7.2 Amide bond linkage
The most attractive feature of amide bond linkages is a long life of ca. 600 years at neutral 
pH.108 Amide bonds are formed by the reaction of molecules possessing an amino group and 
compounds having an activated ester. The formation of an amide bond through amine 
containing amino acids on peptides can produce impure products because of the presence of 
several primary amines in peptides. An amide bond could be formed at the lysine moiety, or,
at the N-terminus of the peptide and these possibilities can result in a complicated product 
mixture that leads to difficult purification, and hence an expensive bioconjugation strategy. 
The bioconjugation strategy named native chemical ligation offers another means to form an 
amide bond between peptides and proteins.108 This approach has often been used to connect 
fluorescent molecules to proteins.109 
A reaction can occur between the thiol of a N-terminal cysteine residue-possessing peptide 
and a thioester peptide to form an amide bond and regenerate the free thiol functional group. 
The reaction takes place through a trans-thioesterification followed by a S- to N- acyl 
migration, as in Scheme 1.30. The free thiol next to the new amide bond could also contribute 
a functional group for a second subsequent bioconjugation reaction, or produce undesired 
products via side reactions and dimerisation of the bioconjugate by disulfide bond formation. 
To resolve this problem, desulfurisation can be used to remove an unwanted cysteine,110 
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provided that the peptide or protein does not naturally include cysteine as a requisite for its 
structure or function.
Scheme 1.30: The native chemical ligation method to produce amide bonds. 
Another approach to produce bioconjugates via amide bond formation is by Staudinger 
ligation.111 This approach is similar to the original Staudinger procedure, that involves the 
reduction of an azide group to an amine by using the reagent triphenylphosphine. The 
formation of an amide bond through the Staudinger ligation method involves conjugating a 
ligand derivatised with an azide group to another ligand possessing a phosphine group and 
an acyl group that it utilises for the production of the amide bond. The Staudinger ligation
could be performed in a non-traceless manner (Scheme 1.31 A), leaving a phosphine oxide in 
the product, or in a traceless way (Scheme 1.31 B). The Staudinger ligation method has been 
used to introduce glycans onto cell surfaces. Generally, this technique is a very important 
strategy to generate homogenous bioconjugates that can be purified and characterised easily. 
The drawback of this method is the challenge of introducing non-natural azide-containing 
amino acids or carbohydrates into the cellular structure.112, 113
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Scheme 1.31: (A) Staudinger ligation with a phosphine oxide in the conjugate (B) Staudinger 
ligation without a phosphine oxide in the conjugate.112 
1.2.7.3 C-N Double bond conjugation
The formation of a carbon-nitrogen double bond is another approach that could be used in 
bioconjugation chemistry. This double bond is formed by the reversible reaction between an 
amine with an aldehyde or ketone functional group to produce an imine bond. Subsequently, 
the formation of a more stable linkage can be achieved by reducing the imine bond. This 
approach could be used specifically in order to connect carbohydrates to proteins.114 Another 
strategy to generate a carbon-nitrogen double bond was achieved by the reaction between 
hydrazine or alkoxyamine compounds, with an aldehyde or ketone functional group, to 
generate hydrazone (C=N-N) and oxime (C=N-O) linkages. The stability of these linkages is 
higher than imine linkages but they can also be susceptible to hydrolysis. However, this 
strategy could also be applied in bioconjugation chemistry, especially in applications that do 
not need long term stability. An elegant example of this approach is the linkage between 
peptides and glass slides to generate microarrays to reveal antibodies in blood samples and 
cell adhesion assays.115, 116 Figure 1.13 depicts the E geometry of the C-N double bond in an 
imine, hydrazine and oxime.
Figure 1.13: C-N Double bond bioconjugation.
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Typically, the Schiff base can be reduced to a secondary amine by utilising sodium 
cyanoborohydride; this reaction is called reductive amination as outlined in Scheme 1.32. 
 
Scheme 1.32: The formation of a secondary amine by reductive amination.
1.2.7.4 Linkages by cycloaddition
The usage of Cu(I) as a catalyst contributes to the acceleration of the Huisgen azide-alkyne 
1,3-dipolar cycloaddition to produce a stable 1,4-disubstituted (1,2,3)-triazole linkage and this 
is one example of a “click reaction” (Scheme 1.33 A). Sharpless intended the term to be used 
for reliable, selective, mild reactions. This azide-alkyne reaction has many positive features 
that leads to its utilisation in generating bioconjugates; these features include purification by 
simple product filtration,117 and high stability at elevated temperature and over a range of pH. 
Another advantage for the click reaction is that both reactants in the click reaction (the azide 
and alkyne functional groups) do not react with other functional groups found in biomolecules 
leading to the formation of homogenous conjugates. The rigidity of the formed triazole 
linkage leads to minimised interactions between the combined ligands, thus resulting in a low 
propensity to aggregate and minimising the potential for a reaction to occur between two 
ligands. However, the copper catalysed click reaction is not useful in vivo due to the presence 
of Cu (I) that leads to cytotoxicity.98 The strain promoted reaction (Scheme 1.33 B) is a copper 
free alternative that is suitable for in vivo use.118 The applications of the click reaction have 
included a wide range of bioconjugations, such as labelling of peptides, proteins and DNA.118 
Scheme 1.33: (A) Cu (I)-catalysed Huisgen 1, 3-dipolar azide-alkyne cycloaddition and (B) 
strain-induced Huisgen 1, 3-dipolar azide-alkyne cycloaddition.
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1.2.7.5 Ether linkage
The ether linkage has been used to produce organic peptidomimetic antagonists for inhibiting 
angiogenesis in inflamed and tumour tissues and metastases. The synthetic route for these 
compounds started with a protected tyrosine 171, and then used a conjugation to attach an 
alkyl halide to the side chain, and ultimately gave guanidine 177.119 Scheme 1.34 shows one 
of the synthetic routes to small molecules that contribute to construction of a polypeptide. 
Scheme 1.34: The synthesis of a non-natural amino acid through ether linkage.119
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Recently, a non-canonical amino acid, possessing long side-chain thiols was produced through 
forming an ether linkage.120 After that, a library of random β-lactamase mutants having these 
noncanonical amino acid was also constructed. Liu et al. reported that these noncanonical 
amino acids contribute to improved stability of the protein through the introduction of 
disulfide bridges. These bioconjugates have been synthesised by the reaction between a 
protected tyrosine amino acid with dibromo alkanes in the presence of potassium carbonate 
as outlined in Scheme 1.35. The resulting ether 179 was reacted with KSAc to produce 
compound 180. Compound 181 was formed in two steps, the first step included hydrolysis of 
the thioacetate by adding 2 M NaOH followed by the second step of adding HCl to cleave off 
the Boc protecting group. 
Scheme 1.35: The synthesis of a non-canonical amino acid through an ether linkage.120
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1.2.8 The aim of this research
As described in the previous sections, arginine forms crucial interactions for the molecular 
recognition of nucleic acids by proteins. The formation of bicyclic guanidine provides a 
constraint on the orientation of the guanidine group which could then result in a smaller loss 
in conformational entropy on binding to its target. Furthermore, a rigid bicyclic framework on 
the guanidine group would produce only one mode hydrogen bond when it interacts with its 
targets. Thus, bicyclic guanidines may be superior building blocks to arginine for specific 
recognition of nucleic acids by small molecules. From the literature survey, it is observed that 
the synthesis of bicyclic guanidine has attracted growing attention due to their usage in many 
fields of chemistry. The present work considers the synthesis of differently sized rings of 
bicyclic guanidine, having alcohol or amine functional groups in the side chain and then 
conjugation of these functional groups with an amino acid moiety to produce modified amino 
acids possessing a bicyclic guanidine in the side chain. The next chapter deals with the design 
and synthesis of differently sized rings of bicyclic guanidine derivatives, the synthesis of 
modified amino acids and the formation of dimer-bicyclic guanidine. 
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2.1 Introduction   
Due to the specific properties of guanidinium on the side chain of arginine, it is considered an 
important component commonly used by proteins to recognise its nucleic acid target. These 
specific properties that involve exact patterns of hydrogen bonding and the high degree of 
basicity leads the guanidinium group to play an important role in the recognition between a 
protein/peptide and its nucleic acid target. The arginine amino acid side chain contains a 
three-carbon aliphatic straight chain linked to the guanidinium group, which gives much 
torsional freedom, a group that then interacts with its target molecules through dual H-
bonding donation.               
Converting the guanidine group into a rigid framework, bicyclic guanidine, would minimise 
the loss in conformational entropy on contacting its target and the hydrophobic hydrocarbon 
residues will certainly result in a well-defined structure. Thus, orienting the hydrogen bonding 
direction in only one mode with accurate positioning of the guest relative to the host 
structure, might produce the highest of degree of specificity when discriminating between a 
wide range of targets. However, the formation of a rigid bicyclic framework causes a decrease
of rotational freedom about C-N bonds and total absence of geometric isomerisation of the 
C=N double bond. On the other hand, producing differently sized rings of bicyclic guanidine 
derivatives could contribute to the hydrophobic interaction with DNA as the hydrophobicity 
increases gradually with the increase of the size of the ring of bicyclic guanidine. 
As it has been discussed in the introductory chapter, it was observed that the “N2-C=N1” 
amidine component for the different sized rings of bicyclic guanidine has the same 
distribution of carbon-nitrogen bond distances in all structures of non-functionalised bicyclic 
guanidine. On the other hand, it was noticed that the tertiary nitrogen N3 is responsible for 
attaining a different value for the degree of pyramidalization (DP%) which affects another 
parameter named ∆′CN. This parameter measures the contribution of N3 to the delocalisation 
of the “N2-C=N1” amidine. Looking back to the figure 1.12 in the introductory chapter, we 
can notice that the (DP%) of hppH (0.11) is less than that of H-tbu (4.20) so ∆′CN of hppH 
(0.038) is not too much bigger than that of H-tbu (0.034). Consequently, the geometry of the 
guanidine group of hppH is likely to be more planar than H-tbu and we can assume that our 
targets possess the same geometries. In addition, it is expected that the six membered ring 
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of our targets do not have a chair conformation because the guanidine has a desirable planar 
shape.
However, it is important to realize that the high basicity of guanidine leads to production
of the corresponding guanidinium cation upon protonation. Therefore, the formation of 
guanidinium cation leads to hydrogen bonding and electrostatic interactions with anions like 
phosphate groups. So, the purpose of preparing differently sized rings of bicyclic guanidine
(Figure 2.1) in the current work is to compare their interactions with DNA.
Figure 2.1: The structures of functionalised bicyclic guanidine [6,6] and [6,7].
In this chapter, there are four themes in our research concerned with design and synthesis of
bicyclic guanidine derivatives and non-natural amino acids. The first theme discusses the 
synthesis of bicyclic guanidine methylene amine. As mentioned previously in the introductory 
chapter, functionalised bicyclic guanidine can be generated via the cyclisation of thiourea, as 
reported by Schmidtchen et al.78 and Munster et al.121 Our novel strategy for the synthesis of 
bicyclic guanidine included modification of this synthetic route. The goal is to synthesise a 
non-natural amino acid containing a bicyclic guanidine residue, so production of a bicyclic 
guanidine is needed with functional groups in the side chain to permit its introduction into 
the moiety of an amino acid. In our group, the protected bicyclic guanidine methylene iodide 
was synthesised by Steven Hill but encountered many problems incorporating the amino acid 
moiety.122 It had a tosyl nitrogen protection (Figure 2.2), as an inexpensive model for Pbf. The 
tosyl group is not suitable for Fmoc solid phase synthesis though, as it cannot be removed 
using trifluoroacetic acid. One of the problems was that the alkyl iodide was unreactive 
towards nucleophiles which meant that attachment of the amino acid was not successful.
Therefore, our concern was to find a new strategy to address this goal. The synthesis of 
bicyclic guanidines containing an amine group in the side chain was considered as one of the 
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choices to investigate this goal. Then a reaction with Fmoc-glutamic acid or Fmoc-aspartic 
acid is necessary to prepare a non-natural amino acid through an amide linkage. 
Figure 2.2: Protected bicyclic guanidine methylene iodide which has been prepared by 
Steven Hill.122
Producing bicyclic guanidines with differently sized rings is considered as the second goal of 
this project; 1, 3-Diaminopropane-Pbf 183 and 1, 4-diaminobutane-Pbf 187 have been 
synthesised; these then form the unsubstituted ring of their respective bicyclic guanidine. The 
second theme of our project is the novel strategy to generate a differently sized rings of 
bicyclic guanidine methylene alcohol (Scheme 2.14), in a high yield, starting from an azido 
alkane amine and Boc-L-methionine as precursors for the synthesis of these bicyclic guanidine 
derivatives. Our focus was concentrated on the thiourea intermediate 196 which was used to 
produce bicyclic guanidine.  In the original procedure,78 the conversion of the thiourea to the 
functionalised bicyclic guanidine was achieved in one pot and in low yield due to the 
formation of a monocyclic by-product. In our strategy, monocyclic isothiourea was first 
produced and then the bicyclic guanidine formation was subsequently triggered by the 
hydrogenation of an azide group in the monocyclic isothiourea. This modification of the route 
will open a promising way to produce the functionalised bicyclic guanidine. The third theme 
involved a new strategy toward the synthesis of bicyclic guanidine methylene amine followed 
by conjugation with Fmoc-Glu-OAll to generate a modified amino acid.
The fourth theme in our research includes the preparation of a dimer-bicyclic guanidine. 
Furthermore, the crystal structure of 233 was successfully determined from crystals produced
by vapour diffusion during the routes to synthesise bicyclic guanidine derivatives.
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2.2 Result and Discussion
2.2.1 Retrosynthetic analysis
In this section, we approach the disconnection of functionalised bicyclic guanidine with Pbf 
protecting group for retrosynthetic analysis. We then propose three retrosynthetic routes 
towards functionalised bicyclic guanidine from simple starting materials. Retrosynthetic route 
A (Scheme 2.1) involved the disconnection of bicyclic guanidine to a substituted triamine 
intermediate that has been reported by Cotton and co-workers.75 The key challenge in this 
approach is presented by the final step involving the cyclisation of thiourea especially 
considering that Cotton and co-workers have used a substituted triamine without a protecting 
group, which leads to decreased reactivity of the amine group and thus inhibition of the 
production of bicyclic guanidine. It was reported that the cyclisation of triamine by utilising 
CS2 produced only monocyclised thiourea and the yield of the reaction was optimised by using 
a high boiling point solvent (triethylene glycol dimethyl ether) for three days.123 However, the 
production of bicyclic guanidine from monocyclised isothiourea needs harsh conditions, thus, 
synthesising bicyclic guanidine-N-Pbf seemed implausible to achieve especially with the 
presence of a deactivating Pbf protecting group.
Scheme 2.1: Retrosynthetic route A for bicyclic guanidine derivative.
Retrosynthetic route B (Scheme 2.2), involved the disconnection of a bicyclic guanidine 
derivative that formed the monocyclised isothiourea as in Scheme 2.2. The key challenge of 
this approach is the cyclisation of the monocyclic intermediate. A second potential obstacle 
in this reaction is steric hindrance from the methylene azide group which might be expected 
to inhibit the production of bicyclic guanidine. Consequently, the existence of the azide and 
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Pbf group around the nucleophile lead us to avoid using this route to produce our target 
molecule.
Scheme 2.2: Retrosynthetic route B of bicyclic guanidine derivative.
Retrosynthetic route C in Scheme 2.3 included the disconnection of bicyclic guanidine 
methylene to a monocyclic isothiourea which could be obtained from a thiourea. The thiourea 
can be obtained from the coupling of an isothiocyanate and diamino alkane-Pbf where the 
isothiocyanate is derived from the corresponding azido methionine derivative. Azido 
methionine is accessible from protected-methioninol, which in turn can be obtained from the 
commercially available Boc-L-methionine which is a cheap source of the stereocentre. 
Scheme 2.3: Retrosynthetic route C of bicyclic guanidine derivative.
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2.2.2 Novel strategy to synthesise functionalised bicyclic guanidine 
It was noticed that the synthetic pathway proposed by Schmidtchen et al. was undesirably 
long to synthesise a bicyclic guanidine derivative, commencing from a starting material of 
Boc-L-methionine to reach the target.78 Thus, we devised a novel strategy for the synthesis of 
the protected bicyclic guanidine methylene amine that had a shorter pathway than the 
previous synthetic route. Our new synthetic protocol depends on the conversion of the 
alcohol group of Boc-L-methioninol to a good leaving group by reaction with mesyl chloride 
in the presence of triethylamine. Then the resulting product was heated with sodium azide in 
dry dimethylformamide to generate the corresponding azide. Deprotection of the Boc group 
was achieved followed by the formation of isothiocyanate by the reaction with thiophosgene. 
Furthermore, diaminoalkane-Pbf is considered to be an important part of this synthetic route 
to generate of bicyclic guanidine rings of different sizes; so, if the alkane contains 3 carbon 
atoms, the unsubstituted ring of the bicyclic guanidine will be 6-membered while if it contains 
4, it will be 7-membered. It is important to mention that the Pbf protecting group is the 
standard one that is used for Arg. It has the advantage that it is removed relatively rapidly 
with TFA. By introducing it at the start of the synthesis, it was hoped that this would reduce 
the need for protecting group manipulations later on. There was a precedent for the 
cyclisation reactions working, even with the sulfonamide protection (e.g. Steven Hill’s work 
with tosyl).122 The coupling of diaminoalkane-Pbf with the azido isothiocyanate resulted in 
the formation of an azido thiourea. The next step included the formation of bicyclic guanidine 
methylene azide via two steps. The first step was methylation at the sulfur atom and then the 
next step involved induced cyclisation. Finally, the hydrogenation of the azide group was used 
to obtain a bicyclic guanidine methylene amine 201.
2.2.1.2 The synthesis of Pbf-Cl reagent
In synthetic organic chemistry, compounds need appropriate protection during reactions to 
achieve the clean formation of new compounds and prevent the formation of undesired by-
products. Arginine is one of the compounds that needs protecting because of the propensity 
of the guanidine group to undergo side reactions due to its nucleophilicity. The main features 
of Pbf are its stability towards bases and catalytic hydrogenation and complete protection of 
guanidino side chain. In our synthetic protocol, the reagent PbfCl was used frequently and 
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although it is commercially available, unfortunately, it is expensive and of variable quality.
Therefore, it has been prepared as in Scheme 2.4 by using the cheap starting materials of 
isobutyraldehyde and 2, 3, 5-trimethyl phenol in the presence of sulfuric acid, as discussed in 
the literature.124 Purification of this product has been achieved by Kugelrohr distillation to 
attain the white solid, Pbf, 178. 
Scheme 2.4: The synthesis of reagent PbfCl.
The chlorosulfonation of Pbf was performed by adding 2 equivalents of chlorosulfonic acid to 
the compound 178 at 0 °C.125 It is important to mention that the duration of addition plays a 
significant role in obtaining a good yield as shown in the Table 2.1. After that, the mixture was 
poured into an iced solution of sodium bicarbonate to quench and then extracted with 
dichloromethane; thus, producing a silver solid PbfCl which has been used without further 
purification. This reagent was verified by 1H and 13C NMR spectroscopy, mass spectrometry 
and IR spectroscopy, all of which showed consistency with the literature spectra.
Entries Duration of addition (min) Yield (%)
1 30 50
2 60 65
3 120 70
4 150 75
5 180 80
Table 2.1: The conditions of PbfCl formation.
Results and discussion                                                                                                       Chapter two
54
2.2.1.3 The synthesis of diamino alkane-Pbf
The production of diaminoalkane-Pbf with different alkyl chain lengths has been 
accomplished by using two different starting materials as shown in Scheme 2.5. The 
commercially available 3-bromo-1-amino-propane hydrobromide was reacted with sodium 
azide to produce 3-azidopropyl-1-amine via nucleophilic substitution. The resulting 
compound was protected with the Pbf protecting group. Compound 187 was synthesised by 
using 1,4-dibromobutane as a starting material, which was reacted with sodium azide to 
generate 1,4-diazidobutane. Selective hydrogenation was achieved by using a biphasic 
mixture of triphenyl phosphine in ether/ethyl acetate and aqueous HCl.126 The initially formed 
azidoamine is protonated by the acid and partitions into the aqueous layer to prevent the 
over-reduction to diamine. After the organic layer is removed, the aqueous layer was washed 
with diethyl ether to remove the residual triphenylphosphine oxide and non-ionic organic 
reagents. A base was added to the aqueous layer followed by extraction with 
dichloromethane to give 1-azido-4-amino-butane 185 followed by adding PbfCl to generate 
compound 186.
The hydrogenation of the azido compound 186 was achieved by using Pd on activated carbon 
in ethanol in a hydrogen atmosphere to obtain diamino alkane-Pbf 187. Before embarking on
alternative conditions, the yield was about 75%; then another attempt was used to improve 
the resulting yield by using methanol instead of ethanol and this gave a good yield of 92%.
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Scheme 2.5: The synthesis of diaminoalkane-Pbf.
Another approach that was used to reduce azido alkane-Pbf was by using ammonium chloride 
and activated zinc in ethanol and water. After heating for 2 h, an ammonia solution was 
added. The advantages of this procedure are the short time (2 hours) taken to obtain the 
product and attaining a high yield 98%. A longer reaction time (12 hours) was required using
the alternative approach (cat. hydrogenation) to complete consumption of starting material. 
Interestingly, a crystal structure was obtained of Pbf-protected-3-aminopropanenitrile (183A)
as a by-product contained within the crude protected-1,3-diamino-propane, 183. Similarly, a
crystal structure of protected-4-aminobutanenitrile (187A) was obtained from the crude 
sample of protected 1,4-diamino-butane, 187. Palladium catalysed decomposition of azides 
to nitriles has been reported in the literature127 and it appears that this reaction has competed 
with the desired hydrogenation. The samples were crystallised from EtOH/H2O solution by 
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vapour diffusion, and the polar solvent mixture has favoured crystallisation of the minor 
nitrile impurity in preference to the more polar amine. Compound 183A and compound 187A
crystallised in the orthorhombic system space group P212121. Full crystallographic data are 
included in Appendix 6.1 and 6.2.
It is preferable to discuss the propyl compound (Figure 2.3 A), as the R factor is lower and 
there is less disorder at the terminus of the alkyl chain. The structure is consistent with a 
nitrile and not the amine due to the linearity of atoms (CCN angle 179.2°) and short C-N 
distance (1.16 Å). The 1H NMR spectrum recorded for 183A using CDCl3 as a solvent showed 
the appearance of a triplet peak at 3.10 ppm that corresponds to the terminal CH2CN protons
of 183A. A comparison of the integration of this triplet with the integration of a singlet peak 
belonging to a methyl group showed the presence of 7% of the nitrile compound 183A in the 
sample of crude amine sample.
Figure 2.3:  Thermal ellipsoid plot of A -183A and B -187A showing ellipsoids at the 50% 
probability level. 187A is modelled as two conformations with occupancies of 0.61 and 0.39.
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2.2.1.4 The synthesis of azido isothiocyanate
The synthetic route to prepare azido isothiocyanate 195 as shown (Scheme 2.6) started with 
the precursor Boc-L-methionine which was reduced to Boc-L-methioninol 191 by using two 
steps. The first step involved activation of the Boc-L-methionine by stirring it with ethyl 
chloroformate and N-methyl morpholine to form a mixed anhydride. The second step being
reduction of this anhydride to the Boc-L-methionine by utilising the reducing agent sodium 
borohydride. The Boc-L-methioninol was collected in a yield of 75% and needed no further 
purification. Converting the alcohol group of the Boc-L-methioninol to a good leaving group 
was achieved by the reaction with mesyl chloride in triethylamine. To run this reaction 
successfully, anhydrous conditions were required under a nitrogen atmosphere. Azido 
methionine was synthesised via nucleophilic substitution by the heating of mesylated 
methioninol with sodium azide. The 1H and 13C NMR spectra of 193 recorded were in very 
good agreement with the literature spectra.128 Deprotection of the Boc protecting group for 
193 was then carried out via acidic conditions, by adding 2 M HCl. The 1H and 13C NMR spectra 
of 194 showed that peaks at 1.38 and 28.5 ppm for 1H and 13C NMR respectively, belonging 
to the Boc protecting group, were absent from the spectrum. In addition, the IR spectrum 
displayed a characteristic stretch for the azide group at 2096 cm−1. Finally, the production of 
azido-isothiocyanate 195 proceeded by the reaction between compound 194 and 
thiophosgene in the presence of sodium carbonate in a relatively high yield. The 13C NMR 
spectrum of this product displayed a resonance at 135 ppm, indicating the existence of the 
N=C=S functionality in this structure.
Results and discussion                                                                                                       Chapter two
58
Scheme 2.6: The synthetic route to azido isothiocyanate 195.
2.2.1.5 Thiourea azide formation
The formation of thiourea azide was achieved by the coupling of equimolar amounts of 
isothiocyanate azide and di-aminoalkyl-Pbf as in Scheme 2.7 below. The azido thiourea was 
generated in a good yield as a yellow foam. 
Scheme 2.7: The formation of azido thiourea 196 and 197.
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With regards to the conformation of the substituted thiourea, earlier studies reported that N, 
N′-disubstituted thioureas could be found in solution in different rotameric forms.129 1H NMR
spectra recorded for compound 196 showed splitting of some peaks which indicated the 
presence of a rotational isomer around CS. It is assumed that these rotamers generate the 
complexity in the NMR spectra. 1H NMR spectra were recorded in the range from 30 °C to 50 
°C in CDCl3 and when the temperature increases, the signal became sharpened and more 
defined. The 13C NMR spectra showed the peaks of CS at 182.1 and 181.4 ppm for azido 
thiourea 196 and 197 respectively; and also, the IR spectra recorded a characteristic azido 
stretch at 2096 cm−1 for 196 and 2093 cm−1 for 197.
2.2.1.6 Bicyclic guanidine methylene azide
This thiourea compound has been utilised as a precursor for the generation of a bicyclic 
guanidine derivative through a one pot, two steps reaction as in Scheme 2.8. The first step 
included the methylation at the sulfur atom by adding methyl triflate at 0 °C and then 
cyclisation was induced by adding an excess of diisopropylethylamine to produce compound 
198. Unfortunately, the yield after purification was only a modest 60%. 
Scheme 2.8: The synthesis of bicyclic guanidine methylene azide 198.
The resulting product was characterized by 1H NMR spectroscopy and the methyl sulfur peak 
at 2.06 ppm in compound 196 was noted as disappearing in compound 198. The 13C NMR 
spectrum showed a disappearing (C=S) peak at 181.4 ppm and the mass spectrometry result 
was consistent with the compound 198. In an effort to produce bicyclic guanidines with 
different sized rings, the same procedure was used as in the previous product. Commencing 
from the compound 197, cyclisation to produce compound 199 was attempted according to 
Scheme 2.9 below:
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Scheme 2.9: Attempt at preparation of a bicyclic guanidine containing a 7-membered ring.
The cyclization of compound 197 using MeOTf and DIPEA yielded the monocyclized 
isothiourea 200 instead of the doubly cyclised product 199 (Scheme 2.9). Unfortunately, all 
attempts to achieve the production of this compound have not succeeded and stopped at the 
monocyclic stage. A high boiling point solvent (triethylene glycol dimethyl ether) was used for 
three days for this reaction to induce cyclisation of the second ring, but the process failed. As 
mentioned, the distance between the protected amine group and the thiocarbonyl group 
became bigger relative to compound 196 and resulted in generating only a monocyclic 
product. 
The low reactivity of the sulfonamide nitrogen represents another challenge in the ring 
closure reaction. The mass spectrum and 1H NMR spectrum for the resulting product showed 
that only a monocyclic product had been produced. However, the double cyclised product, 
bicyclic guanidine containing 7- membered rings was not attained under any conditions. Table 
2.2 shows the various conditions used in an attempt to synthesise 199.
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Entries Reagent Time, 
hours
Temperature,
°C
Solvent % of 
monocyclic
1 DIPEA, 
MeOTf
24 45 DCM 68
2 DIPEA, 
MeOTf
24 63 CHCl3 70
3 DIPEA, 
MeOTf
48 45 DCM 72
4 DIPEA, 
MeOTf
48 216 Triglyme 73
5 DIPEA, 
MeOTf
72 216 Triglyme 75
Table 2.2: The conditions used to synthesise compound 199.
2.2.1.7 The formation of bicyclic guanidine methylene amine
Hydrogenation of the compound 198 into the amine 201 was accomplished by using the 
catalyst Pd/C 10% in methanol under a hydrogen atmosphere to afford the amine in an 84% 
yield as in Scheme 2.10 below. 
Scheme 2.10: The synthesis of bicyclic guanidine methylene amine.
2.2.1.8 Attempts to synthesise a non-natural amino acid 
Starting from a carboxylic acid, a common method to form an amide bond is by first reacting 
the acid with an activating agent. The resulting activated acid derivative is then reactive 
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towards a nucleophilic attack (Scheme 2.11). This part is then more prone to nucleophilic 
attack by an amino group from another molecule to construct the desired amide.
Scheme 2.11: Activation of a carboxylic acid to form an amide.
Several activating agents were employed in attempts to synthesise a non-natural amino acid 
with a protected bicyclic guanidine side chain. Our design used a residue of Fmoc-Glu-OAll or 
Fmoc-Asp-OAll as an amino acid moiety to connect with the amine group in the side chain of 
our small molecule bicyclic guanidine. The first attempt included a modification of a 
procedure to synthesise aryl amides reported in the literature.130 Methanesulfonyl chloride 
and N-methylimidazole in dichloromethane was used to activate the carboxylic acid in the 
Fmoc-Glu-OAll and then compound 201 was added to the resulting solution as in Scheme 2.12 
below. The mixture was stirred for two hours, but unfortunately, the TLC indicated that there 
was no reaction over a 24-hour time period. It was suggested that the Rf of the product might 
be very close to the Rf of the starting material so 1H NMR and mass spectra were recorded
and again showed that no product had been formed.
Scheme 2.12: First attempt to synthesise a non-natural amino acid.
The second attempt was to use N, N'-dicyclohexylcarbodiimide as a reagent to activate Fmoc-
Glu-OAll as an HOBt ester. Unfortunately, the desired non-natural amino acid was not 
obtained. The 1H NMR spectrum showed the starting material’s peaks and mass spectra 
emphasised that no product had been formed. A common procedure that is utilised to 
generate an amide bond in solid phase peptide synthesis by using HOBt and PyBOP in DMF 
was employed in our work, but again the result was not successful. In my opinion, there may 
be a strong intra-molecular hydrogen bonding between the sulfone in the Pbf protecting 
group and the amine group which may prevent the formation of an amide bond.
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After this negative result, another approach was suggested as an alternate route to the non-
natural amino acid, namely the “click reaction” of copper(I) catalysed azide-alkyne 1,3-dipolar 
cycloaddition. Compound 198 was mixed with sodium ascorbate as a reducing agent in the 
presence of CuSO4·5H2O then compound 204 was added,131 as shown in Scheme 2.13 below.
Scheme 2.13: Attempt to synthesise a non-natural amino acid by click reaction.
Unfortunately, the desired non-natural amino acid was not generated. The 1H NMR spectrum 
of the attained material recorded that no product had been produced. The mass spectra 
showed that the isolated material is in fact only the starting material. Although the literature 
has reported that molecules having an arginine amino acid and alkyne could be conjugated 
by a click reaction to other molecules containing azide groups, this was not the case here 
surprisingly. In my opinion, the copper has probably chelated with the guanidine group
diminishing its catalytic activity.
2.2.2 A novel synthetic protocol for functionalising the bicyclic 
guanidine
In this part, we will introduce a novel strategy to generate a functionalised bicyclic guanidine. 
This novel strategy is inspired by the synthetic route that was explained in section 2.2.1 and 
in the Schmidtchen et al. strategy to produce bicyclic guanidine derivatives.78 This strategy 
was developed in an attempt to overcome the lack of reactivity of the protected amine group 
that was the main factor in producing a monocyclic isothiourea 200 as opposed to the desired 
product of a bicyclic guanidine derivative. There are two key challenges which have been 
discussed in the formation of bicyclic guanidine methylene amine; firstly, the monocyclic by-
product that was formed during the cyclisation of compounds 197. The second key challenge 
is the conversion of the alcohol group to the azide group in the first step, which was the
modification of the Schmidtchen route in the previous chapter. The modification avoids the 
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protection and deprotection steps and then conjugates the resulting bicyclic guanidine to the 
amino acid residue. In other words, the azide functional group behaves as a masked amine 
and thus avoids the use of a protecting group that would otherwise be necessary. The other 
potential advantage is the formation of bicyclic guanidine in higher yield due to avoidance of 
the reaction stopping at the monocyclic stage. Therefore, our novel strategy uses the 
precursors 1-amino-3-azido-propane 181, 1-amino-4-azido-butane 185 and 1-amino-5-azido-
pentane 189. Three target compounds were initially suggested namely differently sized rings 
of bicyclic guanidine methylene alcohol including a six, seven and eight membered rings
system as outlined in Figure 2.4. 
 
Figure 2.4: Initial targets.
The next targets are the non-natural amino acids possessing these groups in their side chains. 
2.2.2.1 Retrosynthetic analysis of bicyclic guanidine derivatives
This section discusses a novel route to compound 219. A retrosynthetic analysis of this 
compound is given in Scheme 2.14 below. Retrosynthetically, compound 219 can be 
generated from an isothiourea that could be also derived from a thiourea. The thiourea could 
be obtained from the coupling between isothiocyanate and compounds 181 or 185 or 189.
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Scheme 2.14: A retrosynthetic route for differently sized rings of bicyclic guanidine 
methylene alcohol.
2.2.2.2 The formation of silylated isothiocyanate
The production of silylated isothiocyanate 208 started from Boc-L-methionine as a chiral 
precursor. The first step included the preparation of compound 191 as described in Scheme
2.15. The next step was the de-protection of the Boc group via mild acidic conditions to attain 
the salt of the methioninol as a waxy solid in a 94% yield. The silyl protecting group was 
installed on the hydroxyl function of the methioninol by adding the reagent TBDMS-OTf in the 
presence of imidazole. It is clear that α-L-methioninol contains two functional groups and the 
silylation of the amino group would be much faster than at the desired alcohol, due to a quick 
silylation at the more nucleophilic amino residue and then sluggish migration to the alcohol 
group. It is expected that the pKa of protonated methioninol is about 9-10, therefore, using a 
weak base such as imidazole (imidazolium pKa = 5.5), would support this reaction by 
preventing any nucleophilic attack from the amino group. Compound 206 reacted with the 
TBDMS-OTf in the presence of imidazole in DCM at 0 °C. This reaction was accomplished easily 
and without issue. The purification of the crude product followed the procedure that was 
described by Jadhav et al.80 which included utilising a complex extraction protocol to remove 
any by-products and thus resulting in a pure product. This work up involved washing the crude 
product with distilled water three times to remove the excess of imidazole and then dissolving 
it in a solution containing H2O/ CH3CN/ AcOH 60/40/2.5 mL This was followed by the 
important step of removing the remaining silanol by-product by washing with hexane. Taking 
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into account that the silyl protecting group could be removed by a strong base, the solution 
was basified by adding the weak base sodium bicarbonate, and then it was extracted with 
DCM. Compound 207 was used in the following reaction without further purification. Due to 
the high yield that was obtained by utilising the original procedure to prepare the azido 
isothiocyanate 195,129 the same procedure was used again to generate silylated 
isothiocyanate 208 as in Scheme 2.16. Compound 207 was dissolved in DCM and the inorganic 
weak base NaHCO3 was added following by the addition of thiophosgene. 
Scheme 2.15: The synthetic route to compound 208.
2.2.2.3 The formation of silylated thiourea
The synthesis involved the coupling of one equivalent of compound 208 with one equivalent 
of compound 181 in dry acetonitrile and in the presence of sodium bicarbonate. Once 
complete consumption of the starting material was noticed, the reaction was purified to 
obtain the compound 209 in a 73% yield as outlined in Scheme 2.16. The same chemistry was 
utilised to obtain compounds 210 and 211. 
Scheme 2.16: The formation of silylated thiourea derivatives.
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1H NMR spectrum recorded for compounds 209, 210, 211 showed splitting of some peaks due 
to the presence of a rotational isomer around CS which was proved experimentally in 
compound 196. The 1H NMR spectra of silylated thioureas in CDCl3 at room temperature are 
consistent with a static structure with two singlet methyl groups belonging to the silyl 
protecting group in different chemical environments, given the six hydrogen integrals at 0.01 
ppm and nine hydrogen integrals at 0.88 ppm. The IR spectra of silylated thiourea was
characterised by absorption at 2088 cm−1 belonging to the azide group; finally, 13C NMR 
spectra have recorded a chemical shift at 180 ppm for C=S.
2.2.2.4 The production of monocyclic isothiourea
It was suggested that the bicyclic guanidine methylene azide 198 was installed via isolating 
the monocyclic intermediate, and subsequently the second cyclisation induced to generate 
the bicyclic guanidine. Therefore, our novel strategy included the synthesis of the monocyclic 
compound by utilising the same chemistry that was reported to prepare compound 198
through the methylation at the sulfur atom by using methyl triflate and then cyclisation was 
induced by adding an excess of DIPEA. Finally, these products were achieved in acceptable 
yields as in Scheme 2.17 below. 
Scheme 2.17: The formation of monocyclic isothiourea. 
In this route, three monocyclic isothiourea compounds have been synthesised depending on 
the amino alkyl azide used.
2.2.2.5 The formation of silylated bicyclic guanidine
Our aim in this project is to synthesise a non-natural amino acid possessing a bicyclic 
guanidine in the side chain; thus, the central consideration included the formation of 
functionalised bicyclic guanidine in an easy and trouble-free procedure. Schmidtchen et al.
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have synthesised functionalised bicyclic guanidine with two protecting groups: silyl and tosyl 
groups, which then need to be removed. Experimentally, there are many necessary steps to 
achieve functionalised bicyclic guanidine; the polarity of this compound is high and thus it is 
thought that there might be some problems in purification. In addition, deprotection of two 
protecting groups after many steps to reach the target would decrease the quantity of the 
final compound that is available to make a non-natural amino acid. Synthetically, utilising Pd 
on activated carbon under a hydrogen atmosphere is not the right choice to reduce the azide 
group in the monocyclic isothiourea due to the poisoning of palladium by the sulfur atom. The 
hydrogenation of the azide group of monocyclic thiourea was therefore accomplished by 
using activated zinc and ammonium chloride in an aqueous medium as in Scheme 2.18
below.132 As monitored by TLC, heating the mixture under reflux for two hours was enough 
to complete the consumption of the starting material and then an ammonia solution was 
added to the resulting mixture. Modification in the workup was made, specifically by heating 
the mixture with ammonia solution for one hour instead of the 10 min described in the
original procedure132 to complete the cyclisation reaction and produce bicyclic guanidine. The 
original procedure included washing the crude product with water to remove the excess of 
ammonium chloride, however our bicyclic guanidine is slightly soluble in water, so the 
aqueous solvents were evaporated and then the product re-dissolved in methanol. 
Subsequently, the solid was filtered and the solvent was evaporated again to get the desired 
compound. Interestingly, it was thought that the hydrogenation of the azide group would 
produce the corresponding amine, but the silylated bicyclic guanidine was produced instead 
due to the reactivity of amino group formed by the hydrogenation of azide and the ammonia 
solution used in the work up. The major product of the reaction showed the expected mass
for the guanidine product in the mass spectrum. The FTIR spectrum recorded showed the 
absence of an azide peak. The 13C NMR spectrum however displayed the correct C=N 
resonance at 153.3 ppm.
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Scheme 2.18: The formation of differently sized rings of bicyclic guanidine.
On the other hand, bicyclic guanidine having an eight membered ring 218 was not produced. 
1H, 13C NMR and mass spectrum showed that the product is instead the compound 217. This 
was confirmed by the FTIR spectrum showing the existence of primary amine. Many attempts 
have been made to produce bicyclic guanidine possessing an eight membered ring, including 
an attempt where the corresponding amine was dissolved in DMF and heated under reflux 
for one day in the presence of a weak base DIPEA as in Scheme 2.19, but unfortunately again 
no product was formed. Another attempt was done by using a strong base, sodium hydride,
to induce cyclisation. However, all attempts did not succeed in obtaining the desired 
compound.
Scheme 2.19: Attempts to synthesise compound 218.
2.2.2.6 Deprotection of silyl group 
Removal of the silyl protecting group was accomplished by adding 12 M HCl (aq) in 
tetrahydrofuran as in Scheme 2.20 below. After the completion of the reaction, the solvent 
was evaporated (co-evaporated with ethanol). However, compounds 219 and 220 are soluble 
in water so the residue was washed with hexane and then DCM to obtain the pure product.
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Scheme 2.20: The formation of bicyclic guanidine methylene alcohol.
2.2.2.7 The synthesis of bicyclic guanidine methylene chloride
Conversion of 219 and 220 to 221 and 222 respectively was carried out via a substitution 
reaction by adding thionyl chloride as in Scheme 2.21. At the end of this reaction, the resulting 
mixture was placed under a vacuum and the excess thionyl chloride was evaporated under 
reduced pressure. 
Scheme 2.21: Preparation of bicyclic guanidine methylene chloride.
The production of 221 and 222 is considered as the key point in our synthetic protocol 
towards synthesising a non-natural amino acid containing differently sized rings of bicyclic 
guanidine in the side chain. Thus, these products have been purified through flash column 
chromatography. High-resolution mass spectra for these compounds were identical with the 
calculated mass. 1H and 13C NMR spectra 1H and 13C NMR spectra and also FTIR were 
consistent with the structure of these compounds.
2.2.2.8 The formation of a non-natural amino acid
After completing the synthesis of compounds 221 and 222, the plan was to find a suitable 
amino acid residue that could connect to our molecule. Therefore, it was proposed that Boc-
L-tyrosine could react with 221 in the presence of caesium carbonate to produce a non-
natural amino acid through nucleophilic substitution via Williamson ether synthesis. Although 
Boc-L-tyrosine is commercially available, it was prepared via a one pot process by the reaction 
between L-tyrosine and Boc-anhydride in the presence of triethylamine.133-134 A non-natural 
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amino acid was then prepared in a yield of 68% with compound 224 and 65% with compound 
225 as in Scheme 2.22.135 
Scheme 2.22: The synthesis of a non-natural amino acid.
At the beginning of this reaction, deprotonation of the phenol group in Boc-L-tyrosine was 
achieved by adding caesium carbonate. Then, the phenoxide group was reacted with bicyclic 
compound 221 through an SN2 substitution reaction.135 The resultant high-resolution mass 
spectrum was identical with the calculated mass and also the peak of the carboxylic acid could 
be easily recognised at 12 ppm in the 1H NMR spectra. 13C NMR spectra recorded the peak of 
the carboxylic acid at 180 ppm. 
2.2.2.9 Attempts to synthesise bicyclic guanidine carboxylic acid
When we started this project, our attention concentrated on the design and synthesis of a 
non-natural amino acid with a bicyclic guanidine side chain. Producing compound 219 
encouraged us to oxidise it to the corresponding carboxylic acid; then, the resulting product 
could react with the side chain of the amino acid lysine. Two different oxidation reagents were 
investigated to achieve this conversion. The first attempt used tetrapropylammonium 
perruthenate (TPAP) in acetonitrile in the presence of N-methylmorpholineoxide as in 
Scheme 2.23 below.136 The mixture was stirred for one day. This reaction was monitored by 
TLC. The 1H and 13C NMR spectroscopy and also FTIR spectroscopy recorded that the result 
was just starting material and this experiment was proven to be unsuccessful. 
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Scheme 2.23: Attempt to synthesise bicyclic guanidine carboxylic acid.
Another attempt used the procedure of Corey and Schmidt that involved utilising pyridinium 
dichromate in DMF as in Scheme 2.24.137 Unfortunately, this procedure was not successful as 
the result was again only starting material.
Scheme 2.24: Second attempt 2 to produce bicyclic guanidine carboxylic acid.
2.2.3 The synthesis of bicyclic guanidine methylene amine 
The previous work to produce compound 219 pushed us towards
another attractive synthetic route for functionalised bicyclic guanidine. To avoid the steps 
that are needed for protection and de-protection during the synthetic rote to 219, our new 
protocol circumvented these steps by introducing an azide group instead of an alcohol group 
in compound 206. This protocol has used the same chemistry that was used to synthesise 
compound 198 and 215. This time the compound 194 was used as a precursor for the 
synthesis of compound 229. Scheme 2.25 shows the synthetic route to produce 229.
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Scheme 2.25: The synthesis of bicyclic guanidine methylene amine.
Thus, the oily product for compound 229 was collected and characterised by 1H and 13C NMR
spectroscopy which indicated that this oily compound is the target compound. The high-
resolution mass spectrum was identical with the calculated m/z for compound 229 as well.
2.2.4 The functionalisation of amino acids
Due to the existence of the primary amine in compound 229, the best choice was to conjugate 
it with an amino acid through a peptide bond. Thus, the most ideal option was determined to 
be Fmoc-Glu-OAll, which was used to conjugate with our molecule. The synthesis therefore
included the reaction between 229 and Fmoc-Glu-OAll in the presence of HOBt and PyBOP to
generate compound 231 as outlined in Scheme 2.26. 
 
Scheme 2.26: The synthetic route to a non-natural amino acid.
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This structure for 231 was verified in the 1H, 13C NMR and mass spectra recorded for this 
compound.
2.2.5 The synthesis of a dimer of bicyclic guanidine
The synthesis of molecules possessing two guanidine groups has attracted wide attention,
especially in medicinal chemistry, due to the use of these molecules as antimicrobial drugs.138 
For example, some common antibiotic molecules contain two guanidine groups, such as 
streptomycin and dihydrostreptomycin. Therefore, our synthetic route is the same that was 
used by Schmidtchen et al. to produce 234 (Scheme 2.27). The synthetic route involved the 
reaction between silylated isothiocyanate 208 and compound 183 to produce thiourea 232. 
Bicyclic guanidine derivative 233 was synthesised by the methylation of the sulfur atom in 
thiourea 232 and then cyclisation was achieved by heating under reflux with 
diisopropylethylamine. De-protection of silyl protecting group was then performed by adding
tetra-n-butylammonium fluoride. Two equivalents of compound 234 was finally reacted with 
one equivalent of 1, 5-dibromopentane in the presence of a strong base, sodium hydride, to 
produce a dimer of bicyclic guanidine 236.
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Scheme 2.27: Synthesis of bicyclic guanidine dimer by reacting 2 equivalents of bicyclic       
guanidine methylene alcohol with one equivalent of 1, 5-dibromopentane.
Single crystals of compounds 233 were isolated by vapour diffusion from EtOH/H2O solution. 
The X-ray structure of 233 indicated that the product had been successfully formed as its 
triflate salt. Focussing on the exocyclic methylene group, it can be seen that the atoms around 
the group are occupying an equatorial type position and the sulfonamide group and exocyclic 
CH2 group are in close proximity to the Pbf protecting group. Interestingly the conformation 
of the Pbf is pointing the same way as the CH2 which might lead to a steric hindrance towards 
the reaction of the substituted exocyclic methylene group with a wide range of functional 
groups. Selected atom distances to the carbon of the exocyclic methylene group of compound 
233 are given in Table 2.3.
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Atom A Atom B Distance Å
O1 C1 3.979
O2 C1 6.051
C2 C1 4.344
C3 C1 7.075
Table 2.3: The distance between selected atoms in the crystal structure of 233, triflate 
omitted from the figure.
The C-N bond lengths of the guanidinium group of the compound 233 are C1-N3 = 1.327 Å, 
C1-N1 = 1.376 Å and C1-N2 = 1.321 Å. These lengths are consistent with delocalization of the 
lone pair of the bridge head nitrogen (N3) into the guanidinium group. The bond angles 
around N3 in 233 are C1-N3-C4 = 119.13°, C1-N3-C5 = 123.774° and C4-N3-C5 = 115.88°. The 
sum of the bond angles at both C1 (359.99°) and N3 (358.78°) shows that the geometry of 
these atoms is almost planar, also consistent with delocalization of electron density from the 
tertiary nitrogen N3 into the core of the ring. The calculated N2H – O1 distance is 2.073 Å so 
that there appears to be a hydrogen bond between these groups.
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2.2.4 Stereochemical investigation 
In our research Boc-L-methionine was utilised as a chiral precursor for the synthesis of bicyclic 
guanidine derivatives. No reaction occurred on the chiral centre during the reaction steps to 
produce the target. To verify that no racemisation of the configuration happened during the 
many conditions that had been used to produce the bicyclic guanidine derivatives, an 
experiment was performed to synthesise a genuine sample of the other enantiomer for 
comparison by chiral chromatography. This experiment involved the use of the commercially 
available Boc-D-methionine, followed by the same chemistry that had been used to 
synthesise compound 215, thus, producing 238 as in Scheme 2.28. A chiral HPLC column with 
a stationary phase of cellulose tris (3, 5-dimethylphenylcarbamate) coated on 5 µm silica-gel, 
and mobile phase of isopropanol and hexane, was used to analyse the bicyclic guanidine 
samples derived from L- and D-methionine. At the end of the column, a UV-visible absorbance 
detector was used to detect elution of the compounds. The resulting chromatogram shows 
the retention time and peak area associated with each enantiomer. Identification of the 
substances was achieved through the retention time and the peak area indicates the 
concentration of the substances in the sample. In our experiment, this technique was used to 
verify the chiral integrity of the stereocentre of the bicyclic guanidine derivatives that had 
originated from Boc-L-methionine. At the beginning, 10 µL of D-silylated bicyclic guanidine
solution (1 mg in 100 mL) was injected and the retention time was 5.73 min; then L-silylated 
bicyclic guanidine solution (1 mg in 100 mL) was injected and the retention time was 6.64 
min. D and L isomers of bicyclic guanidine were mixed manually and each one showed a 
different retention time. The D isomer was not visible in the L- sample and the L isomer also 
was not visible in the D-sample, thus proving that only one isomer had been isolated.
Scheme 2.28: Production of D-bicyclic guanidine derivatives.
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2.2.5 Computational binding studies 
The possible interactions of bicyclic guanidine derivatives and arginine (Figure 2.5) with 
nucleobases were modelled using the DFT method (ωB97x-D (dispersion corrected DFT) with 
6-31+G** basis set) in the Spartan 10 software by Dr Jamie Platts. An investigation was 
performed into the effect of the cyclic structure of guanidine and whether this new cyclic
substituent is going to make any difference or not. Calculations were performed in the gas-
phase. Arginine and bicyclic guanidine were bonded to guanine and the binding energy for 
the arginine-guanine interaction was −170 kJ mol−1 while for the bicyclic guanidine-guanine 
interaction the energy was −154 kJ mol−1. The binding energy for compound 302 with a 
guanine-cytosine base pair was −167.7 kJ mol−1. The binding energy for compound 229-
guanine interaction was −153.8 kJ mol−1, compound 219-guanine was −157.8 kJ mol−1 and 
compound 304-guanine was −176.7 kJ mol−1. Thus, these results showed that most of the 
bicyclic guanidine derivatives’ guanine interactions are not planar, theoretically (at least using 
this DFT method) the non-planar interaction appears to be more stable, despite this 
interaction initially being expected to be less favourable than a planar interaction. On the 
other hand, compound 304 might interact well with guanine. It could be concluded that the 
binding energies of the interaction of 219 and 229 with guanine-cytosine are approximately 
the same, −157.8 kJ mol−1 (BCG-OH), −153.8 kJ mol−1 (BCG-NH2), but the binding energy of 
BCG-acetamide ( −176.7 kJ mol−1) indicates a more preferable interaction with guanine-
cytosine. On the other hand, the binding energy of these models was calculated in the gas 
phase and the entropy factor was omitted in our calculations, so the result is only an
approximation. Theoretically, the resulting angles between the planes of the bicyclic 
guanidine and nitrogenous bases during the interaction has suggested that the geometry of 
these molecules during the interaction may not be planar. Figure 2.6 shows the angle 
between 302 and guanine-cytosine as modelled by Jamie Platts.
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Figure 2.5: Bicyclic guanine derivatives and arginine that were modelled with guanine-
cytosine.
Figure 2.6: Angle between the planes of bicyclic guanidine and guanine-cytosine, green 
colour for selected atoms in guanine-cytosine and red colour for selected atoms (guanidine 
group) and two carbon atoms in bicyclic guanidine.
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3.1 Conclusions
As described in the introductory chapter, bicyclic guanidines have many applications in a 
variety of fields in chemistry so our main aim was to find a smooth and easy synthetic route 
to bicyclic guanidine derivatives. A novel synthetic route to functionalised bicyclic guanidines 
has since been devised and thus a number of modified amino acids possessing bicyclic 
guanidine derivatives in their structures and dimer bicyclic guanidine 236 have been 
produced, as outlined in Figure 3.1.
Figure 3.1: The structure of new amino acids having bicyclic guanidine in their structures
that were synthesised by our synthetic protocols.
The utility of a new approach for the synthesis of bicyclic guanidine methylene alcohol, as 
revealed by the synthesis of monocyclic isothiourea, has been demonstrated. A key feature is 
illustrated by the conversion of the azide group in the monocyclic isothiourea into bicyclic 
guanidine methylene alcohol via a hydrogenation process, which in turn triggered the 
production of bicyclic guanidine derivatives through intramolecular substitution. The 
synthesis of the thiourea intermediates can be highlighted as having the potential to be 
improved through minimising the use of protecting groups. A protection/deprotection event 
introduces at least two steps into the synthetic route in the Schmidtchen protocol to produce 
bicyclic guanidine derivatives. This incurs additional costs for chemical reagents and waste 
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disposal, and generally causes a decreased overall yield. In our project, azides were used to 
serve as a protected amino group, thus, removing a 'protecting-group' method that was used 
in Schmidtchen’s route.78 Furthermore, the modification of the step for the cyclisation of 
thiourea was achieved by synthesising a monocyclic isothiourea containing azide group in the 
side chain. The hydrogenation of this azide triggered this molecule to form a bicyclic guanidine 
in a high yield.
Due to the sensitivity of the Pbf protecting group to acidic conditions, as described in the 
literature, the precursor diaminoalkane Pbf was first prepared by hydrogenation of the 
corresponding azide using Pd on activated carbon under hydrogen atmosphere. Alternative 
conditions were utilised to investigate the same reaction, but instead using activated zinc and 
ammonium chloride. This method successfully reduced the azide group to an amine while 
retaining the Pbf protecting group in the structure, and we can conclude that these reaction 
conditions did not cleave off the Pbf protecting group. Furthermore, the resulting product 
was formed in a high yield and short time (ca. 2 hours) when compared with catalytic 
hydrogenation using Pd on activated carbon.
We have demonstrated that a new series of modified amino acids having a bicyclic a guanidine 
in the side chain can be prepared through conjugation. These could allow for the preparation 
of highly diverse libraries based on the bicyclic guanidine scaffold. The most promising 
approach seems to be the modified amino acids having bicyclic guanidine conjugated to a 
tyrosine moiety through an ether linkage.
The synthesis of the Pbf-Cl reagent that is used to protect the amine group, from cheaper 
butyraldehyde and 2,3,5-trimethyl phenol precursors has also been described. These
published synthetic methods allowed this reagent to be produced in a good yield with limited 
difficulty.  
The production of a bicyclic guanidine with a seven-membered ring 199 in the presence of 
the Pbf protecting group has also proved difficult, while the corresponding compound without 
this bulky Pbf protecting group was successfully produced. 
The synthesis of bicyclic guanidines containing an eight-membered ring 218 has proved 
unsuccessful despite a number of different reaction conditions being used to try to produce 
it.
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The attempts to conjugate protected bicyclic guanidine methylene amine 201 with Fmoc-glu-
OAll were not successful while the corresponding compound without a Pbf protecting group 
was successfully conjugated with Fmoc-Glu-OAll (Compound 231). We can conclude that the 
presence of the bulky protecting group inhibited this reaction, preventing formation of the 
amide bond. 
Attempting to produce a modified amino acid containing a bicyclic guanidine through cyclic 
addition (click reaction), via the reaction between 198 and 204 was not successful. Also
attempting to oxidise the alcohol group in the side chain of bicyclic guanidine 219 to produce 
226 was also not successful despite different reagents from literature procedures being 
tested.
Computational chemistry was used via the DFT method to predict the nature of the bicyclic 
guanidine-nitrogenous bases’ binding, and the results inferred that the resulting angles 
between these molecules may not be planar.
3.2 Future work
Incorporation into peptides of our modified amino acids that possess different sized bicyclic 
guanidine rings is the first priority for future work. Two peptide sequences will be synthesised, 
the first peptide sequence will include six amino acids (Fmoc-Ser(tBu)-OH, Fmoc-Trp(Boc)-OH, 
Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH). The second peptide 
sequence will include the same amino acids sequence except for insertion of a modified 
amino acid having our target bicyclic guanidine instead of Fmoc-Arg(Pbf)-OH. The comparison 
between DNA binding affinity of peptides having arginine with comparable sequences having 
our arginine analogue could be investigated in the future.
On the other hand, the bicyclic guanidine dimer research needs further investigation on two 
fronts, the first being the synthesis of the dimer of bicyclic guanidine with different lengths of 
side chain and achieving binding studies for these molecules relating to the hydrogen bonding 
and hydrophobic forces against nitrogenous bases. The other being the potential use of our 
synthesised bicyclic guanidine dimers as antimicrobials, which could also be studied in the 
future.  
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Furthermore, the same chemistry that was used to produce compound 219 could be used to 
generate bicyclic guanidines containing five membered rings as outlined in Scheme 3.1.
Scheme 3.1: Proposal to synthesise bicyclic guanidine containing five membered rings.
If this work is continued, I would recommend trying to synthesise a bicyclic guanidine having 
longer side chains (Scheme 3.2), which might overcome the barrier to producing a non-natural 
amino acid containing protected bicyclic guanidines. Interactions with the Pbf protecting 
group may be inhibiting the amine group in the side chain from forming an amide bond.
Comparisons of the binding affinities of this flexible bicyclic guanidine and the synthesised 
rigid bicyclic guanidine could be made against nitrogenous bases.
Scheme 3.2: Proposal to synthesise bicyclic guanidine having a long side chain.
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Modified amino acids 224 and 225 containing bicyclic guanidine in the side chain were 
successfully synthesised. Future work has therefore to focus primarily on incorporating these 
non-natural amino acids into peptides and then on binding studies for these peptides against 
nitrogenous bases. 
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4.1 Instrumentation and reagents for organic synthesis 
4.1.1 Chemicals and solvents  
Most of the solvents used throughout, including anhydrous dimethylformamide were 
purchased from commercial suppliers and used without further purification. Anhydrous 
tetrahydrofuran, dichloromethane and acetonitrile were collected from a solvent purification 
system. Chemicals were purchased from Acros, Aldrich, Fluka, Fluorochem, Molekula, Alfa 
Aesar and Novabiochem and were used without further purification.
4.1.2 Melting Points
Melting points were measured using a Gallenkamp melting point apparatus with samples in 
open capillary tubes.
4.1.3 Thin-Layer Chromatography
All reactions were monitored by thin-layer chromatography (TLC) which was performed on 
precoated aluminium sheets of Merck silica gel 60 F254 (0.20 m) and visualised by UV 
radiation (254 nm) or/and by staining with ceric ammonium molybdate solution (235 mL 
distilled H2O, 12 g ammonium molybdate, 0.5 g ceric ammonium molybdate, 15 mL sulfuric 
acid), potassium permanganate solution (1.5 g KMnO4, 10 g K2CO3, 1.25 mL 10% NaOH, 200 
mL distilled H2O) or iodine.
4.1.4 Column Chromatography
Manual column chromatography was performed using silica gel 60 (Merck, 230-400 mesh) 
under pressure (Flash Chromatography) or as gravitational column chromatography. The 
solvents used for the purification are indicated in the text and were purchased from Fisher 
Scientific as laboratory grade.
4.1.5 NMR Spectroscopy
All 1H NMR and 13C NMR spectra were recorded on a Bruker DPX 400 (400 MHz for 1H NMR 
and 100 MHz for 13C NMR) or a Bruker Ascend 500 (500 MHz for 1H NMR and 125 MHz for 13C
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NMR) or Bruker Fourier 300 (300 MHz for 1H NMR and 75 MHz for 13C NMR). Deuterated 
solvents CDCl3, D2O, CD3OD and DMSO-d6 were used. Chemical shifts are given in parts per 
million using the residual solvent peak as a reference.. Coupling constants (J) values are 
quoted in Hertz (Hz).
4.1.6 Optical Rotation
Optical rotation was measured with a SCHMIDT and HAENSCH UniPO1 L polarimeter at 20 °C
in a cuvette of 50 mm length with the sodium D-line (589.30 nm). HPLC grade chloroform was 
used to prepare the solution and the concentration is indicated in the data section.
4.1.7 Mass Spectrometry 
Mass spectrometric measurements were performed by the EPSRC Mass Spectrometry Service 
Centre, Swansea University or by R. Jenkins/R. Hick/S. Waller at Cardiff University. Ions were 
generated by the atmospheric pressure chemical ionisation (APCI), electrospray (ES) or 
electron ionisation (EI). Mass fragments usually are given in atomic mass units per elementary 
charge (m/z) with relative abundance of the ions in percentage (%). The high-resolution mass 
spectrometry (HRMS) for most of the compounds was carried out at EPSRC Mass 
Spectrometry Service centre, Swansea University. The molecular ion peak values quoted for 
either molecular ion [M]+, molecular ion plus hydrogen [M+H]+, molecular ion plus 
ammonium ion [M+NH4]+ or molecular ion plus sodium [M+Na]+.
4.1.8 IR Spectroscopy
IR spectra were recorded on a Shimadzu IR Affinity-1S instrument. Wavenumbers are quoted 
in cm−1. All compounds were measured neat directly on the ATR crystal of the IR machine.
4.1.9 X-Ray Crystallography
Single-crystal XRD data were collected on an Agilent SuperNova Dual Atlas diffractometer 
with a mirror monochromator (using either Cu (λ= 1.5418 Å) or Mo (λ=0.7107 Å) radiation), 
equipped with an Oxford cryosystems cooling apparatus. Crystal structures were solved and 
refined using SHELX. Non-hydrogen atoms were refined with anisotropic displacement 
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parameters. A riding model was used with Uiso set at 1.2 or 1.5 times the value of Ueq for the 
atom to which they are bonded. 
4.1.10 Computational chemistry
The possible interactions of bicyclic guanidine derivatives and arginine with nucleobases were 
modelled using the DFT method (ωB97x-D (dispersion corrected DFT) with 6-31+G** basis 
set) in the Spartan 10 software by Dr Jamie Platts.
General procedure for the synthesis of azido alkyl amine from dibromo 
alkane
Sodium azide (10.4 mmol) was added to a solution of 1, n-dibromoalkane (3.4 mmol) in water 
(30 mL). The mixture was heated at 80 °C for 20 h. After that, the mixture was made basic by 
adding 2 M NaOH and then the aqueous phase was extracted with ether (3 × 10 mL). 
Triphenylphosphine (5 mmol) was added to the solution of diazidoalkane over one hour. A 
mixture of 1/1 ether/ethyl acetate (15 mL) and 5% HCl (15 mL) was added to the resulting 
product. The mixture was stirred for 24 h at r.t. The organic phase was removed and the 
aqueous phase washed with diethyl ether (3 × 10 mL). The resulting aqueous phase was made 
basic with 2 M sodium bicarbonate to pH 10 and then extracted again with dichloromethane
(3 × 10 mL). The combined organic layers were dried over Na2SO4. The solvent was evaporated 
under reduced pressure and the resulting products did not need further purification.
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General procedure to protect organic amine with Pbf protecting group
The solution of Pbf-Cl 179 (300 mg, 1 mmol) and diisopropylethylamine (0.9 mL, 1.3 mmol) in 
dry DCM (25 mL) were added to the organic amine (200 mg, 1.7 mmol). The mixture was 
heated to reflux for 4 h under nitrogen. The mixture was washed with sat. aq. NH4Cl, washed
twice further with brine, dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by using flash column chromatography through silica gel using the eluent of hexane 
and ethyl acetate to get the protected organic amine.
General procedure for the hydrogenation of azides to amines 
The appropriate azide compound (1.91 mmol) and 10% Pd/C (150 mg) were suspended in 
methanol. The resulting mixture was stirred at room temperature for 12 h under a hydrogen 
atmosphere. The result was filtered and washed with methanol through a Celite® filter. The 
solvent was evaporated under reduced pressure and then dried under high vacuum to get 
pure amine, no further purification was needed.
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General procedure for deprotection of Boc protecting group
2 M HCl (30 mL) was added to the solution of the relevant compound having a Boc protecting 
group (11.53 mmol) in tetrahydrofuran (10 mL). The mixture was stirred vigorously for 4 h at 
room temperature. The solvent was evaporated (co-evaporation with ethanol) under reduced 
pressure to obtain the desired compound. No further purification was needed. 
General procedure for the synthesis of isothiocyanate compounds from 
amines
The appropriate amine compound (7.49 mmol) and sodium bicarbonate (9.52 mmol) were 
suspended in dichloromethane (25 mL). Thiophosgene (8.95 mmol) was added to the
resulting suspension. The mixture was stirred overnight at room temperature. Distilled water 
(20 mL) was added to this solution. The organic layer was collected and dried over MgSO4. 
The organic solution was concentrated under reduced pressure to attain the desired 
compound.
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General procedure for the synthesis of thiourea compounds by the reaction 
between isothiocyanate and amine
The appropriate isothiocyanate (5.44 mmol) and amine (5.44 mmol) were dissolved in a dry 
acetonitrile (30 mL) and then sodium bicarbonate (11.32 mmol) was added. The mixture was 
heated under reflux with vigorous stirring overnight. The reaction was allowed to reach room 
temperature, filtered and washed with water (3 × 10 mL) and then with brine (3 × 10 mL). The 
solvent was evaporated under reduced pressure to obtain crude product. This residue was 
purified by using flash column chromatography.
General procedure for the cyclisation of thiourea
The appropriate thiourea (2 g, 5.1 mmol) was dissolved in dry dichloromethane (30 mL). 
Diisopropylethylamine (0.32 mL, 0.23 g, 1.8 mmol) was added. Methyl triflate (1.3 mL, 1.88 g, 
11.5 mmol) was added dropwise to the resulting solution at 0 °C. The mixture was stirred for 
4 h at room temperature. Diisopropylethylamine 8.4 mL (6.2 g, 48.2 mmol) was then added 
and the mixture was heated under reflux for 24 h. It was cooled and then washed with NaOH 
(2 M) (× 2). The mixture was washed with water (× 3). The organic layer was dried over MgSO4.
The solvent was evaporated under reduced pressure to obtain crude product. This residue 
was purified by using flash column chromatography.
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General procedure for the hydrogenation of azides to amines by using 
activated zinc and ammonium chloride
The appropriate azide compound (9.63 mmol) and ammonium chloride (22.49 mmol) were 
dissolved in ethanol (26 mL) and H2O (9 mL) followed by the addition of activated zinc (12.84 
mmol). The mixture was heated under reflux for 2 h and allowed to cool to room temperature; 
then ammonia solution (4 mL) was added with efficient stirring for hour. The solid was 
filtered; the solvent was evaporated under reduced pressure and the residue was dissolved 
in methanol (30 mL). The solid (ammonium chloride) was filtered again, the solvent was 
evaporated under reduced pressure again to obtain the amine compound. Flash column 
chromatography was used to acquire a pure product.
Note: activated zinc was synthesised by adding 2 M HCl (10 mL) to the zinc powder (5 g, 77 
mmol) and then the mixture was stirred for 30 minutes followed by the filtration; then, the 
zinc was washed with acetone, ethanol, water and diethyl ether. The activated zinc was dried 
under high vacuum for 14 h.
General procedure for the synthesis of alkyl halides from alcohols
The appropriate alcohol compound (529 mg, 3.1 mmol) was dissolved in thionyl chloride (6 
mL) under nitrogen atmosphere. The mixture was heated under reflux for 10 h. The resulting 
solution was allowed to cool to room temperature. Thionyl chloride was evaporated and then 
the residue was dissolved in dichloromethane; washed with water three times followed by 
washing with brine three times. The combined organics were dried over MgSO4 and 
concentrated in vacuo to obtain the crude product. Flash column chromatography was used 
to acquire a pure product.
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General procedure for the synthesis of modified amino acid having bicyclic 
guanidine in their moiety
Boc-L-tyrosine (312.2 mg, 1.1 mmol) and caesium carbonate (1.8 g. 5.54 mmol) were 
suspended in anhydrous acetonitrile (30 mL) under a nitrogen atmosphere. The mixture was
stirred for 30 minutes. Then, a solution of alkyl halide (1.1 mmol) in acetonitrile (10 mL) was 
added to the resulting mixture. The mixture was heated under reflux overnight. The solid was 
removed by filtration, followed by evaporation of the solvent under reduced pressure from 
the filtrate. Purification of the residue was achieved by using flash column chromatography.
General procedure for the de-protection of silyl group by utilising 
trifluoroacetic acid
Trifluoroacetic acid (5 mL) was added to the solution of the silylated alcohol (750 mg, 2.64 
mmol) in tetrahydrofuran (25 mL). The mixture was stirred vigorously for 5 h. The solvent was 
evaporated under reduced pressure. This product is soluble in water; thus, the residue was 
dissolved in water and then washed with dichloromethane three times. The aqueous solvent 
was re-evaporated under reduced pressure again (co-evaporation with ethanol) to obtain the 
alcohol.
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4.2 Procedures
2, 2, 4, 6, 7-Pentamethyl-2, 3-dihydrobenzofuran-5-sulfonyl chloride (179)139
Sulfuric acid (0.9 g) was added to the solution of 2,3,5-trimethylphenol (30 g, 220.2 mmol) 
and isobutyraldehyde (24 mL, 264.4 mmol) in toluene (30 mL) and heated under reflux for 7
h, using a Dean-Stark apparatus to continually remove the water formed during the reaction. 
The reaction was monitored by TLC. The solvent was evaporated under reduced pressure to 
obtain the crude product. The pure product 178 was collected by using a short path vacuum 
distillation apparatus; (Kugelrohr) and the yield was 88%. Pbf 178 (16.74 g, 87 mmol) was 
dissolved in dry dichloromethane (200 mL). Chlorosulfonic acid (21.3 g, 183 mmol) was added 
to the solution dropwise at 0 °C for 1.5 h. The mixture was stirred at room temperature for 2 
h and was then poured into an ice-cold solution of 5% sodium bicarbonate (150 mL). The 
mixture was extracted by dichloromethane. The combined organics were dried over MgSO4
and then concentrated to obtain the product 179 as a silver solid (20 g, 80%). Further 
purification was not needed. 
TLC (Silica gel, hexane/DCM, 9:1) Rf = 0.41 (UV)
The spectroscopic data are in agreement with those recorded in the literature.139
m.p.= 45-46 °C (lit 44–46 °C)
1H NMR (400 MHz, CDCl3) δ 2.89 (s, 2 H, CH2), 2.19 (s, 3 H, CH3), 2.14 (s, 3 H, CH3), 2.07 (s, 3 
H, CH3), 1.46 (s, 6H, 2 CH3).
13C NMR (75 MHz, CDCl3) δ 157.2 (ArC), 136.4 (ArC), 131.2 (ArC), 122.6 (ArC), 122.1 (ArC), 
115.4 (ArC), 86.0 (C (CH3)2), 42.5 (CH2), 28.7 (CH3), 19.4 (CH3), 18.3 (CH3), 11.6 (CH3).
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FT-IR (CHCl3 film, cm−1) 2973 (s, aliphatic CH), 1457 (m), 1410 (s), 1285 (s), 1152 (s), 1088 (s). 
ESI+ (m/z): 289 [M+H]+
3-Azidopropan-1-amine (181)140
A mixture of compound 180 (2.2 g, 10 mmol) and sodium azide (1.8 g, 27.6 mmol) in water 
(10 mL) was heated at 80 °C for 24 h. The solution was cooled by using an ice bath; then 
dichloromethane (40 mL) and potassium hydroxide were added until the solution reached a 
pH of approximately 12. The aqueous layer was extracted with dichloromethane (2 × 10 mL); 
the combined organics were washed with brine (2 × 10 mL). Subsequently, the organic azide 
was dried over Na2SO4. The solvent was evaporated under reduced pressure to obtain 181
(820 mg, 82%) as a colourless oil.
TLC (silica gel, 3:1 hexane/ EtOAc), Rf= 0.25 (UV)
The spectroscopic data are in agreement with those recorded in the literature.140 
1H NMR (400 MHz, CDCl3) δ 3.33 (t, 2H, 3JHH = 6.7 Hz), 2.84 (t, 2H, 3JHH = 6.8 Hz), 1.72-1.59 
(m, 2H).
13C NMR (100 MHz, CDCl3) δ 51.1 (CH2), 38.1 (CH2), 29.2 (CH2). 
FT-IR (CHCl3 film, cm−1) 3310 (br, s, NH), 2955 (s, aliphatic CH), 2090 (s, CN3).
HRMS-AP+ (m/z): calcd. for C3H9N4 [M+H]+: 101.0822, found 101.0823
Experimental Part                                                                            Chapter four
97
4-Azidobutan-1-amine (185)141
The general procedure for the synthesis of azido alkyl amine from dibromo alkane was 
followed to yield 185 as a colourless oil (244 mg, 63%).
TLC (silica gel, 3:1 hexane/ EtOAc), Rf= 0.22 (UV)
The spectroscopic data are in agreement with those recorded in the literature.141 
1H NMR (400 MHz, CDCl3) δ 5.26 (s, 2H, NH2), 3.33-2.95 (t, 2H, 3JHH=13.5 Hz, N3CH2), 2.75-
2.61 (m, 2H, 3JHH =13.7 Hz, NH2CH2), 1.6-151 (m, 2H, 3JHH =13.5 Hz, N3CH2CH2), 1.49-1.4 (m, 
2H, NH2CH2CH2). 
 
13C NMR (100 MHz, CDCl3) δ 53.2 (CH2), 42.1 (CH2), 31.2 (CH2), 27.0 (CH2). 
FT-IR (CHCl3 film, cm−1) 3372 (br, s, NH), 2979 (s, aliphatic CH), 2093 (s, CN3).
CI+ (m/z): 115.1 [M+H]+
5-Azidopentan-1-amine (189)142
The general procedure for the synthesis of azido alkyl amine from dibromo alkane was 
followed to yield 189 as a colourless oil (261 mg, 60%).
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TLC (silica gel, 3:1 hexane/ EtOAc), Rf= 0.32 (UV)
The spectroscopic data are in agreement with those recorded in the literature.142 
1H NMR (300 MHz, CDCl3) δ 3.34 (t, 2H, 3JHH=6.4 Hz, N3CH2), 2.76-2.45 (t, 2H, 3JHH=6.4 Hz, 
NH2CH2), 1.69-1.58 (m, 2H, NH2CH2CH2), 1.57-1.46 (m, 2H, N3CH2CH2), 1.5-1.33 (m, 2H, 
NH2CH2CH2). 
 
13C NMR (100 MHz, CDCl3) δ 52.2 (CH2), 42.3 (CH2), 33.2 (CH2), 28.0 (CH2), 23.2 (CH2). 
FT-IR (CHCl3 film, cm−1) 3366 (br, s, NH), 2973 (s, aliphatic CH), 2098 (s, CN3).
ESI+ (m/z): 129.1 [M+H]+
N-(3-azidopropyl)-2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-sulfonamide (182)
The general procedure to protect organic amine with Pbf protecting group was followed to 
synthesise 182 as a white powder (1.4 g, 50%).
TLC (silica gel, 3:1 hexane/ EtOAc), Rf= 0.4 (UV)
1H NMR (400 MHz, CDCl3) δ 4.70 (t, 1H, 3JHH = 6.4 Hz, NH), 3.40-3.22 (t, 2H, 3JHH = 6.4 Hz, 
N3CH2), 3.12-3.01 (m, 4H, NHCH2, furan-CH2), 2.57 (s, 3H, ArCH3), 2.52 (s, 3H, ArCH3), 2.22 (s, 
3H, ArCH3), 1.83-1.71 (m, 2H, N3CH2CH2), 1.50 (s, 6H, C(CH3)2).
13C NMR (100 MHz, CDCl3) δ 159.8 (ArC), 141.7 (ArC), 134.1 (ArC), 127.7 (ArC), 125.3 (ArC), 
118.1 (ArC), 86.9 (C (CH3)2), 49.0 (CH2), 43.2 (CH2), 40.1 (CH2), 28.8 (CH2), 28.6 (C (CH3)2), 19.4 
(CH3), 17.7 (CH3), 12.6 (CH3). 
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HRMS-AP+ (m/z): calcd. for C16H25N4O3S [M+H]+: 353.1647, found 353.1650
FT-IR (CHCl3 film, cm−1) 3305 (br, s, NH), 2973 (s, aliphatic CH), 2095 (s, CN3), 1575 (s), 1463 
(s), 1413 (s), 1320 (s), 1259 (s), 1142 (s), 1093 (s), 998 (s).
N-(4-azidobutyl)-2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-sulfonamide (186)
The general procedure to protect organic amine with Pbf protecting group was followed to 
synthesise 182 as a pale-yellow solid (299 mg, 48%).
TLC (silica gel, 3:1 hexane/ EtOAc), Rf = 0.3 (UV).  
1H NMR (400 MHz, CDCl3) δ 4.76 (t, 1H, 3JHH = 6.4 Hz, NH), 3.37-3.25 (t, 2H, 3JHH = 6.4 Hz, 
N3CH2), 2.89-2.81 (m, 4H, NHCH2, furan-CH2), 2.49 (s, 3H, ArCH3), 2.41 (s, 3H, ArCH3), 2.15 (s, 
3H, ArCH3), 1.58 (quin, 2H, 3JHH = 3.4 Hz, N3CH2CH2),1.5-1.42 (m, 2H, NHCH2CH2), 1.40 (s, 6H, 
C(CH3)2).   
13C NMR (100 MHz, CDCl3) δ 159.8 (ArC), 141.5 (ArC), 134.4 (ArC), 127.2 (ArC), 125.31 (ArC), 
118.2 (ArC), 87.8 (C (CH3)2), 49.0 (CH2), 43.2 (CH2), 40.1 (CH2), 28.2 (CH2), 27.0 (CH2), 29.1 (C 
(CH3)2), 19.4 (CH3), 18.1 (CH3), 12.1 (CH3). 
ES- MS (m/z): 401 [M+Cl]-
FT-IR (CHCl3 film, cm−1) 3309 (br, s, NH), 2979 (s, aliphatic CH), 2089 (s, CN3), 1578 (s), 1464 
(s), 1417 (s), 1323 (s), 1257 (s), 1144 (s), 1095 (s), 996 (s).
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N-(3-aminopropyl)-2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-sulfonamide (183) 
The general procedure for the hydrogenation of azides to amines was followed to yield 183
as a white foam (573 mg, 92%). 
TLC (silica gel, 10% AcOH-EtOH), Rf = 0.31 (UV).
1H NMR (400 MHz, CDCl3) δ 5.12 (br, NH2), 3.12 (m, 4H, NHCH2, furan-CH2), 2.85 (t, 2H, 3JHH = 
6.6 Hz, NH2CH2), 2.55 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.09 (s, 3H, ArCH3), 1.69-1.53 (quin, 
2H, NH2CH2CH2), 1.46 (s, 6H, C (CH3)2).  
13C NMR (100 MHz, CDCl3) δ 159.6 (ArC), 128.3 (ArC), 127.2 (ArC), 127.0 (ArC), 118.2 (ArC), 
110.0 (ArC), 77.8 (C (CH3)2), 44.4 (CH2), 42.6 (CH2), 41.5 (CH2), 33.1 (CH2), 27.9 (C (CH3)2), 
19.4 (CH3), 16.9 (CH3), 12.42 (CH3).  
ES+ MS (m/z): 327 [M+H]+
FT-IR (CHCl3 film, cm−1) 3365 (s, NH), 2930 (s, aliphatic CH), 1569 (s, NH), 1460 (s), 1310 (s), 
1144 (s), 1094 (s).
N-(4-aminobutyl)-2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-sulfonamide (187)
The general procedure for the hydrogenation of azides to amines was followed to yield 187 
as a white foam (584.7 mg, 90%).
TLC (silica gel, 2:1 hexane/ EtOAc), Rf = 0.31 (UV, ninhydrin).
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1H NMR (400 MHz, CDCl3) δ 5.06 (br, NH2), 3.12 (m, 4H, NHCH2, furan-CH2), 3.0 (t, 2H, 3JHH = 
6.6 Hz, NH2CH2), 3.0-2.89 (m, 2H, NHCH2CH2), 2.35 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.09 (s, 
3H, ArCH3), 1.53-1.52 (m, 2H, NH2CH2CH2), 1.48 (s, 6H, C(CH3)2).  
13C NMR (100 MHz, CDCl3) δ 159.5 (ArC), 128.2 (ArC), 127.0 (ArC), 126.9 (ArC), 118.4 (ArC), 
110.7 (ArC), 77.9 (C (CH3)2), 44.5 (CH2), 42.8 (CH2), 40.6 (CH2), 41.6 (CH2), 33.0 (CH2), 27 (C 
(CH3)2), 19.2 (CH3), 16.7 (CH3) 12.4 (CH3).
ESI+ MS (m/z): 341 [M+H]+
FT-IR (CHCl3 film, cm−1) 3368 (s, NH), 2935 (s, aliphatic CH), 1567 (s, NH), 1464 (s), 1315 (s), 
1146 (s), 1097 (s).
(S)-Tert-Butyl 1-hydroxy-4-(methylthio) butan-2-ylcarbamate (191)143
NMM (3.72 mL, 3.43 g, 34 mmol) was added to the solution of Boc-N-methionine (8.00 g, 34 
mmol) in anhydrous tetrahydrofuran (45 mL). Ethyl chloroformate 3.6 mL (4.16 g, 38.4 mmol) 
was added dropwise to the resulting solution at 0 °C. The mixture was stirred continuously at 
0°C for 1 h until it became a clear solution. It was then filtered, the solid washed with 
tetrahydrofuran and the solution was added dropwise to an ice-cold solution of sodium 
borohydride (3.63 g, 96 mmol) in water (40 mL) over a 20-min period. The reaction was stirred 
at 0 °C for 1 hour and then stirring continued overnight. Subsequently, HCl (1 M) was added 
to the solution until pH 4 was reached. The solution was made basic by adding sodium 
bicarbonate and the aqueous phase was extracted with dichloromethane (3 × 25 mL). The 
combined organics were washed with sat. sodium chloride solution, dried over MgSO4 and 
concentrated in vacuo giving alcohol 191 as a colourless oil (6 g, 75%).
TLC (silica gel, 10:4 Ethyl acetate/ TEA), Rf= 0.28 (UV)
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The spectroscopic data are in agreement with those recorded in the literature143
1H NMR (250 MHz, CDCl3) δ 4.85 (br d, 1H, 3JHH = 7. 6 Hz, NH), 3.73-3. 68 (m, 1H, NHCH), 3.64 
(dd, 1H, 2JHH = 11.2 Hz, 3JHH = 3.9 Hz, HOCHH), 3.62 (dd, 1H, = 11.0 Hz, 2JHH = 5.2Hz, HOCHH), 
2.58-2.43 (m, 2H, SCH2), 2.06 (s, 3H, SCH3), 1.91-1.79 (m, 2H, SCH2CH2), 1.47 (s, 9H, t-Bu).
13C NMR (125 MHz, CDCl3) δ 157.1 (C=O), 80.1 (C (CH3)3), 66.1 (CH2OH), 52.3 (CH), 32.0 (CH2), 
31.7 (CH2), 28.5 (t-Bu), 15.7 (SCH3).
ESI- MS (m/z): 270 [M+Cl]-.
FT-IR (CHCl3 film, cm−1) 3360 (br s, NH), 2978 (m, aliphatic CH), 1685 (s, C=O), 1522 (s, NH), 
1365 (m) 1245 (m), 1175 (s).
= −13.5 (c= 0.25, CHCl3)
(S)-2-(tert-butoxycarbonylamino)-4-(methylthio) butyl methanesulfonate (192)128
Boc-L-methioninol 191 (5 g, 21.2 mmol) was dissolved in dry dichloromethane (30 mL) and 
triethylamine 5.8 mL (4.2 g, 42.4 mmol) was added to this solution. Mesyl chloride (1.96 mL 
(2.91 g, 25.44 mmol) was added dropwise to the resulting product at 0°C in a nitrogen 
atmosphere. The mixture was stirred at 0 °C for 30 minutes and then allowed to reach room 
temperature with vigorous stirring for 2 h. The mixture was washed with water three times. 
The combined organic layers were dried over MgSO4. The solvent was evaporated under
reduced pressure to obtain the crude product. Flash column chromatography was used to 
purify this product through silica gel and using the eluent of hexane and ethyl acetate to 
furnish 192 (5.5 g, 82%) as a yellow oil.
TLC (silica gel, 2/ 1 Hexane/ EtOAc), Rf= 0.2 (UV)
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The spectroscopic data are in agreement with those recorded in the literature.128
1H NMR (300 MHz, MeOD) δ 4.85 (br d, 1H, 3JHH = 7.5 Hz, NH), 3.73-3.68 (m, 1H, NHCH), 3.85-
3.66 (dd, 1H, 2JHH = 11.0 Hz, 3JHH = 3.6 Hz, OCHH), 3.62-3.56 (dd, 1H, = 11.0 Hz, 2JHH = 5.0 Hz, 
OCHH), 2.62–2.51 (m, 2H, SCH2), 3.10 (s, 3H, CH3SO2), 2.05 (s, 3H, SCH3), 1.91–1.75 (m, 2H,
SCH2CH2), 1.42 (s, 9H, t-Bu). 
13C NMR (75 MHz, CDCl3)  155.2 (C=O), 80.1 (C (CH3)3), 70.9 (CH2OS), 48.9 (CH), 37.3 (CH2), 
30.6 (CH2), 29.2 (CH2), 28.3 (t-Bu), 15.5 (SCH3). 
HRMS-AP+ (m/z): calcd. for C11H24NO5S2 [M+H]+: 314.1096, found 314.1096
FT-IR (CHCl3 film, cm−1) 3355 (br s, NH), 2981 (m, aliphatic CH), 1677 (s, C=O), 1517 (s, NH), 
1361 (m), 1251 (m), 1178 (s).
= −16 (c= 0.22, CHCl3)
(S)-Tert-butyl 1-azido-4-(methylthio) butan-2-ylcarbamate (193)128
Sodium azide (2.06 g. 31.8 mmol) was added to the solution of 192 (5.00 g, 15.9 mmol) in dry 
dimethylformamide (30 mL). The mixture was heated under reflux for 4 h and was allowed to 
cool to room temperature. The solvent was evaporated under reduced pressure and then H2O 
(30 mL) was added. The aqueous solution was extracted with dichloromethane three times. 
The combined organic layers were dried over MgSO4 and the solvent was evaporated under 
reduced pressure. Purification of this compound was achieved by using flash column 
chromatography through silica gel and using the eluent of hexane and ethyl acetate to get 
193 (3.2 g, 76%) as a pale-yellow oil.
Experimental Part                                                                            Chapter four
104
TLC (silica gel, 2.2/ 0.8 Hexane/ EtOAc), Rf= 0.7 (UV)
The spectroscopic data are in agreement with those recorded in the literature.128 
1H NMR (400 MHz, CDCl3) δ 3.85-3.8 (m, 1H, NHCH), 3.38-3.32 (m, 2H, SCH2), 2.65-2.45 (m, 
3H, N3CHH, SCH2CH2), 2.03 (s, 3H, SCH3), 1.77-167 (m, 1H, N3CHH), 1.38 (s, 9H, t-Bu).
13C NMR (125 MHz, CDCl3) δ 155.2 (C=O), 79.4 (C (CH3)3), 57.6 (N3CH2), 52.3 (NHCH), 36.0 
(CH2), 31.7 (CH2), 28.5 (t-Bu), 15.7 (SCH3).
HRMS-EI+ (m/z): calcd. for C10H20N4O2S [M]·+: 260.1307, found 260.1302
FT-IR (CHCl3 film, cm−1) 3476 (br s, NH), 2979 (m, aliphatic CH), 2122 (br s, N3), 1753 (s, 
C=O), 1515 (s), 1166 (m), 843 (s), 762 (s)
= −38 (c= 0.21, CHCl3)
(S)-1-azido-4-(methylthio) butan-2-amine (194)
The general procedure for deprotection of Boc protecting group was followed and then the 
mixture was made basic by adding sodium bicarbonate. The aqueous layer was extracted with 
dichloromethane three times. The combined organic layers were dried over magnesium 
sulfate and then concentrated in vacuo to yield 194 as a pale-yellow oil (1.47 g, 80%).
TLC (silica gel, 10/ 1 EtOAc/ MeOH), Rf= 0.33 (UV)
1H NMR (300 MHz, CD3OD) δ 3.86-3.82 (m, 1H, NHCH), 3.4-3.35 (m, 2H, SCH2), 2.67-2.46 (m, 
3H, N3CHH, SCH2CH2), 2.05 (s, 3H, SCH3), 1.79-1.68 (m, 1H, N3CHH).
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13C NMR (75 MHz, MeOD)  59.3 (CH), 58.2 (CH2N3), 34.2 (CH2), 30.1 (CH2), 18.1 (CH3).
HRMS-ESI+ (m/z): calcd. for C5H13N4S [M-H]+: 161.0861, found 161.0857
FT-IR (CHCl3 film, cm−1) 3370 (br s, NH2), 2919 (m, aliphatic CH), 2096 (br s, N3), 1602 (s), 
1499 (s)
= −25 (c= 0.18, CHCl3)
(S)- (4-azido-3-isothiocyanato butyl) (methyl) sulfane (195)
The general procedure for the synthesis of isothiocyanate compounds from amines was 
followed to yield 195 as a golden oil (1.15 g, 76%).
TLC (silica gel, 10:0.1% CHCl3/ Methanol), Rf= 0.4 (UV)
1H NMR (300 MHz, CDCl3) δ 3.87-3.82 (m, 1H, SCNCH), 3.39-3.33 (m, 2H, SCH2), 2.64-2.46 (m, 
3H, N3CHH, SCH2CH2), 2.12 (s, 3H, SCH3), 1.94-1.88 (m, 1H, N3CHH), 1.39 (s, 9H, t-Bu).
13C NMR (125 MHz, CDCl3) δ 136.1 (NCS), 54.2 (CH2N3), 53.3 (CH), 31.6 (CH2), 30.7 (CH2), 15.7 
(CH3).
HRMS-ES+ (m/z): calcd. for C6H11N4S2 [M+H]+: 203.0425, found 203.0429
FT-IR (CHCl3 film, cm−1) 2925 (m, aliphatic CH), 2094 (br s, N3), 2088 (s, NCS), 1605 (s), 1493 
(s)
= −29 (c= 0.215, CHCl3)
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(S)-N-(3-(3-(1-azido-4-(methylthio) butan-2-yl) thioureido) propyl)-2, 2, 4, 6, 7-
pentamethyl-2, 3-dihydrobenzofuran-5-sulfonamide (196)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amino compound was followed to yield 196 as a yellow foam (2.3 g, 
80%).
TLC (Silica gel, 2:1 Hexane: EtOAc) Rf= 0.12 (UV)
1H NMR (300 MHz, CDCl3) δ 3.84-3.71 (m, 3H, NHCH, SCNHCH2), 3.70-3.45 (m, 1H, N3CHH), 
3.38-3.32 (m, 2H, SCH2), 2.99-2.94 (m, 2H, SO2NHCH2), 2.96 (s, 2H, furan-CH2), 2.65-2.58 (m, 
2H, SCH2CH2), 2.52 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.10 (s, 3H, ArCH3), 2.06 (s, 3H, SCH3), 
1.80-1.61 (m, 3H, N3CHH, NHCH2CH2), 1.44 (s, 6H, (CH3)2).
13C NMR (300 MHz, CDCl3) δ 182.1 (C=S), 160.5 (ArC), 139.2 (ArC), 135.2 (ArC), 127.0 (ArC), 
125.1 (ArC), 118 (ArC), 87,1 (C(CH3)2), 54.2 (CH2), 49.1 (CH2), 45 (CH), 42.2 (CH2), 39.5 (CH2), 
33.0 (CH2),30.2 (CH2), 28 (CH2), 27.6 (C(CH3)3, 19.7 (CH3), 18.0 (CH3), 16.6 (CH3), 13.5 (CH3).
HRMS-ESI+ (m/z): calcd. for C22H36N6O3S3 [M-H]+: 529.2089, found 529.2100
FT-IR (CHCl3 film, cm−1) 3360 (br s, NH), 2950 (s, aliphatic CH), 2096 (s, N3), 1550 (m), 1453 
(m), 1302 (s), 1130 (s), 1089 (s).
= −31 (c= 1.1, CHCl3)
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(S)-N-(4-(3-(1-azido-4-(methylthio) butan-2-yl) thioureido) butyl)-2, 2, 4, 6,7-pentamethyl-
2, 3-dihydrobenzofuran-5-sulfonamide (197)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amino compound was followed to yield 197 as a yellow foam (261 mg, 
78%).
TLC (Silica gel, 2:1 Hexane: EtOAc) Rf= 0.12 (UV)
1H NMR (300 MHz, CDCl3) δ 3.85-3.74 (m, 3H, NHCH, SCNHCH2), 3.73-3.47 (m, 1H, N3CHH), 
3.39-3.33 (m, 2H, SCH2), 3.12-2.96 (m, 2H, SO2NHCH2), 2.97 (s, 2H, furan-CH2), 2.67-2.61 (m, 
2H, SCH2CH2), 2.53 (s, 3H, ArCH3), 2.51 (s, 3H, ArCH3), 2.11 (s, 3H, ArCH3), 2.08 (s, 3H, SCH3), 
1.81-1.63 (m, 3H, N3CHH, SO2NHCH2CH2), 1.61-1.58 (m, 2H, NCSNHCH2CH2), 1.43 (s, 6H, 
(CH3)2).
13C NMR (300 MHz, CDCl3) δ 181.4 (C=S), 161.3 (ArC), 138.8 (ArC), 136.1 (ArC), 127.2 (ArC), 
125.3 (ArC), 118.3 (ArC), 87.2 (C(CH3)2), 54.3 (CH2), 49.2 (CH2), 45.1 (CH), 42.3 (CH2), 39.6 
(CH2), 33.1 (CH2), 30.3 (CH2), 28.2 (CH2), 26.4 (CH2), 27.4 (C(CH3)3, 19.8 (CH3), 18.1 (CH3), 16.7 
(CH3), 13.7 (CH3).
HRMS-ESI+ (m/z): calcd. for C23H39N6O3S3 [M+H]+: 543.2246, found 543.2251
FT-IR (CHCl3 film, cm−1) 3365 (br s, NH), 2952 (s, aliphatic CH), 2093 (s, N3), 1552 (m), 1454 
(m), 1303 (s), 1132 (s), 1090 (s).
= −33 (c= 1.2, CHCl3)
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(S)-8-(azidomethyl)-1-(2, 2, 4, 6, 7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)-2, 3,
4, 6, 7, 8-hexahydro-1H-pyrimido [1, 2-a] pyrimidine (198)
The general procedure for the cyclisation of thiourea was followed to synthesise 198 as a 
yellow foam (251.6 mg, 60%).
TLC (silica gel, 10: 0.1% CHCl3: MeOH) 10: 0.1% Rf= 0.21 UV
1H NMR (400 MHz, CDCl3) δ 3.93-3.81 (m, 2H, SO2NCH2), 3.65-3.61 (m, 1H, N3CHH), 3.33-3.22 
(m, 1H, NCH), 3.15-3.1 (m, 4H, NCHCH2CH2, SO2NCH2CH2CH2), 3.00 (s, 2H, furan-CH2),2.98-
2.95 (m, 1H, N3CHH), 2.50 (s, 3H, ArCH3), 2.47 (s, 3H, ArCH3), 2.13 (s, 3H, ArCH3), 2.11-2.02 (m, 
2H, SO2NCH2CH2), 1.39-1.26 (m, 2H, NCHCH2), 1.51 (s, 6H, 2 × ArCH3). 
13C NMR (100 MHz, CDCl3) δ 159.4 (ArC), 140.1 (ArC), 135.7 (ArC), 133.7 (ArC), 125.5 (ArC), 
118.0 (ArC), 86.4 (C (CH3)2), 50.3 (CH), 48.3 (CH2), 47.7 (CH2), 43.2 (CH2), 42.1 (CH2), 40.3 (CH2), 
28.6 (CH3), 28.3 (CH3), 26.7 (CH2), 23.4 (CH2), 19.3 (CH3), 17.2 (CH3), 13.5 (CH3).
HRMS-ES+ (m/z): calcd. for C21H30N6O3S [M+H]+: 447.2173, found 447.2168
FT-IR (CHCl3 film, cm−1) 2954 (s, aliphatic CH), 2091(s, N3), 1634 (s,), 1426 (m), 1317 (s), 1139 
(s), 1093 (s).
= −42 (c= 0.12, CHCl3)
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(S)-(1-(2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-ylsulfonyl)-2, 3, 4, 6, 7, 8-
hexahydro-1H-pyrimido [1, 2-a] pyrimidin-8-yl) methanamine (201)
The general procedure for the hydrogenation of azides to amine was followed to yield 201 
as a colourless oil (139 mg, 84%).
TLC (silica gel, 10: 0.5% CHCl3: MeOH) Rf= 0.32 UV
1H NMR (400 MHz, CDCl3) δ 3.93-3.81 (m, 2H, SO2NCH2), 3.78-3.71 (m, 1H, NH2CHH), 3.33-
3.22 (m, 1H, NCH), 3.21-3.1 (m, 5H, NCHCH2CH2, SO2NCH2CH2CH2, NH2CHH), 3.03 (s, 2H, furan-
CH2), 2.51 (s, 3H, ArCH3), 2.46 (s, 3H, ArCH3), 2.14 (s, 3H, ArCH3), 2.12-2.03 (m, 2H, 
SO2NCH2CH2), 1.39-1.28 (m, 2H, NCHCH2), 1.52 (s, 6H, 2 × ArCH3). 
13C NMR (100 MHz, CDCl3) δ 160.1 (ArC), 140.1 (ArC), 135.7 (ArC), 133.7 (ArC), 125.5 (ArC), 
118.0 (ArC), 88.1 (C (CH3)2), 55.1 (CH), 49.2 (CH2), 47.8 (CH2), 42.3 (CH2), 42.2 (CH2), 41.3 (CH2), 
29.5 (CH3), 28.4 (CH3), 26.8 (CH2), 24.2 (CH2), 19.2 (CH3), 17.5 (CH3), 13.8 (CH3).
HRMS-ES+ (m/z): calcd. for C21H33N4O3S [M+H]+: 421.2273, found 421.2276
FT-IR (CHCl3 film, cm−1) 3445 (br m, NH2), 2953 (s, aliphatic CH), 1633 (s), 1426 (m), 1317 (s), 
1140 (s), 1093 (s).
= −40 (c= 0.18, MeOH)
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(S)-2-Amino-4-(methylthio) butan-1-ol hydrochloride (206)122
The general procedure for deprotection of Boc protecting group was followed to yield 206 as 
a pale yellow waxy solid (2.73 g, 94% yield).
TLC (silica gel, 10% AcOH/ EtOH), Rf = 0.46 (UV)
The spectroscopic data are in agreement with those recorded in the literature122
1H NMR (400 MHz, D2O) δ 3.87-3.82 (m, 1H, HOCHH), 3.70-3.65 (m, 1H, HOCHH), 3.49-3.43 
(m, 1H, NH2CH), 2.64 (m, 2H, SCH2), 2.15 (s, 3H, SCH3), 2.02-1.87 (m, 2H, SCH2CH2).
13C NMR (100 MHz, D2O) δ 60.7 (CH2OH), 53.3 (CH), 28.8 (CH2), 28.6 (CH2), 14.6 (CH3). 
ESI+ MS (m/z): 172 [M+H]+
FT-IR (CHCl3 film, cm−1) 3378 (br s, NH2), 2917 (br s, aliphatic CH), 1604 (s, NH), 1497 (s), 
1051 (s, C-O).
= −22 (c= 0.2, CHCl3)
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(S)-1-((tert-butyldimethylsilyl) oxy)-4-(methylthio) butan-2-amine (207)122
Methioninol hydrochloride 206 (2.28 g, 13.38 mmol) and imidazole (1.82 g, 26.76 mmol) were 
suspended in anhydrous acetonitrile. Tert-butyldimethylsilyl triflate 3.66 mL (4.22 g, 15.98 
mmol) was then added dropwise to the resulting suspension at 0 °C under a nitrogen 
atmosphere. The mixture was stirred vigorously at this temperature for 2 h and then it was 
stirred overnight at room temperature. The solvent was evaporated under reduced pressure 
and the residue was stirred with 2 M NaOH (50 mL) for 15 minutes and then extracted with 
dichloromethane three times. The organic phase was washed with water three times to 
remove the excess of imidazole. The solvent was evaporated under reduced pressure. The 
residue was dissolved in the solution of H2O/CH3CN/CH3COOH (60/40/2, 3 × 35 mL). The 
combined aqueous phases were washed with hexane three times and then acetonitrile was 
evaporated in vacuo. The solution was made basic by adding sodium bicarbonate. The 
aqueous solution was extracted with dichloromethane (3 × 10 mL). The combined organics 
were dried over MgSO4 and evaporated in vacuo to obtain 207 (1.8 g, 53%) as a colourless oil. 
No further purification was needed.
TLC (silica gel, 10:1 CHCl3/ MeOH), Rf = 0.45 (ninhydrin) 
The spectroscopic data are in agreement with those recorded in the literature122
1H NMR (400 MHz, CDCl3) δ 3.57-3.51 (m, 1H, OCHH), 3.37 (m, 1H, OCHH), 2.88-2.84 (m, 1H, 
NH2CH), 2.62-2.52 (m, 2H, SCH2), 2.11 (s, 3H, SCH3), 1.72-1.64 (m, 1H, SCH2CHH), 1.52-1.44 
(m, 1H, SCH2CHH), 0.88 (s, 9H, t-Bu), 0.02 (s, 6H, Si(CH3)2).
13C NMR (100 MHz, CDCl3) δ 68.7 (CH2OH), 52.3 (CH), 33.5 (CH2), 31.7 (CH2), 26.4 (t-Bu), 18.8 
(C (CH3)3), 16.2 (CH3), −5.1 (Si(CH3)2).
ESI+ MS (m/z): 250 [M+H]+
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FT-IR (CHCl3 film, cm−1) 3377 (s, NH2), 2926 (s, aliphatic CH), 1474 (m, NH), 1258 (s, C-O), 
1104 (s).
(S)-Tert-butyl (2-isothiocyanato-4-(methylthio) butoxy) dimethylsilane (208)122
The general procedure for the synthesis of isothiocyanate compounds from amines was 
followed to yield 208 as a brown oil (1.7 g, 97%).
TLC (silica gel, 2:1 hexane/ EtOAc), Rf = 0.45 (UV)
The spectroscopic data are in agreement with those recorded in the literature122
1H NMR (400 MHz, CDCl3) δ 3.89-3.87 (m, 1H, SCNCH), 3.74-3.69 (m, 2H, OCH2), 2.55-2.63 (m, 
1H, SCHH), 2.61-2.54 (m, 1H, SCHH), 2.11 (s, 3H, SCH3), 1.88-1.86 (m, 2H, SCH2CH2), 0.81 (s, 
9H, t-Bu), 0.01 (s, 6H, Si(CH3)2).  
13C NMR (100 MHz, CDCl3) δ 135.0 (NCS), 65.4 (CH2OH), 59.0 (CH), 31.6 (CH2), 30.7 (CH2), 25.9 
(t-Bu), 18.4 (C (CH3)3), 15.7 (CH3), -5.3 (Si (CH3)2).  
FT-IR (CHCl3 film, cm−1) 2960 (s, aliphatic CH), 2088 (br s, NCS), 1135 (S, C-O), 830 (S)
CI+ (m/z): 291 [M+H]+
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(S)-2, 2, 4, 6, 7-pentamethyl-N-(2, 2, 3, 3-tetramethyl-6-(2-(methylthio) ethyl)-8-thioxo-4-
oxa-7, 9-diaza-3-siladodecan-12-yl)-2, 3-dihydrobenzofuran-5-sulfonamide (232)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and an amine compound was followed to yield 232 as a pale-yellow foam
(0.833 g, 89.4%).
TLC (silica gel, 2:1 hexane/ EtOAc), Rf = 0.3 (UV) 
1H NMR (400 MHz, CDCl3) δ 3.70-3.63 (m, 4H, OCH2, SCNHCH2), 2.97-2.92 (m, 2H, SO2NHCH2), 
2.95 (s, 2H, furan-CH2), 2.61-2.51 (m, 2H, SCH2), 2.54 (s, 3H, ArCH3), 2.47 (s, 3H, ArCH3), 2.13 
(s, 3H, ArCH3), 2.09 (s, 3H, SCH3), 1.83-1.55 (m, 5H, SCNHCH, SCH2CH2, NHCH2CH2), 1.46 (s, 6H,
(CH3)2), 0.87 (s, 9H, t-Bu), 0.06 (s, 3H, SiCH3), 0.05 (s, 3H, SiCH3). 
13C NMR (100 MHz, CDCl3) δ 182.6 (C=S), 162.1 (ArC), 155.3 (ArC), 139.3 (ArC), 135.7 (ArC), 
125.4 (ArC), 118.2 (ArC), 86.7 (C(CH3)2), 43.3 (CH2), 39.3 (CH2), 34.6 (CH2), 31.0 (CH2), 28.8 
(C(CH3)2), 25.0 (t- Bu), 19.7 (CH3), 18.6 (C(CH3)3), 18.0 (CH3), 15.6 (CH3), 12.7 (CH3), −5.1 
(Si(CH3)2). 
HRMS-ES+ (m/z): calcd. for C28H52N3O4S3Si [M+H]+: 618.2889 found 618.2892
FT-IR (CHCl3 film, cm−1) 3371 (br s, NH), 2954 (s, aliphatic CH), 1552 (m), 1459 (m), 1305 (s), 
1135 (s), 1093 (s).
= −24 (c= 1.1, CHCl3)
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(S)-2, 2, 4, 6, 7-pentamethyl-N-(2, 2, 3, 3-tetramethyl-6-(2-(methylthio) ethyl)-8-thioxo-4-
oxa-7, 9-diaza-3-silatridecan-13-yl)-2, 3-dihydrobenzofuran-5-sulfonamide (232A)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amino compound was followed to yield 232A as a pale-yellow foam (0.89 
g, 82%).
TLC (silica gel, 2:1 hexane/ EtOAc), Rf = 0.35 (UV) 
1H NMR (400 MHz, CDCl3) δ 3.66-3.52 (m, 4H, OCH2, SCNHCH2), 3.41-3.32 (m, 2H, SO2NHCH2), 
2.92 (s, 2H, furan-CH2), 2.9-2.81 (m, 2H, SO2NHCH2CH2), 2.61-2.51 (m, 2H, SCH2), 2.47 (s, 3H, 
ArCH3), 2.41 (s, 3H, ArCH3), 2.13 (s, 3H, ArCH3), 2.04 (s, 3H, SCH3), 1.83-1.55 (m, 5H, SCNHCH, 
SCH2CH2, NHCH2CH2), 1.41 (s, 6H, (CH3)2), 0.87 (s, 9H, t-Bu), 0.01 (s, 6H, Si(CH3)2. 
13C NMR (100 MHz, CDCl3) δ 180.5 (C=S), 161.2 (ArC), 152.4 (ArC), 139.5 (ArC), 136.2 (ArC), 
125.7 (ArC), 118.5 (ArC), 86.2 (C(CH3)2), 43.3 (CH2), 38.9 (CH2), 34.8 (CH2), 33.2 (CH2), 31.1 
(CH2), 28.9 (C(CH3)2), 25.7 (t- Bu), 18.9 (CH3), 18.7 (C(CH3)3), 18.6 (CH3), 15.7 (CH3), 12.8 (CH3), 
−5.3 (Si(CH3)2). 
HRMS-ES+ (m/z): calcd. for C29H52N3O4S3Si [M-H]-: 630.2889 found 630.2862
FT-IR (CHCl3 film, cm−1) 3373 (br s, NH), 2951 (s, aliphatic CH), 1553 (m), 1457 (m), 1304 (s), 
1134 (s), 1092 (s).
= −22 (c= 1.38, CHCl3)
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(S)-8-(((tert-butyldimethylsilyl) oxy) methyl)-1-((2, 2, 4, 6, 7-pentamethyl-2, 3-
dihydrobenzofuran-5-yl) sulfonyl)-1, 3, 4, 6, 7, 8-hexahydro-2H-pyrimido [1, 2-a] 
pyrimidine (233)
The general procedure for the cyclisation of thiourea was followed to obtain 233 as a yellow 
powder (64 mg, 80%).
TLC (silica gel, EtOAc: 1% TEA), Rf = 0.4 (UV, CAM).
X-Ray Crystallographic structure for 233
1H NMR (400 MHz, CDCl3) δ 3.92-3.79 (m, 2H, SO2NCH2), 3.62-3.60 (m, 1H, OCHH), 3.33-3.28 
(m, 1H, NCH), 3.12-2.99 (m, 4H, NCHCH2CH2, SO2NCH2CH2CH2), 2.83-2.80 (m, 1H, OCHH), 3.00 
(s, 2H, furan-CH2), 2.52 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.13 (s, 3H, ArCH3), 2.06-1.93 (m, 
3H, SO2NCH2CH2, NCHCH2), 1,46 (s, 6H, (CH3)2), 1.37-1.29 (m, 1H, NCHCHH), 0.85 (s, 9H, t-Bu), 
0.01 (s, 6H, Si(CH3)2). 
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13C NMR (100 MHz, CDCl3) δ 159.1 (ArC), 143.2 (ArC), 137.7 (ArC), 132.7 (ArC), 124.3 (ArC), 
117.1 (ArC), 86.4 (C(CH3)2), 60.3 (CH2), 50.3 (CH), 48.3 (CH2), 47.7 (CH2), 43.2 (CH2), 42.1 (CH2), 
40.3 (CH2), 28.5 (CH3), 28.5 (CH3), 27.7 (CH2), 25.9 (t-Bu), 23.3 (CH2), 19.1 (CH3), 18.1 (C(CH3)3), 
17.2 (CH3), 12.5 (CH3), -5.3 (Si(CH3)2)
HRMS-ES+ (m/z): calcd. for C28H52N3O4S3Si [M+H]+: 536.2978 found 536.2999
FT-IR (CHCl3 film, cm−1) 3445 (br m, NH), 2955 (s, aliphatic CH), 1636 (s,), 1426 (m), 1317 (s), 
1136 (s), 1095 (s).
(S)-(9-((2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-yl) sulfonyl)-3, 4, 6, 7 , 8, 9-
hexahydro-2H-pyrimido[1, 2-a] pyrimidin-2-yl) methanol (234)
Compound 233 (150 mg, 0.35 mmol) was dissolved in tetrahydrofuran (5 mL). TBAF (1 M in 
THF, 433 μl, 0.40 mmol) was added dropwise to the resulting mixture. The suspension was 
stirred for 20 h at room temperature. The solvent was evaporated under reduced pressure
and the residue was washed with ether (3×10 mL). The result was concentrated in vacuo and 
purified by using flash column chromatography through silica gel and using the eluent of 
chloroform and methanol to get a white solid 234 after removal of solvent (81 mg, 55%).
TLC (silica gel, 50:1 CHCl3/ MeOH), Rf = 0.36 (CAM)
1H NMR (400 MHz, CD3OD) δ 3.91-3.86 (m, 1H, SO2NCHH), 3.76-3.72 (m, 1H, SO2NCHH), 3.53-
3.50 (m, 1H, HOCHH), 3.29- 3.24 (m, 1H, NCH), 3.18 (s, 2H, furan-CH2), 3.15-3.10 (m, 2H, 
HOCHH, NCHCH2CH2), 3.06-3.04 (m, 2H, SO2NCH2CH2CH2), 2.96-2.92 (m, 1H, NCHCH2CH2), 
2.32 (s, 3H, ArCH3), 2.08-1.91 (m, 2H, SO2NCH2CH2), 1.64-1.51 (m, 2H, NCHCH2). 2.59 (s, 3H, 
ArCH3), 2.58 (s, 3H, ArCH3), 2.28-2.23 (m, 1H, OCH2CHH), 2.22 (s, 3H, ArCH3), 2.04-1.89 (m, 5H, 
NCHCH2, SO2NCH2CH2, OCH2CHH), 1.57 (s, 6H, ArCH3). 
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13C NMR (100 MHz, CDOD) δ 159.3 (ArC), 144 (ArC), 138.5 (ArC), 134.8 (ArC), 124.6 (ArC), 
117.2 (ArC), 86.5 (C(CH3)2), 60.2 (CH2), 50.1 (CH), 48.4 (CH2), 43.4 (CH2), 42.3 (CH2), 40.5 (CH2), 
28.6 (CH3), 28.3 (CH3), 27.8 (CH2), 26 (t-Bu), 23.5 (CH2), 19.1 (CH3), 18.3 (C(CH3)3), 17.2 (CH3), 
12.6 (CH3), -5.4 (Si(CH3)2). 
HRMS-ES+ (m/z): calcd. for C21H32N3O4S [M+H]+: 422.2114 found 422.2110
FT-IR (CHCl3 film, cm−1) 3478 (br m, OH), 2856 (m, aliphatic CH), 1593 (s), 1494 (m), 1313 (s), 
1165(s), 1093 (m), 1037 (m).
= −45 (c= 0.14, MeOH)
1,5-bis(((S)-9-((2, 2, 4, 6, 7-pentamethyl-2, 3-dihydrobenzofuran-5-yl) sulfonyl)-3, 4, 6, 7, 8,
9-hexahydro-2H-pyrimido [1, 2-a] pyrimidin-2-yl) methoxy) pentane (236)
Sodium hydride (10 mg, 0.41 mmol) was added to the solution of compound 234 (90 mg, 0.21 
mmol) in dichloromethane (20 mL). The mixture was stirred vigorously at room temperature 
for 30 min. 1,5-Dibromopentane (24 mg, 0.1 mmol) was added to the resulting product. The 
mixture was stirred at room temperature for 24 h and then H2O (20 mL) was added. The 
aqueous layer was extracted with dichloromethane (3 × 10 mL). The organic layer was washed 
with water and then with brine. The combined organic layers were dried over MgSO4 and then 
concentrated to get crude compound. The yield of compound 236 after purification through 
silica gel and using the eluent of chloroform and methanol was (73.5 mg, 77%) as a colourless 
oil. 
TLC (silica gel, 50:1 CHCl3/ MeOH), Rf = 0.22 (UV)
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1H NMR (400 MHz, CDCl3) δ 3.56-3.46 (t, 4H, OCH2CH2, J= 7.6 Hz), 3.4-3.3 (m, 2H. NCH), 
3.25-3.13 (m, 4H, CHCH2O), 3.11-3.03 (m, 4H, SNCH2), 2.8-2.91 (m, 4H, NCH2), 3.06 (s, 4H, 
CH2-Furan), 2.56 (s, 6H, 2CH3), 2.5 (s, 6H, 2CH3),1.9-1.81 (m, 4H, NCHCH2) 2.13 (s, 6H, 2CH3), 
1.74-153 (m, 10H, NCH2CH2, OCH2CH2CH2) , 1.49 (s, 12H, 4CH3, Furan), 1.4-1.25 (m, 4H, 
OCH2CH2).
13C NMR (100 MHz, CDCl3) δ 159.3 (ArC), 138.9 (ArC), 136.1 (ArC), 133.8 (ArC), 125.3 (C=N), 
124.8 (ArC), 116.7 (ArC), 86.5 (C (CH3)2), 78.5 (CH2), 76.1 (CH2), 74.2 (CH2), 54.3 (CH), 48.1 
(CH2), 45.3 (CH2), 42.5 (CH2), 41.2 (CH2), 32.1 (CH2), 29.3 (CH3), 25.1 (CH2), 22.4 (CH2), 23.3 
(CH2), 19.2 (CH3), 18.2 (CH3), 17.1 (CH3).
MS-ESI: m/z = 911.4 [M+H]+
FT-IR (CHCl3 film, cm−1) 2866 (m, aliphatic CH), 1593 (s), 1494 (m), 1313 (s), 1137 (s, C-O), 
1093 (m), 1037 (m).
(S)-1-(3-azidopropyl)-3-(1-((tert-butyldimethylsilyl) oxy)-4-(methylthio) butan-2-yl) 
thiourea (209)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amino compound was followed to yield 209 as a pale-yellow oil (0.83 g, 
73%).
TLC (silica gel, 2:1 hexane/ EtOAc), Rf= 0.31 (UV)
1H NMR (300 MHz, CDCl3) δ 3.67-3.56 (m, 3H, OCH2, NHCH), 3.4-3.29 (m, 2H, NHCH2), 2.53-
2.45 (t, 2H, SCH2, J=7.6 Hz) 2.03 (s, 3H, SCH3), 1.81-1.72 (m, 2H, SCH2CH2), 1.6-151 (m, 4H, 
N3CH2, N3CH2CH2), 0.82 (s, 9H, C (CH3)3), 0.01 (s, 6H, Si (CH3)2).   
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13C NMR (300 MHz, CDCl3) δ 181.1 (CS), 67.2 (CH2), 55.1 (CH), 50.5 (CH2), 49.1 (CH2), 33.2 
(CH2), 29.2 (C (CH3)3), 27.1 (CH3), 25.3 (C (CH3)3, 19.2 (CH2), 13.5 (SCH3), -5.3 (Si(CH3)2).
HRMS-ES+ (m/z): calcd. for C15H34N5OS2Si [M+H]+: 392.1969, found 392.1969
FT-IR (CHCl3 film, cm−1) 3363 (br s, NH), 2952 (s, aliphatic CH), 2089 (s, N3), 1551 (m), 1456 
(m), 1303 (s), 1137 (s), 1090 (s).
= −25 (c= 0.14, CHCl3)
(S)-1-(4-azidobutyl)-3-(1-((tert-butyldimethylsilyl) oxy)-4-(methylthio) butan-2-yl) thiourea 
(210)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amino compound was followed to yield 210 as a colourless oil (2.1 g, 75%).
TLC (silica gel, hexane: diethyl ether), Rf= 0.08 (UV)
1H NMR (400 MHz, CDCl3) δ 3.65-3.55 (m, 2H, OCH2),3.41-3.39 (m, 2H SCNHCH2), 3.29-3.21 
(m, 3H, NHCH, SCH2), 2.5-2.38 (m, 2H, NHCH2CH2), 1.99 (s, 3H, SCH3), 1.89-1.52 (m, 4H, 
SCH2CH2, N3CH2), 1.51-1.49 (m, 2H, N3CH2CH2), 0.89 (s, 9H, t-Bu), 0.01 (s, 6H, Si(CH3)2).
13C NMR (100 MHz, MeOD) δ 182 (CS), 62.4 (CH2), 58.3 (CH), 51.3 (CH2), 31.1 (CH2), 29,3 (C 
(CH3)3), 28.4 (CH2), 26.1 (CH2), 23.3 (CH2), 22.9 (CH2), 22.5 (t-Bu), 15.9 (SCH3), -5.2 (Si (CH3)2).
HRMS-ES+ (m/z): calcd. for C16H36N5OS2Si [M+H]+: 406.2125, found 406.2130
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FT-IR (CHCl3 film, cm−1) 3368 (br s, NH), 2954 (s, aliphatic CH), 2087 (s, N3), 1554 (m), 1453 
(m), 1301 (s), 1135 (s), 1092 (s).
= −22 (c= 0.55, CHCl3)
(S)-1-(5-azidopentyl)-3-(1-((tert-butyldimethylsilyl) oxy)-4-(methylthio) butan-2-yl) 
thiourea (211)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amino compound was followed to yield 211 as a colourless oil (518 mg, 
75%).
TLC (silica gel, hexane: diethyl ether), Rf= 0.12 (UV)
1H NMR (400 MHz, CDCl3) δ 3.68-3.58 (m, 2H, OCH2), 3.27-3.16 (m, 3H, NCH, NHCH2), 2.55-
2.44 (m, 2H, SCH2), 2.03 (s, 3H, SCH3), 1.83-1.72 (m, 2H, SCH2CH2), 162-1.48 (m, 4H, N3CH2, 
NHCH2CH2), 1.4-131 (m, 2H, N3CH2CH2CH2), 1.29-1287 (m, 2H, N3CH2CH2), 0.82 (s, 9H, t-Bu), 
0.01 (s, 6H, Si(CH3)2).
13C NMR (100 MHz, MeOD) δ 181.9 (CS), 63.6 (CH2), 58.2 (CH), 51.4 (CH2), 50.2 (CH2), 49.1 
(CH2), 48.3 (CH2), 32.1 (CH), 27.5 (CH2), 25.8 (t-Bu), 24.1 (CH2), 18.2 (CH2), 15.5 (SCH3), −5.7 (Si 
(CH3)2).
HRMS-ES+ (m/z): calcd. for C17H38N5OS2Si [M+H]+: 420.2287, found 420.2281.
FT-IR (CHCl3 film, cm−1) 3366 (br s, NH), 2952 (s, aliphatic CH), 2088 (s, N3), 1556 (m), 1454 
(m), 1302 (s), 1137 (s), 1095 (s).
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= −30 (c= 0.54, CHCl3)
(S)-1-(3-azidopropyl)-4-(((tert-butyldimethylsilyl) oxy) methyl)-2-(methylthio)-1, 4, 5, 6-
tetrahydropyrimidine (212)
The general procedure for the cyclisation of thiourea was followed to obtain 212 (1.24 g, 68%) 
as a colourless oil.
TLC (silica gel, 2:1 hexane/ EtOAc), Rf= 0.3 (UV)
1H NMR (300 MHz, MeOD) δ 3.8-3.71 (m, 2H, OCH2), 3.4-3.31 (m, 4H, NCH2, N3CH2), 3.25-3.1 
(m, 3H, NCH2CH2, NCH), 2.21 (s, 3H, SCH3), 1.61-1.48 (m, 4H, N3CH2CH2, NCH2), 0.82 (s, 9H, t-
Bu), 0.01 (s, 6H, Si (CH3)2).   
13C NMR (300 MHz, CDCl3) δ 154.6 (C=N), 67.7 (CH2), 56.2 (CH), 52.9 (CH2), 50.9 (CH2), 49.1
(CH2), 45.2 (CH2), 27.2 (C (CH3)2), 26.1 (CH2), 25.0 (C (CH3)3), 13.2 (SCH3), −5.3 (Si (CH3)2). 
HRMS-ES+ (m/z): calcd. For C15H32N5OSSi [M+H]+: 358.2097, found 358.2106
= −33 (c= 0.26, CHCl3)
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(S)-8-(((tert-butyldimethylsilyl) oxy) methyl)-1, 3, 4, 6, 7, 8-hexahydro-2H-pyrimido [1, 2-a] 
pyrimidine (215)
The general procedure for the hydrogenation of azides to amines by using activated zinc and 
ammonium chloride was followed to yield 215 as white foam (2.3 g, 85%).
TLC (silica gel, 10:1 CH3Cl/ MeOH), Rf= 0.66 (UV)
1H NMR (400 MHz, MeOD) δ 3.61-3.52 (m, 2H, OCH2), 3.45-3.35 (m, 2H, NHCH2), 3.21-3.15 
(m, 4H, NCH2, NCH2), 3.14-3.091 (m, 4H, NHCH2CH2), 1.82-1.68 (m, 2H, NCH2CH2, 0.84 (s, 9H, 
t-Bu), 0.01 (s, 6H, Si (CH3)2).
13C NMR (100 MHz, MeOD) δ 153.5 (C=N), 68.3 (CH2), 58.7 (CH), 45.7 (CH2), 43.5 (CH2), 42.3 
(CH2), 30.5 (C (CH3)3), 25.9 (t-Bu), 23.7 (CH2), 21.3 (CH2), −5.5 (Si (CH3)2).
HRMS-ES+ (m/z): calcd. for C14H29N3OSi [M+H]+: 284.2158, found 284.2166
FT-IR (CHCl3 film, cm−1) 3450 (br m, NH), 2953 (s, aliphatic CH), 1631 (s,), 1429 (m), 1317 (s), 
1136 (s, C-O), 1093 (s).
= −45 (c= 0.133, CHCl3)
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(S)-1-(4-Azidobutyl)-4-(((tert-butyldimethylsilyl) oxy) methyl)-2-(methylthio)-1, 4, 5, 6-
tetrahydropyrimidine (213) 
The general procedure for the cyclisation of thiourea was followed to yield 213 as a 
colourless oil (1.1 g, 65%).
TLC (silica gel, diethyl ether), Rf= 0.52 (UV)
1H NMR (300 MHz, MeOD) δ 3.9-3.73 (m, 2H, OCH2), 3.6-3.34 (m, 4H, NCH2, N3CH2), 3.31-2.9 
(m, 3H, NCH2CH2, NCH), 2.21 (s, 3H, SCH3), 1.64-1.49 (m, 4H, N3CH2CH2, NCH2), 1.39-1.28 (m, 
2H, NCHCH2), 0.83 (s, 9H, t-Bu), 0.01 (s, 6H, Si (CH3)2).   
13C NMR (300 MHz, CDCl3) δ 151.0 (C=N), 68.2 (CH2), 57.1 (CH), 53.3 (CH2), 49.1 (CH2), 48.8 
(CH2), 33.1 (C (CH3)2), 29.3 (CH2), 28.2 (CH2), 26.1 (C (CH3)3, 24.3 (CH2), 12.2 (CH3), -1 (Si (CH3)2.
HRMS-ES+ (m/z): calcd. for C16H34N5OSSi [M+H]+: 372.2253, found 372.2258
FT-IR (CHCl3 film, cm−1) 3366 (br s, NH), 2955 (s, aliphatic CH), 2089 (s, N3), 1552 (m), 1453 
(m), 1303 (s), 1130 (s, C-O), 1090 (s).
= −35 (c= 0.14, CHCl3)
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(S)-1-(5-azidopentyl)-4-(((tert-butyldimethylsilyl) oxy) methyl)-2-(methylthio)-1, 4, 5, 6-
tetrahydropyrimidine (214)
The general procedure for the cyclisation of thiourea was followed to yield 214 as a 
colourless oil (1.8 g, 66%).
TLC (silica gel, diethyl ether), Rf= 0.62 (UV)
1H NMR (300 MHz, MeOD) δ 4.1-3.83 (m, 2H, OCH2), 3.75-3.38 (m, 4H, NCH2, N3CH2), 3.34-
2.95 (m, 3H, NCH2CH2, NCH), 2.22 (s, 3H, SCH3), 1.71-1.52 (m, 4H, N3CH2CH2, NCH2), 1.42-1.29 
(m, 4H, NCHCH2, N3CH2CH2CH2), 0.83 (s, 9H, t-Bu), 0.01 (s, 6H, Si (CH3)2).   
13C NMR (300 MHz, CDCl3) δ 158.1 (C=N), 62.3 (OCH2), 52 (CH2), 51.2 (CH2), 50.5 (CH2), 49.8 
(CH2), 40.2 (C (CH3)3), 29.1 (CH2), 28.0 (CH2), 27.6 (CH2), 24.1 (C (CH3)3, 23.2 (CH2), 18.2 (SCH3), 
0.4 (Si (CH3)2.
HRMS-ES+ (m/z): calcd. for C17H36N5OSSi [M+H]+: 386.2415, found 386.2410
FT-IR (CHCl3 film, cm−1) 3363 (br s, NH), 2952 (s, aliphatic CH), 2091(s, N3), 1553 (m), 1455 
(m), 1302 (s), 1131 (s, C-O), 1091 (s).
= −38 (c= 0.2, CHCl3)
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(S)-2-(((tert-butyldimethylsilyl) oxy) methyl)-2, 3, 4, 6, 7, 8, 9, 10-octahydropyrimido [1, 2-
a] [1, 3] diazepine (216)
The general procedure for the hydrogenation of azides to amines by using activated zinc and 
ammonium chloride was followed to yield 216 as a white foam (686.5 mg, 70%).
TLC (silica gel, EtOAc: 1% TEA) Rf= 0.11 (UV)
1H NMR (300 MHz, CDCl3) δ 3.71-3.55 (dd, 2H, OCH2), 3.51-3.32 (m, 4H, (NCH2, NHCH2), 3.1-
2.89 (m, 2H, NCHCH2CH2), 1.82-2.21 (m, 4H, NHCH2CH2CH2, NHCH2CH2), 1.52-1.5 (m, 3H, 
NCHCH2, NCH), 0.83 (s, 9H, t-Bu), -0.01 (s, 6H, Si (CH3)2).
13C NMR (300 MHz, CDCl3) δ 158.2 (C=N), 62.5 (OCH2), 54 (CH2), 52.4 (CH2), 51.3 (CH2), 50.2 
(CH2), 41.5 (C (CH3)3), 25 (CH2), 23.0 (CH2), 22.6 (CH2), 23.2 (C (CH3)3), -0.39 (Si (CH3)2).
HRMS-ES+ (m/z): calcd. for C15 H32 N3 O Si [M+H]+: 298.2315, found 298.2325
FT-IR (CHCl3 film, cm−1) 3452 (br m, NH), 2950 (s, aliphatic CH), 1634 (s,), 1430 (m), 1318 (s), 
1137 (s, C-O), 1092 (s).
= −42 (c= 0.16, CHCl3)
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(S)- (3, 4, 6, 7, 8, 9-hexahydro-2H-pyrimido [1, 2-a] pyrimidin-2-yl) methanol (219)
The general procedure for the de-protection of silyl group by utilising trifluoroacetic acid was 
followed to yield 219 as a pale-yellow oil (366 mg, 82%).
TLC (silica gel, 5:2 MeOH/ DCM), Rf = 0.25 (CAM)
1H NMR (400 MHz, MeOD) δ 3.21-3.11 (m, 3H, OCH2, NCH), 3.09-3.0 (m, 2H, NHCH2), 2.91-
2.75 (m, 4H, NCH2, NCH2), 1.69-1.45 (m, 4H, NHCH2CH2, NCH2CH2).
13C NMR (100 MHz, MeOD) δ 150.4 (C=N), 63.5 (CH2), 50.25 (CH), 46.2 (CH2), 45.1 (CH2), 37.8 
(CH2), 22.5 (CH2), 20.6 (CH2).
HRMS-ES+ (m/z): calcd. for C8H15N3O [M+H]+: 170.1288, found 170.1283
FT-IR (CHCl3 film, cm−1) 3475 (br m, OH), 3380 (br, NH) 2859 (m, aliphatic CH), 1633 (s, NH), 
1604 (C=N), 1590 (m), 1491 (m), 1315 (s).
= −75 (c= 0.12, MeOH)
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(S)- (2, 3, 4, 6, 7, 8, 9, 10-octahydropyrimido [1, 2-a] [1, 3] diazepin-2-yl) methanol (220)
The general procedure for the de-protection of silyl group by utilising trifluoroacetic acid was 
followed to yield 220 as a pale-yellow oil (293 mg, 80%).
TLC (silica gel, 5:2 MeOH/ DCM), Rf = 0.21 (CAM)
1H NMR (400 MHz, MeOD) δ 3.78-3.64 (m, 3H, OCH2, NCH), 3.63-3.53 (m, 4H, NHCH2, NCH2), 
3.16-3.08 (m, 2H, NCH2), 2.11-2.01 (m, 2H, NHCH2CH2), 1.89-1.66 (m, 2H, NCH2CH2), 1.3 (m, 
2H, NCH2CH2).
13C NMR (100 MHz, MeOD) δ 151.5 (C=N), 63.0 (CH2), 58.5 (CH), 48.5 (CH2), 45.1 (CH2), 38.3
(CH2), 27.1 (CH2), 25.3 (CH2), 24.1 (CH2).
HRMS-ES+ (m/z): calcd. for C9H18N3O [M+H]+: 184.1444, found 184.1443
FT-IR (CHCl3 film, cm−1) 3469 (br m, OH), 3383 (br, NH) 2855 (m, aliphatic CH), 1636 (s, NH), 
1608 (C=N), 1590 (m), 1491 (m), 1317 (s).
= −72 (c= 0.14, MeOH)
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(S)-1-(1-azido-4-(methylthio) butan-2-yl)-3-(3-azidopropyl) thiourea (227)
The general procedure for the synthesis of thiourea compounds by the reaction between 
isothiocyanate and amines was followed to yield 227 as a yellow oil (1.81 mg, 77%).
TLC (silica gel, 2:1 Hexane/ EtOAc), Rf = 0.17 (KMnO4)
1H NMR (400 MHz, CDCl3) δ 3.53-3.45 (m, 2H, (NHCH2), 2.83-2.75 (m, 1H, NHCH), 2.65-2.55 
(m, 2H, SCH3CH2), 2.06 (s, 3H, SCH3), 1.97-1.88 (m, 2H, NHCHCH2), 179-1.72 (m, 4H, (N3CH, 
N3CH2CH2), 1.7-1.61 (m, 2H, N3CH2CH)
13C NMR (125 MHz, CDCl3) δ 182.4 (C=S), 59.2 (CH), 54.1 (CH2), 49.7 (CH2), 48.3 (CH2), 32.5 
(CH2), 30.1 (CH2), 28.3 (CH2), 16.2 (CH3).
HRMS-ES+ (m/z): calcd. for C9H18N8S2 [M+H]+: 303.1174, found 303.1172 
FT-IR (CHCl3 film, cm−1) 3368 (br s, NH), 2953 (s, aliphatic CH), 2088 (s, N3), 1553 (m), 1450 
(m), 1304 (s), 1094 (s).
= −29 (c= 0.20, CHCl3)
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(S)-4-(azidomethyl)-1-(3-azidopropyl)-2-(methylthio)-1, 4, 5, 6-tetrahydropyrimidine (228)
Azide 227 (1 g, 3.31 mmol) was dissolved in dichloromethane (30 mL). Diisopropylethylamine 
(0.21 mL) (155.82 mg, 1.2 mmol) was added to the resulting reaction. Methyl triflate (0.9 mL) 
(1.3 g, 7.94 mmol) was added dropwise at 0 °C. The mixture was stirred at r.t. for 4 h. Then 
diisopropylethylamine (5.5 mL) (4.08 g, 31.57 mmol) was added to the resulting mixture and 
heated under refluxed overnight. The mixture was cooled and then washed with 2M NaOH 
and H2O. The organic layer was dried over MgSO4 and then concentrated to obtain the crude 
product. Purification by using column chromatography purification through silica gel and 
using the eluent of hexane and ethyl acetate (1:1) afforded the product after removal of 
solvent as a yellow oil (612 mg, 69%).
TLC (silica gel, 1:1 Hexane/ EtOAc), Rf = 0.31 (UV)
1H NMR (300 MHz, CDCl3) δ 3.42-3.38 (m, 1H, NCH), 2.82-3.72 (m, 2H, NCH2), 2.43 (s, 3H, 
SCH3), 2.4-2.29 (m, 2H, N3CH2CH2CH2), 1.93-1.72 (m, 2H, NCHCH2), 1.65-1.55 (m, 2H, N3CH2),
1.52-1.4 (m, 2H, N3CH2CH2), 1.39-1.3 (m, 2H, N3CH2).
13C NMR (125 MHz, CDCl3) δ 167.0 (C=N), 63.1 (CH), 55.0 (CH2), 49.2 (CH2), 45.1 (CH2), 35.0 
(CH2), 27.1 (CH2), 18.2 (CH2), 14.2 (SCH3).
HRMS-ES+ (m/z): calcd. for C9H16N8S [M+H]+: 269.1297, found 269.1285
FT-IR (CHCl3 film, cm−1) 2956 (s, aliphatic CH), 2090 (s, N3), 1556 (m), 1452 (m), 1303 (s), 
1092 (s).
= −33 (c= 0.28, CHCl3)
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(S)- (3, 4, 6, 7, 8, 9-hexahydro-2H-pyrimido [1, 2-a] pyrimidin-2-yl) methanamine (229)
The general procedure for the hydrogenation of azides to amines by using activated zinc and 
ammonium chloride was followed to yield 229 as a pale-yellow foam (322.6 mg, 82%).
TLC (silica gel, 5:2 MeOH/ DCM), Rf = 0.25 (CAM)
1H-NMR (300 MHz, CDCl3) δ 3.45 (m, 2H, NHCH), 3.41-3.35 (m, 2H, NH2CH2), 3.31-3.24 (m, 
2H, NHCH2), 3.1-2.95 (m, 2H, NCH2), 2.92-2.81 (m, 2H, NCH2) 1.73-1.65 (m, 2H, NCH2CH2), 
1.52-1.43 (m, 2H, NCH2CH2).
13C-NMR (100 MHz, CDCl3) δ 150.1 (C=N), 63.0 (CH2), 50.3 (CH), 45.1 (CH2), 40.1 (CH2), 38,4
(CH2), 33.2 (CH2), 22.0 (CH2)
HRMS-ES+ (m/z): calcd. for C8H17N4 [M+H]+: 169.1453, found 169.1447
FT-IR (CHCl3 film, cm−1) 3477 (br m, NH2), 2860 (m, aliphatic CH), 1631 (s, NH), 1603 (C=N) 
1591(s), 1493 (m), 1317 (s), 1166 (s), 1098 (m), 1037 (m).
= −70 (c= 0.16, MeOH)
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(S)-8-(chloromethyl)-1, 3, 4, 6, 7, 8-hexahydro-2H-pyrimido [1, 2-a] pyrimidine (221)
The general procedure for the synthesis of alkyl halides from alcohols was followed to yield 
221 (423.3 mg, 73%) as a brown oily product.
TLC (silica gel, 10:0.2% DCM/ MeOH), Rf = 0.32 (UV)
1H-NMR (300 MHz, CDCl3) δ 3.68-3.70 (m, H, NCH), 3.60-3.64 (m, 2H, CH2Cl), 3.59-3.55 (m, 
2H, NHCH2), 3.46-3.51 (m, 2H, NCH2), 3.39-3.44 (m, 2H, NCH2), 1.69-1.65 (m, 2H, 
NCH2CH2)1.59-1.64 (m, 2H, NCH2CH2).
13C-NMR (100 MHz, CDCl3) δ 150.1 (C=N), 59.1 (CH), 52.4 (CH2), 47.3 (CH2), 44.3 (CH2), 41.1
(CH2), 30.3 (CH2), 26.0 (CH2).
HRMS-ES+ (m/z): calcd. for C8H15N3 [M-H]+: 188.0955, found 188.0958
FT-IR (CHCl3 film, cm−1) 3472 (br s, NH), 2860 (m, aliphatic CH), 1633 (s, NH), 1605 (C=N) 
1593(s), 1490 (m), 1315 (s).
= −52 (c= 0.15, MeOH)
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(S)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl) propanoic acid (223)134
L-tyrosine (7.4 g, 40.8 mmol) was suspended in 1/1 dioxane/ water (50 mL/ 50 mL). TEA (8.5 
mL) was added to the resulting solution. Then Boc anhydride (11 g, 50.4 mmol) was added to 
the resulting reaction at 0 °C. After 30 min, the cold bath was removed and then the mixture 
was stirred for 18 h at room temperature. The solvent was evaporated under reduced 
pressure and then dichloromethane (25 mL) and water (25 mL) were added. The aqueous 
layer was washed with dichloromethane three times. The aqueous layer was made acidic with 
1 M HCl and then extracted with dichloromethane three times. Combined organic layers were 
dried over MgSO4 and then the solvent was evaporated under reduced pressure to get a white 
foam of 223 (8.6 g, 75%), for which no further purification was needed.
TLC (silica gel, EtOAc), Rf = 0.35 (UV)
The spectroscopic data are in agreement with those recorded in the literature.134 
1H-NMR (300 MHz, DMSO) δ 7.01 (d, 2H, 2ArH, J= 7.8 Hz), 6.66 (d. 2H, 2ArH, J=7.8 Hz), 4.02 
(m, 1H, CH), 2.83 (m, 2H, ArCH2), 1.33 (s, 9H, Boc)
13C NMR (125 MHz, DMSO) δ 174.5 (COOH), 155.9 (C=O, Boc), 157.1 (COH), 130.4 (2ArC), 
128.2 (ArC), 127.0 (ArC), 115.1 (2ArC), 78.1 (C (CH3)), 56.1 (NHC), 36.2 (CH2), 30.1 (C (CH3)3), 
28.4 C (CH3)3.
FT-IR (CHCl3 film, cm−1) 3366 (br s, OH, phenolic), 3290 (br s, OH, COOH), 2930 (m, aliphatic 
CH), 1711 (s, C=O, COOH), 1480 (m), 1540 (m), 1367 (m), 1226 (s), 823 (s).
HRMS-ES+ (m/z): calcd. for C14H19NNaO5 [M+ Na]+: 304.1161, found 304.1169.
Experimental Part                                                                            Chapter four
133
(R)-2-((tert-butoxycarbonyl) amino)-3-(4-(((S)-3, 4, 6, 7, 8, 9-hexahydro-2H-pyrimido [1, 2-
a] pyrimidin-2-yl) methoxy) phenyl) propanoic acid (224)
The general procedure for the synthesis of modified amino acid having bicyclic guanidine in 
their side chain was followed to yield 224 (323 mg, 68%) as a white foam.
TLC (silica gel, 10:1 DCM/ MeOH), Rf = 0.7 (UV)
1H-NMR (300 MHz, CDCl3) δ 6.8 (d, 2H, 3JHH=7.8 Hz), 6.5 (d, 2H, 3JHH=7.8 Hz), 4.69-4.58 (m, 
1H, CHCOOH), 4.06-4.19 (m, 2H, NCHCH2), 3.37-3.43 (m, 2H, NHCH), 2.8-3.1 (m, 2H, ArCH2), 
2.78-2.69 (m, 2H, NHCH2), 2.68-2.63 (m, 2H, NCH2), 2.62-2.56 (m,2H,NCH2), 1.73-1.67 (m, 
2H, NHCH2CH2), 1.59-1.49 (m, 2H, NCH2CH2), 1.39 (s, 9H, C(CH3)3). 
 
13C-NMR (100 MHz, CDCl3) δ 174 (COOH), 157.8 (ArC), 155.3 (Boc, CO), 151.3 (C=N), 129.3 
(2ArC), 126.8 (ArC), 114.5 (2ArC), 77.1 (C(CH3), 71.3 (CH2), 68.1 (CH), 53.4 (CH), 49.5 (CH2), 
43.8 (CH2), 37.8 (CH2), 28.2 (CH2), 27.6 (C(CH3)3), 24.6 (CH2). 
 
HRMS-ES+ (m/z): calcd. for C22H33N4O5 [M+H]+: 433.2451, found 433.2451
FT-IR (CHCl3 film, cm−1) 3372(br s, NH), 3292 (br s, OH, COOH), 2933 (m, aliphatic CH), 1713 
(s, C=O, COOH), 1482 (m), 1543 (m), 1365 (m), 1270 (s, C-O), 822 (s)
λmax (EtOH)/nm: 285.5
= −67 (c= 0.1, MeOH)
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(S)-2-(chloromethyl)-2, 3, 4, 6, 7, 8, 9, 10-octahydropyrimido [1, 2-a] [1, 3] diazepine (222) 
2
The general procedure for the synthesis of alkyl halides from alcohols was followed to yield 
222 (605.31 mg, 70%) as a brown oily product.
TLC (silica gel, 10:0.2% DCM/ MeOH), Rf = 0.3 (UV)
Chlorine  %wt/wt: 29.77, found 29.38
1H-NMR (300 MHz, CDCl3) δ 3.71-3.65 (m, 1H, NCH), 3.63-3.51 (m, 2H, CH2Cl), 2.8-2.91 (m, 
2H, NHCH2), 2.68-2.75 (m, 2H, NCH2), 2.61-2.66 (m, 2H, NCH2), 1.7-1.79 (m, 2H, NHCH2CH2), 
1.66-1.69 (m, 2H, NCH2CH2), 1.56-1.5 (m, 2H, NCH2CH2). 
 
13C-NMR (100 MHz, MeOD) δ 155.1 (C=N), 59.0 (CH), 50.3 (CH2), 49.1 (CH2), 48.3 (CH2), 42.2
(CH2), 33.2 (CH2), 30.5 (CH2), 28.6 (CH2).
HRMS-ES+ (m/z): calcd. for C9H17ClN3 [M+H]+: 202.1106, found 202.1105
FT-IR (CHCl3 film, cm−1) 3476(br s, NH), 2869 (m, aliphatic CH), 1631 (s, NH), 1603 (C=N) 
1590 (s), 1497 (m), 1313 (s).
= −55 (c= 0.22, MeOH)
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(R)-2-((tert-butoxycarbonyl) amino)-3-(4-(((S)-2, 3, 4, 6, 7, 8, 9, 10-octahydropyrimido [1, 2-
a] [1, 3] diazepin-2-yl) methoxy) phenyl) propanoic acid (225)
The general procedure for the synthesis of modified amino acid having bicyclic guanidine in 
their moiety was followed to yield 225 (249 mg, 65%) as a white foam.
TLC (silica gel, 10:1 DCM/ MeOH), Rf =0.72 (UV)
1H-NMR (300 MHz, CDCl3) δ 6.9 (d, 2H, 3JHH=7.8 Hz), 6.5 (d, 2H, 3JHH=7.8 Hz), 4.7-4.65 (m, 1H, 
CHCOOH), 4.19-4.09 (m, 2H, NCHCH2), 3.39-3.31 (m, 1H, NCH), 2.92-2.89 (m, 2H, ArCH2), 2.8-
3.1 (m, 2H, NHCH2), 2.78-2.7 (m, 2H, NCH2), 2.69-2.6 (m, 2H, NCH2), 1.79-1.7 (m, 2H,
NHCH2CH2), 1.66-1.59 (m, 2H, NCH2CH2), 1.45-1.57 (m, 2H, NCH2CH2), 1.41 (s, 9H, C(CH3)3.
13C-NMR (100 MHz, CDCl3) δ 173 (COOH), 172.9 (ArC), 156.6 (Boc, CO), 155.3 (C=N), 130.2 
(2ArC), 127.2 (ArC), 114.8 (2ArC), 79.3 (C(CH3), 70.5 (CH2), 69.1 (CH), 54.3 (CH), 50.1 (CH2), 
44.4 (CH2), 38.2 (CH2), 29.5 (CH2), 28.1 (CH2), 27.3 (C(CH3)3), 25.5 (CH2).
HRMS-ES+ (m/z): calcd. for C23H35N4O5 [M+H]+: 447.2607, found 447.2620
FT-IR (CHCl3 film, cm−1) 3374 (br s, NH), 3295 (br s, OH, COOH), 2931 (m, aliphatic CH), 
1713(s, C=O, COOH), 1481 (m), 1540 (m), 1364 (m), 1273 (s, C-O), 821(s)
= −65 (c= 0.15, MeOH)
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Allyl N2-(((9H-fluoren-9-yl) methoxy) carbonyl)-N5-(((S)-3, 4, 6, 7, 8, 9-hexahydro-2H-
pyrimido [1, 2-a] pyrimidin-2-yl) methyl)-L-glutaminate (231)
HOBt (221.5 mg, 1.64 mmol) and PyBOP (145.69 mg, 0.9 mmol) were added to a solution of 
Fmoc-Glu-OAll (670.7 mg, 1.64 mmol) in dry dimethylformamide (15 mL). The mixture was 
stirred at room temperature for 10 minutes. Compound 229 (278.5 mg, 1.64 mmol) was 
added to the resulting solution at 0 °C. The mixture was stirred at room temperature for 10 
h. The solvent was evaporated under reduced pressure and then the residue was redissolved 
in dichloromethane. The solid was filtered. The solvent was evaporated in vacuo from the 
filtrate to give the crude product. The yield after purification through silica gel and using the 
eluent of DCM and MeOH (10:0.1) and removal of solvent was 633 mg (69%) as a pale-yellow 
oil.
TLC (silica gel, 10:0.1% DCM/ MeOH), Rf = 0.5 (UV)
1H-NMR (300 MHz, MeOH) δ 7.79 (d, 2H, 3JHH=7.5 Hz), 7.66 (d, 2H, 3JHH=7.4 Hz), 7.43 (t, 2H, 
J=7.4 Hz), 7.33 (t, 2H, J=7.4 Hz), 5.97 (m, 1H, CH2=CH), 5.26 (m, 2H, CH2=CH) 4.73-4.71 ( m, 
2H, OCH2), 4.71-4.69 (m, 2H, OCH2 CH-All), 4.48-4.39 (m, 1H, furan), 4.38-4.28 (m, 1H, 
NHCH), 3.27-3.19 (m,1H,-NCH), 3.15-3.0 (m,2H,NCHCH2), 2.71-2.69 (m, 2H, NHCH2), 2.69-
2.58 (m, 2H, NCH2 ), 2.55-2.43 (m,2H,NCH2), 2.13-2.09 (m, 2H, NHCHCH2), 2.0-1.89 (m, 2H, 
COCH2), 1.75-1.68 (m, 2H, NCH2CH2), 1.55-1.63 (m, 2H, NCH2CH2).
13C-NMR (100 MHz, MeOH) δ 173.0 (CO-OH), 172.6 (CO-OAll), 161.3 (CO-Fmoc), 152.0
(C=N), 145.0 (2C, Fmoc-ArC), 143.0 (2C-Fmoc-ArC), 138.1 (C -Allyl), 128.3(2C-ArC), 127.2 
(2C-ArC), 126.2 (2C-ArC), 122.4 (2C-ArC), 119.2 (C -Allyl), 70.5 (CH2), 68.1 (CH2), 59.0
(CH), 50.2 (CH2), 49.4 (CH2), 47.1 (CH-furan), 45.5 (CH), 44.3 (CH2), 42.1 (CH2), 35.3 (CH2), 
29.1 (CH2), 26.5 (CH2), 23.1 (CH2).
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HRMS-ES+ (m/z): calcd. for C31H38N5O5 [M+H]+: 560.2873, found 560.2877
FT-IR (CHCl3 film, cm−1) 3340 (br s, NH), 3050 (s, OH, COOH), 2950 (m, aliphatic CH), 1750 (s, 
C=O, COOH), 1690 (s, C=C, amide), 1530 (m), 1450 (m), 1420 (m), 1340 (m), 1280 (s), 1250
(m).
= −72 (c= 0.22, MeOH)
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6.1 Crystallography data for 183A
N-(2-cyanoethyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonamide 183A
Table 1.  Crystal data and structure refinement for 183A.
Identification code shelx
Empirical formula C16 H21 N2 O3 S
Formula weight 321.41
Temperature 298(2) K
Wavelength 0.71073 Å
Crystal system Orthorhombic
Space group P212121
Unit cell dimensions a = 28.292(3) Å = 90°.
b = 10.8440(9) Å = 90°.
c = 5.6300(4) Å  = 90°.
Volume 1727.2(3) Å3
Z 4
Density (calculated) 1.236 Mg/m3
Absorption coefficient 0.201 mm-1 
F(000) 684
Crystal size 0.620 × 0.163 × 0.061 mm3
Theta range for data collection 3.439 to 30.058°.
Index ranges -34<=h<=36, -14<=k<=11, -7<=l<=5
Reflections collected 8052
Independent reflections 4118 [R(int) = 0.0414]
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Completeness to theta = 25.242° 99.7 % 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4118 / 0 / 204
Goodness-of-fit on F2 1.023
Final R indices [I>2sigma(I)] R1 = 0.0648, wR2 = 0.1421
R indices (all data) R1 = 0.1241, wR2 = 0.1766
Absolute structure parameter 0.20(7)
Extinction coefficient n/a
Largest diff. peak and hole 0.232 and -0.252 e.Å-3 
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Table 2. Atomic coordinates (× 104) and equivalent isotropic displacement parameters (Å2× 103)
for 183A. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
C(1) -334(2) 10198(5) 7394(9) 64(1)
C(2) -50(2) 9327(5) 8922(10) 73(1)
C(3) 454(2) 9693(4) 8477(8) 54(1)
C(4) 453(2) 10543(4) 6644(8) 54(1)
C(5) 865(2) 9305(4) 9502(7) 54(1)
C(6) 1287(2) 9836(4) 8637(8) 54(1)
C(7) 1284(2) 10710(4) 6726(8) 54(1)
C(8) 856(2) 11060(4) 5705(7) 52(1)
C(9) -548(2) 11213(6) 8854(12) 94(2)
C(10) -697(3) 9580(8) 5842(12) 118(3)
C(11) 825(2) 8375(4) 11505(9) 72(1)
C(12) 1723(2) 11301(5) 5743(10) 76(2)
C(13) 821(2) 11930(5) 3640(9) 70(1)
C(14) 1890(2) 7455(5) 7042(10) 74(1)
C(15) 2239(2) 6741(6) 5577(15) 107(2)
C(16) 2012(4) 5653(8) 4620(20) 163(4)
N(1) 2115(1) 8577(4) 7903(8) 65(1)
N(2) 1826(5) 4786(9) 3870(30) 273(8)
O(1) 8(1) 10791(3) 5797(6) 70(1)
O(2) 2131(1) 10500(3) 10107(7) 86(1)
O(3) 1763(1) 8673(4) 11863(6) 89(1)
S(1) 1843(1) 9414(1) 9835(2) 68(1)
________________________________________________________________________________ 
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Table 3. Bond lengths [Å] and angles [°] for 183A.
_____________________________________________________ 
C(1)-O(1) 1.468(6)
C(1)-C(9) 1.501(7)
C(1)-C(10) 1.506(8)
C(1)-C(2) 1.509(7)
C(2)-C(3) 1.500(6)
C(2)-H(2A) 0.9700
C(2)-H(2B) 0.9700
C(3)-C(5) 1.364(6)
C(3)-C(4) 1.383(6)
C(4)-O(1) 1.373(5)
C(4)-C(8) 1.377(6)
C(5)-C(6) 1.412(6)
C(5)-C(11) 1.517(6)
C(6)-C(7) 1.434(6)
C(6)-S(1) 1.771(5)
C(7)-C(8) 1.392(6)
C(7)-C(12) 1.504(6)
C(8)-C(13) 1.501(6)
C(9)-H(9A) 0.9600
C(9)-H(9B) 0.9600
C(9)-H(9C) 0.9600
C(10)-H(10A) 0.9600
C(10)-H(10B) 0.9600
C(10)-H(10C) 0.9600
C(11)-H(11A) 0.9600
C(11)-H(11B) 0.9600
C(11)-H(11C) 0.9600
C(12)-H(12A) 0.9600
C(12)-H(12B) 0.9600
C(12)-H(12C) 0.9600
C(13)-H(13A) 0.9600
C(13)-H(13B) 0.9600
C(13)-H(13C) 0.9600
C(14)-N(1) 1.456(6)
C(14)-C(15) 1.503(8)
C(14)-H(14A) 0.9700
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C(14)-H(14B) 0.9700
C(15)-C(16) 1.448(12)
C(15)-H(15A) 0.9700
C(15)-H(15B) 0.9700
C(16)-N(2) 1.157(12)
N(1)-S(1) 1.612(4)
O(2)-S(1) 1.441(4)
O(3)-S(1) 1.414(4)
O(1)-C(1)-C(9) 106.2(4)
O(1)-C(1)-C(10) 106.7(4)
C(9)-C(1)-C(10) 111.7(6)
O(1)-C(1)-C(2) 105.8(4)
C(9)-C(1)-C(2) 111.2(5)
C(10)-C(1)-C(2) 114.6(5)
C(3)-C(2)-C(1) 104.2(4)
C(3)-C(2)-H(2A) 110.9
C(1)-C(2)-H(2A) 110.9
C(3)-C(2)-H(2B) 110.9
C(1)-C(2)-H(2B) 110.9
H(2A)-C(2)-H(2B) 108.9
C(5)-C(3)-C(4) 121.6(4)
C(5)-C(3)-C(2) 131.0(4)
C(4)-C(3)-C(2) 107.4(4)
O(1)-C(4)-C(8) 123.2(4)
O(1)-C(4)-C(3) 113.1(4)
C(8)-C(4)-C(3) 123.7(4)
C(3)-C(5)-C(6) 116.6(4)
C(3)-C(5)-C(11) 117.2(4)
C(6)-C(5)-C(11) 126.1(4)
C(5)-C(6)-C(7) 121.6(4)
C(5)-C(6)-S(1) 120.9(3)
C(7)-C(6)-S(1) 117.5(3)
C(8)-C(7)-C(6) 119.6(4)
C(8)-C(7)-C(12) 116.7(4)
C(6)-C(7)-C(12) 123.6(4)
C(4)-C(8)-C(7) 116.8(4)
C(4)-C(8)-C(13) 119.9(4)
Appendix                                                                                                                     Chapter Six
153
C(7)-C(8)-C(13) 123.2(4)
C(1)-C(9)-H(9A) 109.5
C(1)-C(9)-H(9B) 109.5
H(9A)-C(9)-H(9B) 109.5
C(1)-C(9)-H(9C) 109.5
H(9A)-C(9)-H(9C) 109.5
H(9B)-C(9)-H(9C) 109.5
C(1)-C(10)-H(10A) 109.5
C(1)-C(10)-H(10B) 109.5
H(10A)-C(10)-H(10B) 109.5
C(1)-C(10)-H(10C) 109.5
H(10A)-C(10)-H(10C) 109.5
H(10B)-C(10)-H(10C) 109.5
C(5)-C(11)-H(11A) 109.5
C(5)-C(11)-H(11B) 109.5
H(11A)-C(11)-H(11B) 109.5
C(5)-C(11)-H(11C) 109.5
H(11A)-C(11)-H(11C) 109.5
H(11B)-C(11)-H(11C) 109.5
C(7)-C(12)-H(12A) 109.5
C(7)-C(12)-H(12B) 109.5
H(12A)-C(12)-H(12B) 109.5
C(7)-C(12)-H(12C) 109.5
H(12A)-C(12)-H(12C) 109.5
H(12B)-C(12)-H(12C) 109.5
C(8)-C(13)-H(13A) 109.5
C(8)-C(13)-H(13B) 109.5
H(13A)-C(13)-H(13B) 109.5
C(8)-C(13)-H(13C) 109.5
H(13A)-C(13)-H(13C) 109.5
H(13B)-C(13)-H(13C) 109.5
N(1)-C(14)-C(15) 109.0(5)
N(1)-C(14)-H(14A) 109.9
C(15)-C(14)-H(14A) 109.9
N(1)-C(14)-H(14B) 109.9
C(15)-C(14)-H(14B) 109.9
H(14A)-C(14)-H(14B) 108.3
C(16)-C(15)-C(14) 109.4(6)
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C(16)-C(15)-H(15A) 109.8
C(14)-C(15)-H(15A) 109.8
C(16)-C(15)-H(15B) 109.8
C(14)-C(15)-H(15B) 109.8
H(15A)-C(15)-H(15B) 108.2
N(2)-C(16)-C(15) 179.2(12)
C(14)-N(1)-S(1) 119.1(4)
C(4)-O(1)-C(1) 107.7(4)
O(3)-S(1)-O(2) 118.0(2)
O(3)-S(1)-N(1) 107.5(2)
O(2)-S(1)-N(1) 105.2(2)
O(3)-S(1)-C(6) 108.2(2)
O(2)-S(1)-C(6) 109.3(2)
N(1)-S(1)-C(6) 108.2(2)
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: 
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Table 4. Anisotropic displacement parameters (Å2× 103) for 183A. The anisotropic
displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2 h k a* b* U12]
______________________________________________________________________________ 
U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
C(1) 51(3) 74(3) 67(3) 0(3) 11(2) -3(3)
C(2) 58(3) 69(3) 93(4) 12(3) 19(3) 4(3)
C(3) 56(3) 49(2) 57(2) 3(2) 11(2) -1(2)
C(4) 55(3) 50(2) 57(2) -6(2) 8(2) 1(2)
C(5) 60(3) 47(2) 57(2) -2(2) 8(2) -1(2)
C(6) 57(3) 51(2) 56(2) -6(2) 7(2) 0(2)
C(7) 53(3) 53(2) 58(2) -8(2) 11(2) -5(2)
C(8) 57(3) 49(2) 52(2) -1(2) 10(2) 2(2)
C(9) 100(5) 96(4) 86(4) 11(4) 25(3) 30(4)
C(10) 116(6) 146(6) 90(4) 0(5) -12(4) -52(5)
C(11) 75(4) 68(3) 74(3) 17(3) 4(3) -3(3)
C(12) 65(3) 80(3) 83(3) 5(3) 14(3) -7(3)
C(13) 73(4) 65(3) 72(3) 11(3) 25(3) 7(3)
C(14) 71(4) 67(3) 84(4) 3(3) 6(3) -1(3)
C(15) 98(5) 81(4) 142(7) -7(4) 12(4) 18(4)
C(16) 158(9) 95(5) 236(12) -52(8) 64(8) 4(6)
N(1) 49(2) 66(2) 80(3) 2(2) 1(2) 2(2)
N(2) 252(13) 144(7) 423(19) -147(10) 125(13) -45(8)
O(1) 55(2) 76(2) 78(2) 16(2) 10(2) 6(2)
O(2) 72(2) 92(2) 94(2) -16(3) -13(2) -21(2)
O(3) 81(3) 120(3) 66(2) 24(2) -9(2) 0(2)
S(1) 60(1) 80(1) 64(1) -1(1) -6(1) -4(1)
______________________________________________________________________________ 
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Table 5. Hydrogen coordinates (× 104) and isotropic displacement parameters (Å2× 10 3)
for 183A.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(2A) -131 9424 10586 88
H(2B) -104 8477 8460 88
H(9A) -309 11574 9844 141
H(9B) -795 10881 9832 141
H(9C) -676 11832 7820 141
H(10A) -831 10176 4775 176
H(10B) -942 9237 6817 176
H(10C) -549 8934 4943 176
H(11A) 932 8744 12958 109
H(11B) 1017 7668 11148 109
H(11C) 502 8124 11676 109
H(12A) 1695 11376 4050 114
H(12B) 1993 10800 6121 114
H(12C) 1762 12105 6431 114
H(13A) 984 11585 2298 105
H(13B) 964 12704 4056 105
H(13C) 495 12058 3245 105
H(14A) 1616 7663 6084 89
H(14B) 1784 6959 8374 89
H(15A) 2356 7252 4291 128
H(15B) 2506 6501 6556 128
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6.2 Crystallography data for 187A
N-(3-cyanopropyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonamide 187A
Table 1.  Crystal data and structure refinement for 187A.
Identification code shelx
Empirical formula C17 H24 N2 O3 S
Formula weight 336.44
Temperature 298(2) K
Wavelength 0.71073 Å
Crystal system Orthorhombic
Space group P 21 21 21
Unit cell dimensions a = 5.5730(15) Å = 90°.
b = 11.201(5) Å = 90°.
c = 29.510(7) Å  = 90°.
Volume 1842.1(10) Å3
Z 4
Density (calculated) 1.213 Mg/m3
Absorption coefficient 0.191 mm-1 
F(000) 720
Crystal size 0.620 × 0.163 × 0.061 mm3
Theta range for data collection 3.638 to 29.890°.
Index ranges -5<=h<=7, -10<=k<=15, -38<=l<=41
Reflections collected 8264
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Independent reflections 4391 [R(int) = 0.0689]
Completeness to theta = 25.242° 99.7% 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4391 / 153 / 254
Goodness-of-fit on F2 0.965
Final R indices [I>2sigma(I)] R1 = 0.0794, wR2 = 0.1970
R indices (all data) R1 = 0.1836, wR2 = 0.2741
Absolute structure parameter -0.04(13)
Extinction coefficient n/a
Largest diff. peak and hole 0.229 and -0.277 e.Å-3 
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Table 2. Atomic coordinates (× 104) and equivalent isotropic displacement parameters (Å2× 103)
for jer1605b. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________________________
x y z U(eq)
________________________________________________________________________________
C(1) -88(13) 2854(8) 2784(3) 92(2)
C(2) -1669(16) 2050(7) 2488(3) 104(2)
C(3) -938(12) 2372(6) 2009(2) 76(2)
C(4) 900(12) 3211(6) 2034(3) 77(2)
C(5) -1778(10) 1953(5) 1599(2) 73(2)
C(6) -722(11) 2447(6) 1196(2) 75(2)
C(7) 1207(11) 3313(5) 1232(3) 78(2)
C(8) 1986(11) 3691(6) 1656(2) 71(2)
C(9) 1531(17) 2132(12) 3078(4) 187(6)
C(10) -1522(19) 3761(11) 3024(4) 156(4)
C(11) -3766(14) 1043(6) 1603(3) 97(2)
C(12) 2409(13) 3834(7) 818(3) 102(3)
C(13) 3976(13) 4586(6) 1711(3) 97(2)
N(1) 363(12) 1169(5) 428(2) 94(2)
O(1) 1493(9) 3511(4) 2467(2) 96(2)
O(2) -1860(10) 3044(5) 367(2) 107(2)
O(3) -3815(9) 1288(6) 702(2) 117(2)
S(1) -1697(3) 2010(2) 653(1) 91(1)
C(14) 980(16) 33(7) 635(3) 100(2)
C(15) 2570(60) -550(50) 289(13) 132(8)
C(16) 750(80) -1000(50) -43(12) 142(7)
C(17) 1640(80) -1620(40) -463(13) 146(7)
N(2) 2170(100) -2330(30) -746(11) 204(12)
C(14A) 980(16) 33(7) 635(3) 100(2)
C(15A) 2350(40) -770(30) 308(7) 137(6)
C(16A) 1250(50) -840(20) -166(6) 122(5)
C(17A) 2870(60) -1490(20) -476(8) 148(6)
N(2A) 4260(60) -1990(20) -712(8) 203(10)
________________________________________________________________________________
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Table 3. Bond lengths [Å] and angles [°] for 187A.
_____________________________________________________
C(1)-C(10) 1.474(12)
C(1)-O(1) 1.482(9)
C(1)-C(9) 1.490(12)
C(1)-C(2) 1.533(11)
C(2)-C(3) 1.516(9)
C(2)-H(2A) 0.9700
C(2)-H(2B) 0.9700
C(3)-C(5) 1.378(9)
C(3)-C(4) 1.392(9)
C(4)-O(1) 1.360(8)
C(4)-C(8) 1.378(9)
C(5)-C(6) 1.439(8)
C(5)-C(11) 1.505(9)
C(6)-C(7) 1.452(9)
C(6)-S(1) 1.762(7)
C(7)-C(8) 1.392(9)
C(7)-C(12) 1.509(9)
C(8)-C(13) 1.504(9)
C(9)-H(9A) 0.9600
C(9)-H(9B) 0.9600
C(9)-H(9C) 0.9600
C(10)-H(10A) 0.9600
C(10)-H(10B) 0.9600
C(10)-H(10C) 0.9600
C(11)-H(11A) 0.9600
C(11)-H(11B) 0.9600
C(11)-H(11C) 0.9600
C(12)-H(12A) 0.9600
C(12)-H(12B) 0.9600
C(12)-H(12C) 0.9600
C(13)-H(13A) 0.9600
C(13)-H(13B) 0.9600
C(13)-H(13C) 0.9600
N(1)-C(14) 1.452(10)
N(1)-S(1) 1.626(6)
N(1)-H(12) 0.996(13)
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O(2)-S(1) 1.437(5)
O(3)-S(1) 1.438(5)
C(14)-C(15) 1.498(13)
C(14)-H(14A) 0.9700
C(14)-H(14B) 0.9700
C(15)-C(16) 1.497(13)
C(15)-H(15A) 0.9700
C(15)-H(15B) 0.9700
C(16)-C(17) 1.502(13)
C(16)-H(16A) 0.9700
C(16)-H(16B) 0.9700
C(17)-N(2) 1.194(13)
C(15A)-C(16A) 1.529(12)
C(15A)-H(15C) 0.9700
C(15A)-H(15D) 0.9700
C(16A)-C(17A) 1.480(12)
C(16A)-H(16C) 0.9700
C(16A)-H(16D) 0.9700
C(17A)-N(2A) 1.181(12)
C(10)-C(1)-O(1) 106.5(7)
C(10)-C(1)-C(9) 115.0(10)
O(1)-C(1)-C(9) 106.1(6)
C(10)-C(1)-C(2) 111.6(7)
O(1)-C(1)-C(2) 105.9(6)
C(9)-C(1)-C(2) 111.1(8)
C(3)-C(2)-C(1) 103.7(6)
C(3)-C(2)-H(2A) 111.0
C(1)-C(2)-H(2A) 111.0
C(3)-C(2)-H(2B) 111.0
C(1)-C(2)-H(2B) 111.0
H(2A)-C(2)-H(2B) 109.0
C(5)-C(3)-C(4) 121.9(6)
C(5)-C(3)-C(2) 130.2(7)
C(4)-C(3)-C(2) 107.9(6)
O(1)-C(4)-C(8) 123.8(6)
O(1)-C(4)-C(3) 113.4(6)
C(8)-C(4)-C(3) 122.9(7)
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C(3)-C(5)-C(6) 117.0(6)
C(3)-C(5)-C(11) 118.4(6)
C(6)-C(5)-C(11) 124.5(6)
C(5)-C(6)-C(7) 120.0(6)
C(5)-C(6)-S(1) 121.3(5)
C(7)-C(6)-S(1) 118.7(5)
C(8)-C(7)-C(6) 120.0(6)
C(8)-C(7)-C(12) 118.1(6)
C(6)-C(7)-C(12) 121.9(7)
C(4)-C(8)-C(7) 118.2(6)
C(4)-C(8)-C(13) 119.8(6)
C(7)-C(8)-C(13) 121.9(6)
C(1)-C(9)-H(9A) 109.5
C(1)-C(9)-H(9B) 109.5
H(9A)-C(9)-H(9B) 109.5
C(1)-C(9)-H(9C) 109.5
H(9A)-C(9)-H(9C) 109.5
H(9B)-C(9)-H(9C) 109.5
C(1)-C(10)-H(10A) 109.5
C(1)-C(10)-H(10B) 109.5
H(10A)-C(10)-H(10B) 109.5
C(1)-C(10)-H(10C) 109.5
H(10A)-C(10)-H(10C) 109.5
H(10B)-C(10)-H(10C) 109.5
C(5)-C(11)-H(11A) 109.5
C(5)-C(11)-H(11B) 109.5
H(11A)-C(11)-H(11B) 109.5
C(5)-C(11)-H(11C) 109.5
H(11A)-C(11)-H(11C) 109.5
H(11B)-C(11)-H(11C) 109.5
C(7)-C(12)-H(12A) 109.5
C(7)-C(12)-H(12B) 109.5
H(12A)-C(12)-H(12B) 109.5
C(7)-C(12)-H(12C) 109.5
H(12A)-C(12)-H(12C) 109.5
H(12B)-C(12)-H(12C) 109.5
C(8)-C(13)-H(13A) 109.5
C(8)-C(13)-H(13B) 109.5
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H(13A)-C(13)-H(13B) 109.5
C(8)-C(13)-H(13C) 109.5
H(13A)-C(13)-H(13C) 109.5
H(13B)-C(13)-H(13C) 109.5
C(14)-N(1)-S(1) 120.3(6)
C(14)-N(1)-H(12) 118(4)
S(1)-N(1)-H(12) 110(4)
C(4)-O(1)-C(1) 109.0(5)
O(2)-S(1)-O(3) 117.4(3)
O(2)-S(1)-N(1) 105.8(4)
O(3)-S(1)-N(1) 107.2(4)
O(2)-S(1)-C(6) 109.3(3)
O(3)-S(1)-C(6) 108.5(3)
N(1)-S(1)-C(6) 108.3(3)
N(1)-C(14)-C(15) 104(2)
N(1)-C(14)-H(14A) 111.0
C(15)-C(14)-H(14A) 111.0
N(1)-C(14)-H(14B) 111.0
C(15)-C(14)-H(14B) 111.0
H(14A)-C(14)-H(14B) 109.0
C(16)-C(15)-C(14) 101(2)
C(16)-C(15)-H(15A) 111.5
C(14)-C(15)-H(15A) 111.5
C(16)-C(15)-H(15B) 111.5
C(14)-C(15)-H(15B) 111.5
H(15A)-C(15)-H(15B) 109.3
C(15)-C(16)-C(17) 118(3)
C(15)-C(16)-H(16A) 107.7
C(17)-C(16)-H(16A) 107.7
C(15)-C(16)-H(16B) 107.7
C(17)-C(16)-H(16B) 107.7
H(16A)-C(16)-H(16B) 107.1
N(2)-C(17)-C(16) 165(4)
C(16A)-C(15A)-H(15C) 108.8
C(16A)-C(15A)-H(15D) 108.8
H(15C)-C(15A)-H(15D) 107.7
C(17A)-C(16A)-C(15A) 110.0(17)
C(17A)-C(16A)-H(16C) 109.7
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C(15A)-C(16A)-H(16C) 109.7
C(17A)-C(16A)-H(16D) 109.7
C(15A)-C(16A)-H(16D) 109.7
H(16C)-C(16A)-H(16D) 108.2
N(2A)-C(17A)-C(16A) 177(3)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms: 
Appendix                                                                                                                     Chapter Six
165
Table 4. Anisotropic displacement parameters (Å2×103) for 187A. The anisotropic
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12]
______________________________________________________________________________
U11 U22 U33 U23 U13 U12
______________________________________________________________________________
C(1) 84(4) 117(6) 76(5) -1(5) 11(4) 6(5)
C(2) 125(6) 105(5) 82(5) 7(5) 20(5) -11(6)
C(3) 70(3) 79(4) 78(5) 9(3) 12(3) 4(3)
C(4) 73(4) 76(4) 82(5) -8(4) 12(3) 0(3)
C(5) 68(3) 72(3) 80(5) 10(3) 10(3) -5(4)
C(6) 71(3) 84(4) 71(5) 4(3) 5(3) 3(3)
C(7) 64(3) 67(4) 102(6) 7(3) 21(4) 7(3)
C(8) 69(3) 68(3) 77(4) 0(3) 9(3) 5(3)
C(9) 100(6) 269(15) 192(11) 140(11) -34(7) -30(9)
C(10) 120(7) 181(10) 165(10) -89(8) 42(7) -34(8)
C(11) 99(5) 94(5) 100(5) 0(4) 21(5) -22(4)
C(12) 104(5) 110(5) 93(6) 20(5) 27(4) -14(4)
C(13) 76(4) 88(5) 126(6) -4(4) 19(4) -3(4)
N(1) 110(5) 81(4) 91(5) 1(3) 13(4) -1(4)
O(1) 102(3) 104(3) 80(4) -6(3) 15(3) -16(3)
O(2) 117(4) 115(3) 89(3) 28(3) -10(3) 9(4)
O(3) 87(3) 151(5) 113(4) 8(4) -15(3) -35(4)
S(1) 85(1) 105(1) 83(1) 8(1) -1(1) -1(1)
C(14) 121(5) 87(5) 93(5) 4(4) 4(5) -7(5)
C(15) 172(13) 97(13) 128(12) 2(10) -27(11) 14(11)
C(16) 179(12) 109(11) 138(12) -4(10) -20(11) 8(10)
C(17) 179(14) 124(12) 135(12) -10(11) 17(13) 20(13)
N(2) 280(30) 210(20) 126(17) -25(17) 40(20) 10(20)
C(14A) 121(5) 87(5) 93(5) 4(4) 4(5) -7(5)
C(15A) 182(11) 104(11) 124(10) -11(9) -24(9) 12(10)
C(16A) 171(10) 95(8) 100(10) -9(8) -18(9) 12(9)
C(17A) 181(13) 129(10) 134(11) -11(9) 2(11) 21(11)
N(2A) 270(20) 181(16) 155(14) -21(13) 31(16) 59(16)
______________________________________________________________________________
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Table 5. Hydrogen coordinates (× 104) and isotropic displacement parameters (Å2× 103)
for jer1605b.
________________________________________________________________________________
x y z U(eq)
________________________________________________________________________________
H(2A) -1361 1213 2550 125
H(2B) -3357 2214 2538 125
H(9A) 2533 1637 2892 281
H(9B) 586 1638 3275 281
H(9C) 2516 2655 3256 281
H(10A) -479 4373 3139 233
H(10B) -2360 3393 3272 233
H(10C) -2660 4109 2819 233
H(11A) -3958 732 1904 146
H(11B) -3374 404 1399 146
H(11C) -5235 1414 1507 146
H(12A) 1936 4653 784 154
H(12B) 1937 3391 555 154
H(12C) 4120 3790 854 154
H(13A) 4067 4833 2022 145
H(13B) 3660 5268 1523 145
H(13C) 5471 4229 1623 145
H(14A) -443 -444 690 120
H(14B) 1827 149 918 120
H(15A) 3648 25 151 158
H(15B) 3491 -1195 420 158
H(16A) -224 -327 -138 170
H(16B) -297 -1549 115 170
H(14C) -477 -369 730 120
H(14D) 1953 174 902 120
H(15C) 2430 -1570 434 164
H(15D) 3986 -478 281 164
H(16C) -284 -1252 -150 147
H(16D) 962 -42 -280 147
H(12) 1700(90) 1670(50) 310(20) 100(20)
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6.3 Crystallographic data for 233
(S)-8-(((tert-butyldimethylsilyl) oxy) methyl) -1-((2, 2, 4, 6, 7-pentamethyl-2,3-dihydrobenzofuran-
5-yl) sulfonyl)-1, 3, 4, 6, 7, 8-hexahydro-2H-pyrimido [1,2-a] pyrimidine 233
Table 1. Crystal data and structure refinement for 233.
Identification code jer1502
Empirical formula C28 H46 F3 N3 O7 S2 Si
Formula weight 685.89
Temperature 150(2) K
Wavelength 1.54184 Å
Crystal system Monoclinic
Space group P 21
Unit cell dimensions a = 8.5784(3) Å = 90°.
b = 14.4797(5) Å = 96.052(4)°.
c = 13.6961(5) Å  = 90°.
Volume 1691.75(10) Å3
Z 2
Density (calculated) 1.346 Mg/m3
Absorption coefficient 2.317 mm-1 
F(000) 728
Crystal size 0.330 × 0.057 × 0.037 mm3
Theta range for data collection 4.457 to 73.830°.
Index ranges -10<=h<=10, -10<=k<=17, -16<=l<=16
Reflections collected 6602
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Independent reflections 4492 [R(int) = 0.0226]
Completeness to theta = 67.684° 99.7% 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4492 / 1 / 407
Goodness-of-fit on F2 1.026
Final R indices [I>2sigma(I)] R1 = 0.0369, wR2 = 0.0944
R indices (all data) R1 = 0.0393, wR2 = 0.0970
Absolute structure parameter 0.004(14)
Extinction coefficient n/a
Largest diff. peak and hole 0.639 and -0.455 e.Å-3 
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Table 2. Atomic coordinates (×104) and equivalent isotropic displacement parameters (Å2× 103)
for 233. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________________________
x y z U(eq)
________________________________________________________________________________
C(1) 4903(4) 3475(3) 13994(3) 33(1)
C(2) 4708(7) 3823(4) 15024(3) 59(1)
C(3) 4752(8) 4299(4) 13300(4) 75(2)
C(4) 6546(5) 3073(4) 14004(5) 68(2)
C(5) 1353(5) 2945(4) 13702(4) 51(1)
C(6) 3768(6) 1480(3) 14332(3) 47(1)
C(7) 2759(4) 1732(3) 11814(3) 33(1)
C(8) 3644(4) 1581(2) 10935(2) 29(1)
C(9) 2892(4) 889(3) 10197(3) 33(1)
C(10) 4040(4) 680(3) 9468(2) 35(1)
C(11) 6034(3) 633(2) 10847(2) 24(1)
C(12) 6408(5) -292(3) 9383(3) 45(1)
C(13) 7666(5) -811(3) 10016(3) 50(1)
C(14) 8558(4) -125(3) 10679(3) 41(1)
C(15) 8054(3) -888(2) 12787(2) 25(1)
C(16) 6615(3) -1379(2) 12654(2) 26(1)
C(17) 6587(3) -2332(3) 12823(2) 27(1)
C(18) 8016(4) -2752(2) 13105(3) 29(1)
C(19) 9422(3) -2277(3) 13240(2) 30(1)
C(20) 9498(3) -1334(3) 13095(2) 27(1)
C(21) 5054(3) -923(3) 12335(3) 34(1)
C(22) 5107(4) -2899(3) 12728(3) 34(1)
C(23) 11084(4) -877(3) 13296(3) 35(1)
C(24) 10691(4) -2964(3) 13566(4) 45(1)
C(25) 9847(4) -3896(3) 13449(3) 39(1)
C(26) 10083(5) -4485(3) 14356(3) 49(1)
C(27) 10219(5) -4403(4) 12529(3) 53(1)
C(28) 8067(5) 3080(3) 10769(4) 53(1)
N(1) 5221(3) 1252(2) 11289(2) 27(1)
N(2) 5494(3) 299(2) 9974(2) 29(1)
N(3) 7459(3) 337(2) 11293(2) 30(1)
O(1) 3654(3) 2364(2) 12448(2) 36(1)
O(2) 6884(3) 785(2) 13001(2) 33(1)
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O(3) 9591(3) 654(2) 12604(2) 38(1)
O(4) 8160(3) -3672(2) 13293(2) 40(1)
O(5) 8250(4) 3440(3) 8962(3) 79(1)
O(6) 7404(5) 1905(3) 9413(3) 74(1)
O(7) 10089(4) 2370(3) 9773(3) 65(1)
Si(1) 3399(1) 2560(1) 13610(1) 31(1)
S(1) 8039(1) 303(1) 12509(1) 26(1)
S(2) 8497(1) 2651(1) 9591(1) 42(1)
F(1) 6552(4) 3308(3) 10729(4) 103(2)
F(2) 8339(4) 2461(3) 11485(2) 70(1)
F(3) 8888(5) 3838(3) 11022(3) 92(1)
________________________________________________________________________________
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Table 3. Bond lengths [Å] and angles [°] for 233.
_____________________________________________________
C(1)-C(3) 1.521(6)
C(1)-C(4) 1.523(6)
C(1)-C(2) 1.524(5)
C(1)-Si(1) 1.885(4)
C(5)-Si(1) 1.859(4)
C(6)-Si(1) 1.860(4)
C(7)-O(1) 1.429(4)
C(7)-C(8) 1.505(5)
C(8)-N(1) 1.468(4)
C(8)-C(9) 1.517(5)
C(9)-C(10) 1.505(5)
C(10)-N(2) 1.469(5)
C(11)-N(1) 1.322(4)
C(11)-N(2) 1.326(4)
C(11)-N(3) 1.376(4)
C(12)-N(2) 1.461(5)
C(12)-C(13) 1.512(7)
C(13)-C(14) 1.501(6)
C(14)-N(3) 1.487(4)
C(15)-C(16) 1.420(4)
C(15)-C(20) 1.421(4)
C(15)-S(1) 1.766(4)
C(16)-C(17) 1.399(5)
C(16)-C(21) 1.515(4)
C(17)-C(18) 1.386(5)
C(17)-C(22) 1.507(4)
C(18)-O(4) 1.361(4)
C(18)-C(19) 1.383(5)
C(19)-C(20) 1.383(5)
C(19)-C(24) 1.507(5)
C(20)-C(23) 1.512(4)
C(24)-C(25) 1.531(6)
C(25)-O(4) 1.477(4)
C(25)-C(26) 1.503(6)
C(25)-C(27) 1.522(6)
C(28)-F(3) 1.330(5)
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C(28)-F(2) 1.331(6)
C(28)-F(1) 1.337(6)
C(28)-S(2) 1.803(5)
N(3)-S(1) 1.687(3)
O(1)-Si(1) 1.654(3)
O(2)-S(1) 1.436(2)
O(3)-S(1) 1.419(2)
O(5)-S(2) 1.434(4)
O(6)-S(2) 1.433(4)
O(7)-S(2) 1.421(4)
C(3)-C(1)-C(4) 108.9(5)
C(3)-C(1)-C(2) 108.0(4)
C(4)-C(1)-C(2) 108.0(4)
C(3)-C(1)-Si(1) 111.5(3)
C(4)-C(1)-Si(1) 109.8(3)
C(2)-C(1)-Si(1) 110.6(3)
O(1)-C(7)-C(8) 107.2(3)
N(1)-C(8)-C(7) 107.9(3)
N(1)-C(8)-C(9) 108.6(3)
C(7)-C(8)-C(9) 114.5(3)
C(10)-C(9)-C(8) 108.2(3)
N(2)-C(10)-C(9) 110.2(3)
N(1)-C(11)-N(2) 120.6(3)
N(1)-C(11)-N(3) 119.6(3)
N(2)-C(11)-N(3) 119.8(3)
N(2)-C(12)-C(13) 111.5(3)
C(14)-C(13)-C(12) 107.8(4)
N(3)-C(14)-C(13) 109.0(3)
C(16)-C(15)-C(20) 122.0(3)
C(16)-C(15)-S(1) 118.4(2)
C(20)-C(15)-S(1) 119.6(2)
C(17)-C(16)-C(15) 120.2(3)
C(17)-C(16)-C(21) 116.6(3)
C(15)-C(16)-C(21) 123.3(3)
C(18)-C(17)-C(16) 116.6(3)
C(18)-C(17)-C(22) 119.8(3)
C(16)-C(17)-C(22) 123.5(3)
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O(4)-C(18)-C(19) 113.6(3)
O(4)-C(18)-C(17) 122.8(3)
C(19)-C(18)-C(17) 123.5(3)
C(20)-C(19)-C(18) 121.6(3)
C(20)-C(19)-C(24) 130.6(3)
C(18)-C(19)-C(24) 107.7(3)
C(19)-C(20)-C(15) 116.0(3)
C(19)-C(20)-C(23) 117.5(3)
C(15)-C(20)-C(23) 126.5(3)
C(19)-C(24)-C(25) 103.4(3)
O(4)-C(25)-C(26) 106.7(3)
O(4)-C(25)-C(27) 105.9(3)
C(26)-C(25)-C(27) 112.9(4)
O(4)-C(25)-C(24) 105.5(3)
C(26)-C(25)-C(24) 113.1(4)
C(27)-C(25)-C(24) 112.0(4)
F(3)-C(28)-F(2) 108.5(5)
F(3)-C(28)-F(1) 107.0(4)
F(2)-C(28)-F(1) 106.9(4)
F(3)-C(28)-S(2) 111.5(3)
F(2)-C(28)-S(2) 113.0(3)
F(1)-C(28)-S(2) 109.8(4)
C(11)-N(1)-C(8) 125.5(3)
C(11)-N(2)-C(12) 123.7(3)
C(11)-N(2)-C(10) 119.1(3)
C(12)-N(2)-C(10) 115.9(3)
C(11)-N(3)-C(14) 118.3(3)
C(11)-N(3)-S(1) 127.1(2)
C(14)-N(3)-S(1) 114.0(2)
C(7)-O(1)-Si(1) 125.3(2)
C(18)-O(4)-C(25) 108.1(3)
O(1)-Si(1)-C(5) 109.80(18)
O(1)-Si(1)-C(6) 109.57(18)
C(5)-Si(1)-C(6) 109.0(2)
O(1)-Si(1)-C(1) 103.44(15)
C(5)-Si(1)-C(1) 113.2(2)
C(6)-Si(1)-C(1) 111.72(19)
O(3)-S(1)-O(2) 118.05(16)
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O(3)-S(1)-N(3) 104.85(15)
O(2)-S(1)-N(3) 107.64(13)
O(3)-S(1)-C(15) 110.15(15)
O(2)-S(1)-C(15) 111.31(16)
N(3)-S(1)-C(15) 103.60(16)
O(7)-S(2)-O(6) 114.5(3)
O(7)-S(2)-O(5) 114.3(2)
O(6)-S(2)-O(5) 116.5(2)
O(7)-S(2)-C(28) 103.0(2)
O(6)-S(2)-C(28) 102.7(2)
O(5)-S(2)-C(28) 103.4(3)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms: 
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Table 4. Anisotropic displacement parameters (Å2× 103) for 233. The anisotropic
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12]
______________________________________________________________________________
U11 U22 U33 U23 U13 U12
______________________________________________________________________________
C(1) 41(2) 28(2) 31(2) 1(1) 2(1) 0(2)
C(2) 83(3) 52(3) 44(2) -13(2) 14(2) -19(3)
C(3) 104(4) 53(3) 59(3) 25(3) -25(3) -25(3)
C(4) 40(2) 64(3) 100(4) -34(3) -1(2) -5(2)
C(5) 36(2) 52(3) 68(3) -13(2) 13(2) 9(2)
C(6) 57(2) 32(2) 53(2) 5(2) 13(2) 1(2)
C(7) 25(2) 39(2) 35(2) -6(2) 0(1) 3(1)
C(8) 26(2) 26(2) 33(2) 1(1) -1(1) 3(1)
C(9) 28(2) 35(2) 36(2) -2(2) -4(1) 1(1)
C(10) 39(2) 37(2) 29(2) -1(2) -1(1) -3(2)
C(11) 24(1) 21(1) 28(1) 2(1) 10(1) -2(1)
C(12) 40(2) 58(3) 40(2) -20(2) 13(2) 1(2)
C(13) 51(2) 44(2) 58(2) -12(2) 21(2) 6(2)
C(14) 34(2) 52(2) 38(2) 1(2) 14(1) 12(2)
C(15) 20(1) 28(2) 27(1) 0(1) 6(1) 1(1)
C(16) 18(1) 32(2) 29(1) 0(1) 6(1) 1(1)
C(17) 22(1) 31(2) 30(1) -2(1) 6(1) -3(1)
C(18) 25(2) 25(2) 37(2) 1(1) 6(1) 1(1)
C(19) 20(1) 32(2) 36(2) -1(1) 5(1) 3(1)
C(20) 19(1) 33(2) 30(2) -5(1) 4(1) 0(1)
C(21) 15(1) 42(2) 44(2) 10(2) 3(1) -2(1)
C(22) 25(2) 36(2) 42(2) -1(2) 4(1) -6(2)
C(23) 19(1) 34(2) 50(2) -2(2) -2(1) 0(1)
C(24) 27(2) 33(2) 73(3) 3(2) 3(2) 6(2)
C(25) 32(2) 33(2) 52(2) 2(2) 9(2) 9(2)
C(26) 46(2) 48(3) 52(2) 5(2) 8(2) 8(2)
C(27) 48(2) 55(3) 56(2) -4(2) 11(2) 12(2)
C(28) 50(2) 26(2) 87(3) -5(2) 30(2) -7(2)
N(1) 23(1) 23(1) 33(1) -5(1) 0(1) 4(1)
N(2) 32(1) 28(1) 28(1) -2(1) 7(1) -2(1)
N(3) 24(1) 34(2) 34(1) 1(1) 9(1) 6(1)
O(1) 34(1) 37(2) 37(1) -7(1) 4(1) 0(1)
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O(2) 31(1) 37(1) 31(1) -9(1) 2(1) 10(1)
O(3) 24(1) 28(1) 59(2) 1(1) -2(1) -3(1)
O(4) 29(1) 26(1) 67(2) 1(1) 8(1) 3(1)
O(5) 48(2) 91(3) 96(3) 62(3) -6(2) -11(2)
O(6) 92(3) 74(3) 52(2) 5(2) -4(2) -42(2)
O(7) 53(2) 69(3) 72(2) -8(2) 8(2) 23(2)
Si(1) 30(1) 28(1) 35(1) -3(1) 7(1) 4(1)
S(1) 20(1) 26(1) 33(1) -2(1) 2(1) 2(1)
S(2) 40(1) 41(1) 44(1) 11(1) -6(1) -7(1)
F(1) 58(2) 74(2) 188(5) 4(3) 63(2) 6(2)
F(2) 89(2) 74(2) 46(1) -2(2) 8(1) -24(2)
F(3) 107(3) 59(2) 119(3) -47(2) 53(2) -42(2)
______________________________________________________________________________
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Table 5. Hydrogen coordinates ( × 104) and isotropic displacement parameters (Å2× 103)
for 233.
________________________________________________________________________________
x y z U(eq)
________________________________________________________________________________
H(2A) 4860 3310 15490 89
H(2B) 3652 4078 15037 89
H(2C) 5487 4305 15207 89
H(3A) 3678 4538 13256 112
H(3B) 4995 4106 12647 112
H(3C) 5485 4784 13551 112
H(4A) 7323 3551 14203 103
H(4B) 6702 2850 13346 103
H(4C) 6669 2558 14471 103
H(5A) 1115 3478 13272 77
H(5B) 1236 3119 14382 77
H(5C) 628 2440 13501 77
H(6A) 2981 1016 14103 70
H(6B) 3702 1609 15028 70
H(6C) 4816 1245 14244 70
H(7A) 1708 1990 11607 40
H(7B) 2628 1140 12157 40
H(8) 3741 2186 10594 34
H(9A) 2627 316 10537 40
H(9B) 1916 1149 9856 40
H(10A) 3572 230 8978 42
H(10B) 4277 1253 9118 42
H(12A) 6901 92 8903 54
H(12B) 5700 -739 9012 54
H(13A) 7185 -1285 10411 60
H(13B) 8380 -1124 9599 60
H(14A) 9396 -443 11104 49
H(14B) 9054 341 10281 49
H(21A) 4815 -985 11622 50
H(21B) 5109 -267 12511 50
H(21C) 4229 -1223 12664 50
H(22A) 5373 -3554 12821 51
Appendix                                                                                                                     Chapter Six
178
H(22B) 4548 -2809 12073 51
H(22C) 4437 -2704 13227 51
H(23A) 11853 -1331 13574 52
H(23B) 11016 -369 13763 52
H(23C) 11409 -634 12681 52
H(24A) 11113 -2857 14258 53
H(24B) 11560 -2930 13146 53
H(26A) 9796 -4131 14921 73
H(26B) 11185 -4670 14473 73
H(26C) 9421 -5036 14267 73
H(27A) 9599 -4972 12455 79
H(27B) 11338 -4557 12585 79
H(27C) 9960 -4008 11954 79
H(1) 5663 1487 11843 32
